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Paediatric mature B-cell non-Hodgkin lymphoma (B-NHL) is a highly aggressive disease 
with one of the fastest growth rates of any human malignancy. The subtypes are Burkitt 
and Burkitt-like lymphoma/leukaemia, diffuse large B-cell lymphoma and primary 
mediastinal B-cell lymphoma; with Burkitt lymphoma/leukaemia alone accounting for 
38% of NHL diagnoses in patients under 15 years. Outcomes have improved 
significantly in recent years with the introduction of intensive multi-agent 
chemotherapy, followed by the addition of Rituximab, resulting in a survival rate 
exceeding 90%. Despite this, those patients who acquire resistance to chemotherapy 
and/or Rituximab have a dismal prognosis with few salvage therapy options. The aim 
of this thesis was to identify cell populations that are driving therapy resistance in order 
to develop targeted treatments for relapsed and therapy-refractory patients. 
Utilising samples obtained from patients enrolled in the Inter-B-NHL ritux 2010 clinical 
trial, we established 5 paediatric Patient Derived Xenografts (PDXs) – to our knowledge 
the largest paediatric B-NHL resource of this type. These PDXs faithfully recapitulate 
tumour characteristics through passage and enable the identification of 
heterogeneous populations within these malignancies. One such population, known as 
the side population (SP), exhibits tumour initiating potential, expresses stemness-
related genes and shows increased resistance to chemotherapy. In vitro, the SP 
produces soluble factors necessary for growth of the main population (MP) of cells 
(depleted of SP); indeed, MP and SP produce different cytokine profiles suggestive of 
cross-talk between the populations to maintain tumour cell growth. Furthermore, the 
PI 3-Kinase (PI3K) pathway was shown to be an important regulator of SP survival by 
regulating ATP-binding cassette (ABC) transporters hinting towards future therapeutic 
applications. 
 ii 
Due to the rarity of biopsy samples taken at relapse in paediatric B-NHL, resistance to 
chemotherapy was induced both in vivo and in vitro mimicking relapse. In vivo, this was 
achieved by administering multi-agent chemotherapy over an extended period to mice 
bearing established PDX tumours until apparent cure. The subsequent relapsed 
tumours contain a significantly increased proportion of SP cells and RNA sequencing 
identified PI3K and B cell receptor pathways as potential therapeutic targets in a subset 
of chemo-resistant tumours.  
In order to identify further protein targets for the treatment of paediatric B-NHL that 
is resistant to standard chemotherapeutic agents including Rituximab, a CRISPR/Cas9-
based genome-wide overexpression screen (SAM) was conducted with the human 
Burkitt lymphoma cell line Raji. The screen and subsequent validation highlighted 
several potential therapeutic targets including proteins in the PI3K, MAP kinase and 
Toll-Like receptor (TLR) signalling pathways, with different mechanisms of resistance 
identified between cells treated with standard chemotherapy drugs or Rituximab. 
Overall, this thesis describes data showing that paediatric B-NHL consists of 
heterogeneous populations of tumour cells, including tumour initiating SP cells and MP 
progeny. The SP has significantly increased resistance to chemotherapy and supports 
the growth and survival of the MP through production of soluble factors with the PI3K 
pathway important in driving the SP phenotype. Furthermore, using both in vivo and in 
vitro models of resistance we have identified pathways that may be therapeutic targets 
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Summary 
Paediatric mature B-cell non-Hodgkin lymphoma (B-NHL) is a highly aggressive disease 
with one of the fastest growth rates of any human malignancy. The subtypes are Burkitt 
and Burkitt-like lymphoma/leukaemia, diffuse large B-cell lymphoma and primary 
mediastinal B-cell lymphoma; with Burkitt lymphoma/leukaemia alone accounting for 
38% of NHL diagnoses in patients under 15 years. Outcomes have improved 
significantly in recent years with the introduction of intensive multi-agent 
chemotherapy, followed by the addition of Rituximab, resulting in a survival rate 
exceeding 90%. Despite this, those patients who acquire resistance to chemotherapy 
and/or Rituximab have a dismal prognosis with few salvage therapy options. The aim 
of this thesis was to identify cell populations that are driving therapy resistance in order 
to develop targeted treatments for relapsed and therapy-refractory patients. 
Utilising samples obtained from patients enrolled in the Inter-B-NHL ritux 2010 clinical 
trial, we established 5 paediatric Patient Derived Xenografts (PDXs) – to our knowledge 
the largest paediatric B-NHL resource of this type. These PDXs faithfully recapitulate 
tumour characteristics through passage and enable the identification of 
heterogeneous populations within these malignancies. One such population, known as 
the side population (SP), exhibits tumour initiating potential, expresses stemness-
related genes and shows increased resistance to chemotherapy. In vitro, the SP 
produces soluble factors necessary for growth of the main population (MP) of cells 
(depleted of SP); indeed, MP and SP produce different cytokine profiles suggestive of 
cross-talk between the populations to maintain tumour cell growth. Furthermore, the 
PI 3-Kinase (PI3K) pathway was shown to be an important regulator of SP survival by 
regulating ATP-binding cassette (ABC) transporters hinting towards future therapeutic 
applications. 
Due to the rarity of biopsy samples taken at relapse in paediatric B-NHL, resistance to 
chemotherapy was induced both in vivo and in vitro mimicking relapse. In vivo, this was 
achieved by administering multi-agent chemotherapy over an extended period to mice 
bearing established PDX tumours until apparent cure. The subsequent relapsed 
tumours contain a significantly increased proportion of SP cells and RNA sequencing 
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identified PI3K and B cell receptor pathways as potential therapeutic targets in a subset 
of chemo-resistant tumours.  
In order to identify further protein targets for the treatment of paediatric B-NHL that 
is resistant to standard chemotherapeutic agents including Rituximab, a CRISPR/Cas9-
based genome-wide overexpression screen (SAM) was conducted with the human 
Burkitt lymphoma cell line Raji. The screen and subsequent validation highlighted 
several potential therapeutic targets including proteins in the PI3K, MAP kinase and 
Toll-Like receptor (TLR) signalling pathways, with different mechanisms of resistance 
identified between cells treated with standard chemotherapy drugs or Rituximab. 
Overall, this thesis describes data showing that paediatric B-NHL consists of 
heterogeneous populations of tumour cells, including tumour initiating SP cells and MP 
progeny. The SP has significantly increased resistance to chemotherapy and supports 
the growth and survival of the MP through production of soluble factors with the PI3K 
pathway important in driving the SP phenotype. Furthermore, using both in vivo and in 
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Chapter 1. Introduction 
1.1 Lymphoma 
Lymphomas are a highly heterogeneous group of cancers that are characterised by 
neoplastic transformation of lymphocytes at specific stages in lymphocyte ontogeny. 
Due to the diversity of this group of malignancies, the field is ever-evolving and in the 
4th version of the World Health Organisation (WHO) classifications, which was updated 
in 2016 there are now greater than 70 distinct forms of this disease. These are classified 
broadly based on cell of origin; initially distinguishing B cell, T cell and natural killer (NK) 
cell disorders, with subsequent characterization based on the stage of lymphocyte 
ontogeny as well as morphology, molecular profile and clinical characteristics1.  
Lymphoma is a relatively rare cancer with just under 16,000 cases diagnosed in the UK 
in 20152. These cases are classified clearly as either Hodgkin or non-Hodgkin lymphoma 
(NHL) with the former, characterised by the presence of Reed–Sternberg cells, 
accounting for only 10-14% of all diagnoses2. B-cell non-Hodgkin lymphoma (B-NHL) 
represents the most common subtype of NHL in childhood and adolescence, accounting 
for up to 60% of all newly diagnosed lymphomas3,4. In contrast to adults, NHL in children 
and adolescents are almost exclusively highly aggressive. Most paediatric B-NHLs (pB-
NHL) are Burkitt lymphoma/leukaemia (BL/B-AL) and diffuse large B-cell lymphoma 
(DLBCL), whereas only a small percentage are represented by primary mediastinal large 
B-cell lymphoma (PMLBL), follicular lymphoma (FL), nodal marginal zone lymphoma and 
intermediate lymphoma5. BL alone accounts for almost two-thirds of B-NHL in children 
and adolescents but the incidence varies with age as outlined in Figure 1.16. BL is the 
predominant form of NHL in 0-14 year old children but in the 15-19 adolescent age 
category DLBCL becomes more prominent. This age-related reduction in BL incidence 
continues in adulthood with only approximately 5% of NHL diagnosed as BL above the 
age of 20. DLBCL is one of the most common forms of NHL in adults accounting for 30% 















Figure 1.1. Incidence of non-Hodgkin lymphoma subtypes in (A) 0-14 years age group, 
(B) 15-19 years age group, and (C) 20 years and older age group.6 
1.2 B cell lymphomagenesis 
A detailed understanding of the development processes involved in healthy B cells has 
been paramount in elucidating potential stages when oncogenic perturbations may 
occur. The end result of B cell development is the generation of a large pool of cells with 
a broad range of antigen recognition, capable of producing antigen-specific 
immunoglobulins (Ig)7. The processes involved in producing high affinity B cells include 
V(D)J recombination, somatic hypermutation (SHM) and class switch recombination 
(CSR). The involvement of these mechanisms in B cell lymphomagenesis is evidenced by 
the fact that approximately 95% of lymphomas are derived from B cells despite there 
being a similar proportion of T and B cells in the human body8,9. B cell development 
begins in the bone marrow with the rearrangement of the heavy and light chain genes 
in the process of V(D)J recombination to produce a B cell receptor (BCR) on a committed 
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B cell. The cells pass several selection processes and checkpoints before entering the 
blood as mature, naïve B cells7,10,11. Naïve B cells then accumulate in secondary lymphoid 
organs where antigen-dependent development initiates and further risk of DNA damage 
and translocation emerge. Following antigen engagement, mature B cells become 
activated and enter T cell rich areas of the lymphoid organs to generate germinal centres 
(GCs). Here, the cells undergo clonal expansion as well as the processes of SHM and CSR 
which take place in the dark and light zones, respectively, and result in further 
remodelling of the Ig loci12. SHM increases antigen affinity while B cells undergo CSR to 
produce alternative isotypes of antibody by rearrangement of the constant region of the 
Ig heavy chain. Cells in the light zone are also subject to selection based on affinity of 
their BCR and will either progress into plasma or memory cells, or alternatively be 
returned to the dark zone for further specification of Ig genes13. A key regulator of the 
CSR and SHM processes is the enzyme activation induced cytidine deaminase (AID) 
which has been implicated in lymphomagenesis. Its activity is not specific to the Ig locus 
and hence there is a risk of mutations occurring in oncogenes as well as DNA strand 
breaks resulting in instability and translocations14. 
Studies have highlighted that the status of the Ig genetic regions within lymphoma cells 
can pinpoint their origin to a specific stage of B cell development. A large number of B 
cell lymphomas appear to be GC educated, evidenced by the presence of hypermutated 
V-regions in their Ig loci15. Subtypes can be further assigned to specific compartments 
within the GC owing to their tendency to adopt the gene expression program of their 
normal GC B cell counterparts16,17,18,19. Indeed, the maintenance of some components 
of normal B cell physiology is likely to be important for survival of B-cell lymphomas and 
translocations predominantly occur in the non-productively rearranged Ig locus, rather 
than the allele that produces the productive Ig heavy chain that is required to construct 




1.3 Burkitt Lymphoma 
BL is composed of monomorphic, intermediate-sized lymphocytes with a GC B cell 
immunophenotype. Cells are positive for the pan-B-cell antigens CD20, CD79a and PAX5 
as well as GC antigens CD10 and BCL6, but are negative for the anti-apoptotic protein 
BCL2. BL is the most aggressive tumour known with a turn-over rate of approximately 
24 hours21. It was first discovered by Irish surgeon Denis Burkitt when he described 38 
cases of “sarcomas” involving the jaws of African children at Mulago Hospital in Kampala 
Uganda, providing the first clinical description of BL22. BL has played a fundamental role 
in our understanding of tumourigenesis over the years. In collaboration with Burkitt, 
virologists Epstein and Barr documented the first case of a tumour-associated virus 
when they extracted viral particles of the Epstein Barr virus (EBV) from a sample of 
endemic BL in 196423. BL was also pivotal in elucidating the role of MYC in cancer and 
led to the discovery of the first oncogenic chromosomal translocation24–26.  
1.3.1 Epidemiology and aetiology of BL 
There are three distinct subtypes of BL – sporadic BL (sBL), endemic BL (eBL) and 
immunodeficiency associated BL. Although they display unique geographical patterns 
and have slightly different clinical features, they have common morphology and 
immunophenotype, and genetic profiling highlights few differences between the 
entities27–30. 
- Endemic BL 
After discovering BL, Burkitt mapped the incidence across sub-Saharan Africa and 
noticed a trend whereby prevalence of BL and endemic malarial infection overlapped. 
Further studies also elucidated that the incidence of BL correlated with the intensity of 
malarial infection and not just geographical distribution31,32. Despite strong evidence for 
its potential causative role in BL, the exact role of malaria in tumourigenesis has not 
been established. The ability of malaria to drive chronic B cell activation has been 
proposed as one possible mechanism as this may predispose B cells to the acquisition of 
IG/MYC translocations33. A second potential mechanism involves EBV and proposes that 
exposure to malarial antigens during multiple episodes of infection could reactivate EBV 
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in memory B cells where it had been latent, thereby increasing viral load and the number 
of EBV-infected cells34,35. Like malaria, the role of EBV in eBL is also elusive, despite being 
present in over 95% of cases36,37. Indeed because it is present in only a minority of sBL 
cases it cannot be deemed necessary for pathogenesis. EBV induces the proliferation of 
resting human B cells, leading to the expression of a variety of EBV-encoded latency 
proteins, many of which modulate key regulatory pathways such as Phosphoinositide 3-
kinase (PI3K) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB)38. The current understanding therefore, is a ‘hit-and-run’ role for EBV in 
carcinogenesis. By inhibiting the apoptosis of premalignant tumour cells, EBV facilitates 
the occurrence of transforming events following which the majority of its latency 
proteins are no longer required39. 
- Sporadic BL 
Soon after the clinical description of BL was established in Africa, pathologists in Europe 
and the USA described lymphomas that were histologically identical to the African 
entity. It was therefore realised that this disease was not exclusive to Africa, although 
the incidence there is markedly higher. The most significant difference between the two 
forms is that EBV is only associated with around 20% of non-endemic forms39. The 
unknown aetiology of the malignancy led to the name ‘sporadic’ BL. Other interesting 
clinical characteristics of sBL are that it appears to have a bimodal age-related incidence 
in males with a peak in childhood and again at above 60 years of age. sBL is also 
predominantly a male disease with one study of 80 paediatric patients having 89% males 
and a second study of 67 patients giving a slightly lower male dominance at 67%40,41.  BL 
is considered to be GC-derived, although the origin of the c-MYC translocation has not 
been fully elucidated in BL and is suggested to be different in sBL and eBL. The 
translocation present in eBL seems to be acquired due to aberrant SHM in early GC-
phases whereas the translocation mechanism in sBL is thought to be faulty CSR in the 




- Immunodeficiency-related BL 
Human immunodeficiency virus (HIV) patients were observed to be predisposed to NHL, 
with BL accounting for 10-40% of cases42. This led to the inclusion of a third BL variant 
in the WHO classification of haematological malignancies known as immunodeficiency-
related BL. Although an increased risk of BL exists in other immunocompromised 
patients, it is not as great as in HIV-infected individuals43. Approximately 30-40% of 
immunodeficiency-related BL cases are associated with EBV, and immunosuppression is 
believed to contribute to its genesis by conferring an increased EBV load and 
deregulating immune mechanisms44–46.  
1.3.2 Molecular background to BL 
1.3.2.1 C-MYC translocation 
All forms of BL are invariably associated with chromosomal translocations that 
dysregulate the expression of c-MYC, a gene encoding a basic helix-loop-helix 
transcription factor that binds to DNA in a sequence-specific fashion. MYC is a global 
transcription factor that normally plays a central role in the transcriptional regulation of 
an emerging set of downstream genes that control diverse cellular processes. It is 
estimated to govern approximately 10-15 % of genes in the genome, influencing several 
aspects of survival and proliferation of cells including cell cycle progression, 
differentiation, metabolism and apoptosis26,47. The chromosomal translocations 
characteristic of BL always result in the juxtaposition of the DNA coding sequences for 
c-MYC with sequences from Ig gene enhancers. Ig enhancer elements bind to B cell–
specific factors capable of activating transcription from genes located up to 500,000 
base pairs away. Due to the fact that Ig enhancer elements are specifically active in 
mature B cells, their juxtaposition to c-MYC in BL cells drives inappropriately high levels 
of c-MYC mRNA and protein expression48,49. In 80% of cases of BL, the translocation 
partner for c-MYC is the IgH locus, resulting in the formation of a t(8;14)(q24;q32) 
aberrant chromosome. These translocations typically occur on the background of a 
simple karyotype lacking additional rearrangements39. The remaining 20% of BL have 
alternative variants of MYC translocations, with the MYC gene partnered with the κ locus 
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on chromosome 2 giving the t(2;8) or the light chain locus on chromosome 22 leading 
to the t(8;22) translocation47.  
1.3.2.2 Other genetic features of BL 
The detection of the t(8;14) translocation in blood cells of healthy individuals 
highlights that this translocation alone is not sufficient for lymphomagensis50. This 
was further supported by the first mouse model of BL.  This model of deregulated 
MYC mimicked the t(8;14) chromosomal translocation by bringing the MYC gene 
under the control of the Ig heavy-chain intronic enhancer (Eμ)51. However, these 
Eμ/MYC transgenic mice are not faithful models for human BL as the tumours that 
develop more closely resemble pre-B or naïve B cells, not GC B cells. 
Independent studies by Love et al., Richter et al., and Schmitz et al. using high 
throughput sequencing approaches provided an overview of the genomic landscape of 
BL and gave greater insights to the molecular basis of BL16,17,52. The most common 
mutation in BL is in MYC itself, present in 70% of cases and often affecting its 
transactivating domain. As deregulated MYC is already present due to the translocation 
these mutations often involve the uncoupling of the pro-proliferative mechanisms of 
MYC from its ability to induce apoptosis by impairing transactivation of the pro-
apoptotic protein BIM53. TP53 mutations are reported in up to 35% of BL cases and also 
likely function to counterbalance the pro-apoptotic effects of MYC while identified 
GNA13 mutations may be involved in GC B cell migration54,55. Novel mutations in the 
Inhibitor of DNA binding 3 (ID3) gene were reported in all three studies but shown to 
vary in incidence between 34% (Love et al.), 58% (Schmitz et al.) and 68% (Richter et al.) 
ID3 inhibits the transcription factor TCF3 and Schmitz et al. showed that TCF3 itself is 
also frequently mutated in BL. Either inactivating mutations in ID3 or activating 
mutations in TCF3 result in increased expression of downstream targets of TCF3 leading 
to increased cell proliferation and survival via PI3K16,17,52. Interestingly, Cyclin D3 
(CCND3), a direct target of TCF3, was also found to have mutations in 38% of cases 
reported by Richter et al16. Due to the discrepancy in mutation rates in these studies 
Rohde et al. undertook a study of 84 uniformly diagnosed paediatric patients and 
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determined a mutation frequency of 78% (ID3), 13% (TCF3) and 36% (CCND3) with a 
total of 88% of patients having a mutation in at least one of these genes56. Taken 
together mutations in this important axis may provide the vital cooperating mutations 









Figure 1.2. The ID3-TCF3-CCND3 oncogenic pathway in BL.56 
1.3.3 Signalling Pathways in BL 
The urgent need to develop less toxic therapies as well as more targeted strategies to 
overcome chemo-resistant disease requires a detailed understanding of oncogenic 
signalling pathways in pBL. A study by Kuppers et al. in 2005 provided the first insights 
into the potentially important role of BCR signalling in BL15. They showed the MYC 
translocation in BL occurs only to the non-productively rearranged Ig heavy-chain locus, 
and not the allele that produces the productive Ig heavy chain that is required to 
construct the BCR. This suggests that BL may rely on BCR signalling for survival. BCR 
signalling takes two forms – tonic BCR signalling which activates PI3K signalling, and 
active BCR signalling which engages multiple pathways including NF-κB in an antigen-
dependent manner57. Unlike other aggressive B cell lymphomas, BL does not show 
strong expression of genes downstream of NF-κB suggesting that this latter method of 




 >88% of BL have a 
mutation in at least 




constitutively active PI3K in conjunction with MYC expression produce tumours 
resembling BL at the histological and gene expression level further implicates this 
signalling pathway in tumourigenesis59. Interestingly, tertiary mutations acquired in 
these murine tumours include those in CCND3 which also occurs in human BL, 
highlighting the validity of this model. 
Evidence of the preferential role of tonic BCR signalling in BL is provided by studies 
conducted with cell lines. In 67% of cases, knockdown of BCR subunits or the BCR-
associated tyrosine kinase SYK, resulted in decreased PI3K activity inducing apoptosis, 
whereas inhibition of NF-κB had no impact on cell viability17. The importance of the 
TCF3-ID3 axis in PI3K signalling is also explained by the presence of TCF3 at the Ig heavy-
chain 3ʹ enhancer, up-regulating expression of the Ig heavy and light chains and 
increasing expression of the BCR on the cell surface17. Further mechanisms involved in 
augmenting PI3K signalling in BL include the presence of PTEN inactivating mutations in 
approximately 7% of cases39. The induction of expression of the mir-17-92 cluster by 
MYC also reduces expression of PTEN via Mir-19a and mir-19b60,61. This evidence, 
together with the knowledge that gene expression signatures of PI3K activity are more 
highly expressed in human BL biopsies than in other lymphoma subtypes, strongly 
supports the important role of PI3K signalling in BL17,59. 
A recent study in pBL identified potential new pathways involved in lymphomagenesis; 
Lee et al. analysed the comparative genomic signature and targetable signalling 
pathways in pBL samples from the Children’s Oncology Group (COG) ANHL01P1 study 
by genomic profiling and compared the results to pBL samples from public databases62. 
This study led to some interesting insights – data from three completely independent 
databases identified significant overexpression of genes involved in Toll-like receptor 
(TLR), Janus kinase/signal transducers and activators of transcription (JAK-STAT) and 
mitogen-activated protein kinase (MAPK) signalling. Several of the genes identified in 
these pathways offer attractive therapeutic targets and warrant further investigation. 
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1.3.4 Prognostic indicators in BL 
Currently, very few genetic prognostic indicators have been determined in pBL and 
staging is based on factors such as bone marrow and CNS involvement as well as lactate 
dehydrogenase levels. Paediatric B-NHL is curable in up to 90% of cases, yet those 
patients who relapse have only a 20-30% chance of survival63. For this reason, it is 
imperative that prognostic indicators are identified to better stratify patients and direct 
the course of therapy. Early studies using conventional cytogenetics and fluorescent in 
situ hybridisation (FISH) identified recurrent genetic abnormalities in BL, including gain 
of 1q and 13q and loss of 17p, and found that 13q abnormalities are associated with a 
worse prognosis64,65. Using more advanced techniques, studies validated the 
significance of the 1q and 17p abnormalities although these studies were not specific to 
pBL66–68. A more recent study utilised a genome-wide, high-resolution molecular 
inversion probe SNP assay to identify copy number gain alterations in DNA isolated from 
FFPE pBL diagnostic biopsy tissues69. Amplification of 13q, 7q gains and copy-neutral loss 
of heterozygosity of 5q were identified as being more common in pBL and although the 
sample size limited statistical power, patients with a 13q31 gain were more likely to 
relapse over a minimum follow-up period of 6.5 months. This region of chromosome 13 
includes 3 genes and 8 miRNAs: GPC5, GPC6, LINC00410, MIR622, and the MIR17HG 
gene encoding the MIR17-92 cassette of 7 miRNAs. The MIR17HG cluster on 
chromosome 13 is oncogenic and has been shown to accelerate lymphoma 
development in a mouse model and increase tumourigenicity in cooperation with 
MYC70,71. MIR17HG has been established as a MYC transactivation target in a B cell line 
model and its expression correlates positively with MYC expression in colorectal 
tumours72,73. Recently it was shown to regulate expression of genes involved in breast 
cancer development and progression74. Interestingly, in this study Schiffman et al. also 
identified a strong correlation between 13q31 gain and loss of 17p13 which includes the 
TP53 locus69. MIR17HG induces anti-apoptotic effects via PTEN and E2F1 and it is 
possible that this could synergise with loss of TP53 to confer a strong proliferative 
program and result in a subset with an increased aggressive phenotype75.  
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1.4 DLBCL  
The DLBCLs are mature B-cell neoplasms characterized by expression of surface Ig and 
B cell–associated surface markers (CD19, CD20, CD22, and CD79a)76. According to gene 
expression profiling (GEP) classification, 2 main molecular subgroups exist with differing 
cells of origin and clinical outcome - Germinal centre B-cell (GCB) and activated B-cell 
(ABC) DLBCL77. It is important to note that the GCB subtype is molecularly more similar 
to BL and accounts for the vast majority of paediatric cases (age 0-9 years 95% GCB, 10-
19 years 80% GCB, adults 42% GCB)78,79. GCB DLBCL has also been consistently 
associated with improved outcomes over non-GCB disease78,80. Common oncogenic 
signatures in both subtypes include genetic aberrations in genes that overcome BCL6 
regulation such as B2M, as well as lesions in chromatin modifiers affecting epigenetic 
regulation (CREBBP, EP300, MLL2)13,81. Frequent mutations in the ABC subtype include 
those in MYD88, KLHL14, CD79B and SIGLEC10 which result in cell survival via chronic 
BCR signalling and activates NF-κB while GC-DLBCL is associated with mutations in 
GNA13, BCL2 and EZH282,83. A t(14;18)(q32;q21) translocation of BCL2 is present in 35% 
of adult but is uncommon in paediatric cases84. Similar to BL, PI3K has been implicated 
in GC-DLBCL with deletion of PTEN found in 11% of cases while amplification of miR-17-
92 is seen in approximately 13% of cases81,85. IRF4 oncogene rearrangements, which 
have been identified in a small subset of B-NHLs with a distinct immunophenotype from 
the GCB and ABC subtypes of DLBCL, occur more commonly in those younger than 18 
years of age86. GEP analysis by Dave et al. compared BL and DLBCL and established a 
reliable method to distinguish the two entities at the molecular level58; MYC and its 
target genes as well as a subgroup of GC B cell genes were more highly expressed in BL. 
DLBCL on the other hand, display higher expression of (major histocompatibility 
complex) MHC class 1 genes and NF-κB  target genes. DLBCL cases were also effectively 
grouped into the ABC and GCB subtypes58. This research was carried out in adult case 
studies although paediatric cases produced similar findings. Klapper et al. reassigned 
diagnoses according to molecular signatures and compared results to the original 
morphological diagnosis in paediatric cases87. Morphological diagnoses of BL were 
confirmed by molecular methods but 31% of DLBCL cases were re-classified as BL 
following molecular analysis. Many of the re-classified cases had interesting features 
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which may have initially excluded them from a BL diagnosis, such as BCL2 expression or 
a below average ki67 index. Between 5 and 10% of paediatric DLBCL cases can carry a 
MYC translocation which can further complicate diagnosis88. 
1.5 Current treatment regimens for paediatric B-NHL 
1.5.1 Chemotherapeutic backbone 
The past three decades have seen a dramatic increase in survival for pB-NHL and event 
free survival (EFS) rates have almost doubled from the late 1970s to the present era21. 
Consecutive prospective trials, such as the French Society of Pediatric Oncology and 
French-American-British/Lymphomes Malins de Burkitt (FAB/LMB), and the oligo-
national Berlin-Frankfurt-Munster (BFM) studies have resulted in significant treatment 
improvements. These focused on risk-stratification to minimise acute and long-term 
toxicity for patients with a favourable prognosis and to intensify treatment for high risk 
patients89,90.   
The FAB/LMB backbone chemotherapy protocols currently used in the UK are based 
upon three risk stratification groups (Figure 1.3). Group A, low risk patients, are treated 
with two cycles of cyclophosphamide, vincristine, prednisone and doxorubicin (COPAD) 
following resection. This yields excellent outcomes, with a 98.3% 4-year EFS91. 
Intermediate-risk patients in group B receive backbone chemotherapy consisting of low-
dose cyclophosphamide, vincristine, and prednisone (COP) followed by two induction 
cycles (COPAD plus methotrexate) and two consolidation cycles (cytarabine plus 
methotrexate), each with intrathecal chemotherapy given throughout, resulting in an 
EFS rate of 91%90. The highest risk patients in group C, achieve 79% EFS with the 
FAB/LMB backbone, strengthened by the addition of high-dose methotrexate during 
induction and cytarabine plus etoposide for two cycles of intensification followed by 
four cycles of maintenance chemotherapy89. 
The BFM chemotherapy backbone is similar to the FAB/LMB regimen, with the main 
difference being the stratification of patients into four groups and the incorporation of 
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Figure 1.3. Risk stratification groups for paediatric B-NHL92 
 
  





Table 1.1. Comparison of chemotherapeutic regimens and doses between FAB and 
BFM treatment protocols for pB-NHL.93 
1.5.2 Introduction of Rituximab to paediatric B-NHL treatment 
In order to try to improve upon the survival rates in pB-NHL and to reduce relapse, the 
anti-CD20 antibody Rituximab was evaluated in combination with chemotherapy in the 
Inter-B-NHL Ritux clinical trial. The rationale for this study was the success of combining 
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Rituximab with multi-agent chemotherapy in adult DLBCL and BL, as well as some 
anecdotal evidence of efficacy in paediatric cases94–101. 
The FAB/LMB chemotherapy back bone strategy was chosen for this study with some 
minor modifications. Rituximab was included at the start of treatment with two 
administrations at 48 hour intervals at the beginning of the two first courses of 
chemotherapy, and one administration at the beginning of the two following courses of 
chemotherapy. An interim analysis highlighted exceptional response in the Rituximab 
arm with a 1-year EFS rate of 94.2% in the Rituximab arm and 81.5% in the control 
arm102. Randomisation was halted and the trial completed with all enrolled patients 
receiving Rituximab. 
1.6 Relapsed and refractory paediatric B-NHL 
Despite significant improvements in overall curative rate brought about by the BFM and 
FAB/LMB trials as well as the success of Rituximab, relapse and refractory disease still 
occur. This is the greatest challenge in the current era of pB-NHL and salvage of these 
patients has remained extremely difficult. Several studies have put the overall survival 
(OS) probability in relapsed and refractory disease at less than 30%21,89.  Rituximab has 
proven effective at reducing the probability of relapse, although, it is not yet known 
whether it will be effective at salvaging those cases that do relapse. One Japanese study 
showed improvement in prognosis of relapse or refractory pB-NHL in the Rituximab era 
but this has not yet been reported in other studies103.  
Based on the dismal salvage rates for patients who experience relapse or refractory 
disease, the urgent requirement for improved targeted therapies is obvious. In addition, 
the significant acute and long-term toxicities associated particularly with the intensity 
of group C FAB/LMB chemotherapy, must be considered. Ideally, targeted therapies 
would be effective in the treatment of relapsed and refractory cases, but might also be 
combined with reduced chemotherapy enabling dose de-escalation in upfront 
treatment of low risk patients. Due to both the rarity of occurrence and often the lack 
of biopsies taken of relapsed disease, few studies have been carried out on relapsed and 
refractory pB-NHL. For this reason, beyond the potential prognostic indictors mentioned 
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earlier, little is known about the cause of resistance and it is imperative that this 
becomes the focus of studies if we are to further improve the treatment of this disease. 
Studies in adult B-NHL are paving the way for potential new treatments including 
humoral and cellular immunotherapies targeting CD20 and CD19104–107. Targeted 
therapies that interfere with the signalling pathways driving lymphomagenesis are also 
likely an important area of novel therapeutics.  The  BTK inhibitor Ibrutinib has shown 
extraordinary potential in adults with chronic lymphocytic leukaemia (CLL), mantle cell 
lymphoma (MCL), and DLBCL108–111 and a trial comparing the efficacy of Ibrutinib to 
Rituximab in paediatric and young adult participants with relapsed or refractory mature 
B-NHL is underway. The PI3K inhibitor Idelalisib has shown an objective response in 
phase II data evaluating adults with relapsed indolent mature B-NHL, as well as 
significantly improved outcomes in combination with Rituximab in adults with relapsed 
CLL112. Interestingly a phase 1b trial has recently opened investigating Idelalisib in 
combination with Rituximab and chemotherapy in children and adolescents with 
relapsed or refractory DLBCL or mediastinal B-cell lymphoma.  
Overall, potential for novel therapies exists, however we must endeavour to gain a 
better understanding of pB-NHL biology, particularly in relapse, in order to identify 







1.7 Mechanisms of action and resistance to current therapeutics in paediatric B-
NHL 
1.7.1 Chemotherapeutic agents 
The main chemotherapeutics common to both the FAB/LMB and BFM regimens and 
utilised during the induction stages of treatment are cyclophosphamide, vincristine, 
prednisone, doxorubicin and methotrexate. Each of these chemotherapeutic agents 
have diverse mechanisms of action leading to cell death.  
Doxorubicin is an anthracycline and two alternative mechanism of actions have been 
proposed113: The first involves intercalation of the agent into DNA and disruption of 
topoisomerase II-mediated DNA repair resulting in DNA damage and cell death114. The 
main methods of resistance to doxorubicin identified involve increased expression of 
TOP2A, often by amplification, as well as enhanced drug efflux mediated by a number 
of ATP-binding cassette (ABC) drug transporters including ABCB1 and ABCC1 as well as 
ABCC2, ABCC3, ABCG2 and RALBP1115–118. The second mechanism of action of 
doxorubicin involves the generation of free radicals and subsequent damage to cellular 
membranes, DNA and proteins119. Doxorubicin is oxidized to semiquinone, an unstable 
metabolite, which is converted back to doxorubicin in a process that releases reactive 
oxygen species and triggers apoptotic pathways of cell death120. A host of emerging 
resistance mechanisms to doxorubicin have been reported in the literature. In T-ALL, 
α2β1 integrin was shown to promote chemoresistance to doxorubicin in cancer cells 
through MAPK/ERK signalling while in BL cell line studies, increased activation of 
PI3K/AKT was shown to mediate resistance to this drug121,122. 
Methotrexate, an antifolate, is a potent inhibitor of dihydrofolate reductase, the rate-
limiting enzyme in the production of tetrahydrofolate. By decreasing the production of 
purines and pyrimidines, which are critical to de novo synthesis of DNA in mammalian 
cells, methotrexate is highly effective at halting cell proliferation and turnover123. A 
number of resistance mechanisms have been elucidated for methotrexate involving 
impaired cellular influx or increased efflux, increased expression, mutation of cellular 
targets, or intra-cellular accumulation of tetrahydrofolate cofactors. In methotrexate-
resistant cell line models, both mutations of the Reduced Folate Carrier gene and 
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overexpression of the protein have been reported, and a deactivating mutation in this 
gene is associated with a worse clinical outcome in children with acute lymphoblastic 
leukaemia (ALL) receiving methotrexate124–126. Efflux mechanisms have also been 
implicated in resistance to antifolates including ABCB1, ABCG2 and ABCC 1-4 while 
amplification of the DHFR gene itself was reported in ALL and ovarian cancer, but the 
clinical relevance was not fully elucidated127–133. 
Vincristine is a member of the vinca alkaloids which inhibit the assembly of microtubules 
by binding to tubulin.  This results in dissolution of the mitotic spindle necessary for 
mitosis, inducing apoptosis via loss of BCL2 function together with elevation of p53 and 
cyclin-dependent kinase inhibitor 1A expression134.  Like methotrexate and doxorubicin, 
vincristine is a substrate for ABC transporters and ABCB1, ABCC1-3, ABCC10 and RALBP1 
have been reported in association with vincristine resistance135–137. More recent studies 
have also begun to highlight the potential role of targetable pathways in mediating 
vincristine resistance. In ALL, resistance to vincristine was shown to be mediated by the 
PI3K-Akt pathway while MAPK signalling increased resistance to vincristine in gastric 
cancer cells by regulating ABCG2138,139.  
Cyclophosphamide is the precursor of an alkylating nitrogen mustard 
antineoplastic used across a wide range of tumour types in childhood cancer. In order 
for cyclophosphamide to exert its antitumor activity, the prodrug requires metabolic 
activation by hepatic cytochrome P-450 enzymes to generate active alkylating 
species140. Alkylating agents have three main mechanisms of DNA damage; 1. Alkyl 
groups attach to DNA bases, resulting in DNA being fragmented by repair enzymes and 
preventing DNA synthesis and RNA transcription at the affected site. 2. They produce 
DNA damage by the formation of cross-links which prevents DNA from being separated 
for synthesis or transcription, and 3. They induce mispairing of the nucleotides leading 
to mutations141. Interpatient variability in the pharmacokinetics of this drug is thought 
to have a significant impact on efficacy of cyclophosphamide while several methods of 
resistance to alkylating agents have also been reported involving the DNA repair enzyme 
MGMT, the MMR pathway and de-regulation of apoptosis genes including TP53 and 
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BCL2142,143. The role of ABC transporter efflux in response to cyclophosphamide is less 
clear but it has been reported to be a substrate of ABCB1144. 
1.7.1.1 Multi Drug Resistance  
The evidence of ABC transporter involvement in mediating resistance to each of these 
chemotherapeutic agents suggests that they may be important in multi drug resistance 
in pB-NHL, although their clinical relevance remains ambiguous. P-glycoprotein, also 
called MDR1, is encoded by the ABCB1 gene and was the first identified drug efflux 
transporter over 40 years ago145. Several years later, multidrug resistance-associated 
protein 1 (MRP1), encoded for by the ABCC1 gene was identified and shown in cell line 
models to mediate resistance to doxorubicin, etoposide and vincristine among 
others146. Three independent groups then identified breast cancer resistance protein, 
BCRP1, encoded by ABCG2, and interest in this area increased147–149.  First-generation 
inhibitors, focusing on MDR1, including verapamil, quinidine, amiodarone and 
cyclosporine A, were identified and added to chemotherapy regimens in clinical 
trials150. However, these agents lacked potency and had high toxicity with little 
evidence of inhibition of MDR1 in patients151. Second generation inhibitors also had 
poor success152. Third generation inhibitors were more potent with fewer 
pharmacokinetic interactions although toxicity linked to inhibition of MDR1 in normal 
tissues was reported153. Some third generation inhibitors showed cross reactivity with 
MRP1 and/or ABCG2 and in Acute Myeloid Leukaemia (AML) combination of 
cyclosporine A with chemotherapy led to increased response in one study154. 
However, despite a few successes the majority of clinical trials did not confirm clinical 
benefit and interest in the area waned153. Several decades after their initial discovery 
and with the emergence of new data and advanced techniques, it has been proposed 
that these transporters may be worth re-evaluating clinically. Recently, attention has 
been paid to the use of drug delivery systems, such as nanoparticles, primarily to restrict 
ABC transporter inhibition to tumour cells and reduce the non-selective inhibition in 
non-target organs155. Furthermore, identification of pathways and oncogenic kinases 
in regulating ABC transporter activity also offers  promising potential for targeting 
these efflux pumps. 
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1.7.2 Rituximab 
Unlike traditional chemotherapeutic agents which target all dividing cells, Rituximab is 
an anti-CD20 monoclonal antibody. The CD20 receptor appears on B cells during the pre-
B-cell stage and is not expressed in other tissues, making Rituximab a targeted therapy 
and the first antibody-based treatment for cancer which received FDA approval156. A 
number of mechanisms of action for Rituximab have been confirmed including 
complement mediated cytotoxicity (CMC), antibody dependent cellular cytotoxicity 
(ADCC), cell cycle arrest and direct apoptosis induction.  
CMC  
The role of rituximab in CMC has been documented in several in vitro and clinical studies. 
In cell lines, the extent of in vitro lysis correlates with expression of complement 
inhibitory molecules (CD55 and CD59) on malignant B cells. In particular, CLL cells with 
greater expression of CD59 are resistant to CMC mediated by rituximab157,158. 
Furthermore, FL is clinically more sensitive to rituximab and these cells are more 
effectively lysed by complement in vitro, compared to large cell lymphoma or mantle 
cell lymphoma cells159. In animal models the importance of complement in anti-tumour 
activity was highlighted by depletion of complement effectors in animal models, 
diminishing the therapeutic response to Rituximab159. 
ADCC 
Rituximab can induce ADCC which is mediated by several effector cells including NK cells, 
granulocytes and macrophages160,161. In this process the Fc region of Rituximab, which 
is bound to its target cell, binds to the Fcγ receptor on the effector cells initiating 
immune cell activation and death of target cell162.  In vitro, rituximab was shown to 
induce ADCC of human lymphoma cell lines by human peripheral blood mononuclear 
cells (PBMCs)163. Studies of Rituximab have focused on its interaction with CD16 on NK 
cells although other Fc receptors likely involved include CD32, CD64 and CD89164–166. The 
strongest data linking ADCC to the clinical response of Rituximab comes from studies 
correlating  polymorphisms of CD16 to clinical response to single agent Rituximab. CD16 
homozygous for valine at position 158 has greater affinity for IgG1, and patients with FL 
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who have a VV genotype have a better clinical response to Rituximab than patients that 
have a VF or FF genotype167–169. 
Direct induction of apoptosis 
Interestingly, Rituximab has also been shown to have significant non-immune related 
functions and has been shown to induce apoptosis via inhibition of several important 
signalling cascades. Studies have identified the p38 MAPK pathway as a potential target 
of Rituximab; Experiments in an AIDS related DLBCL cell line showed Rituximab 
selectively disrupted the IL-10 autocrine/paracrine loop via p38 MAPK signalling 
resulting in downregulation of IL-10, STAT3 and BCL2170.  Other pathways that have been 
identified in modulating Rituximab induction of cell death include the Raf/MEK/ERK, NF-
κB and the Akt signalling pathways. In BL cell lines, Rituximab selectively inhibited BCL-
xL expression, leading to chemosensitization171. The molecular mechanism involved was 
identified as inhibition of the Raf1-MEK1/2-ERK1/2-AP-1 signalling pathway by 
Rituximab. As BCL-xL expression is under the transcriptional regulation of AP-1 it was 
consequently downregulated.  Because NF-κB also regulates BCL-xL, the effect of 
Rituximab on this pathway was investigated in BL cell lines172. Decreased 
phosphorylation of NF-κB–inducing kinase (NIK), IκB kinase (IKK), and IκB-α was 
observed along with BCL-xL downregulation170.  Finally it has also been reported that 
Rituximab inhibits the PI3K/Akt pathway in Ramos cells through inhibition of phospho- 
PI3K, PDK-1 and Akt. This inhibition was also shown to have downstream effects 
including inhibition of the NF-κB pathway and suppression of BCL-xL expression170.  
1.7.2.1 Resistance to Rituximab 
Mechanisms of resistance to Rituximab in vivo remain poorly understood, although 
studies have reported several potential contributors include polymorphisms of the Fc 
receptor on cytotoxic cells, inhibition of CDC, downregulation or loss of CD20 expression 
on the surface of sub-clones, overexpression of anti-apoptotic proteins (e.g. BCL2), 
shedding of CD20-Rituximab complexes and failure to respond to Rituximab-mediated 
cell signaling145,173–176. Independent studies involving induction of acquired resistance to 
Rituximab in vitro showed that it is not associated with genetic changes in the CD20 
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molecule but both global gene and protein down-regulation of CD20 were noted176–178. 
In line with the preliminary evidence that several pathways may mediate the apoptotic 
effects of Rituximab, Bonavida et al. showed in their Rituximab-resistant clones that 
Rituximab failed to inhibit the p38 MAPK, ERK1/2, and NF-κB signalling pathways170,176. 
In addition, these resistant clones showed hyperactivation of these pathways, with 
overexpression of BCL2 and BCL-xL. Interestingly the cells also showed cross-resistance 
to other chemotherapeutics and inhibition of each of these pathways re-sensitized the 
resistant clones to various chemotherapeutic drugs including vincristine, etoposide and 
doxorubicin179,176. 
1.8 Intra-tumour heterogeneity 
Intra-tumour heterogeneity (ITH) is one of the greatest challenges in cancer treatment 
leading to therapeutic failure, drug resistance and relapse180. ITH provides diverse 
genetic and epigenetic material, with varying levels of fitness, upon which selection and 
Darwinian evolution can act. The concept of genetic diversity within tumours dates back 
as far as 1958 to evolutionary biologist Julian Huxley who commented on “genetic 
inhomogeneity” in cancer181. However technical advancements such as next-generation 
sequencing were not in common use and it took many more years to decipher these 
observations. Early studies focused on the clonal nature of cancer; Evidence from 
Chronic Myeloid Leukaemia (CML) showed that each dividing cell carried the same 
chromosomal aberrations suggesting the malignancy had arisen from a single cell 
carrying this abnormality182. This model implies that a single cell acquires the ‘first hit’, 
in this case the BCR-ABL Philadelphia chromosome, possibly as a result of a random 
event or a carcinogenic insult182,183. The translated product is consistently expressed in 
all CML patients suggesting its causative role. However, evidence emerged that this 
alone was not sufficient for leukaemogenesis with as many as 30-70% of healthy 
individuals carrying the BCR-ABL mRNA transcript in their white blood cells184–186. It 
became obvious that additional mutations were necessary for full transformation and 
this random process gave rise to sub-populations of cells. The concept of sub-clonality 
was realised where cells may share a common clonal characteristic but can also 
individually acquire unique mutations. Even after malignant transformation, a cancer 
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remains dynamic and continues to evolve. This ongoing evolution might ultimately 
generate a molecularly heterogeneous bulk tumour consisting of cancer cells harbouring 
distinct molecular signatures with differential levels of fitness and sensitivity to 
anticancer therapies. This heterogeneity can result from genetic, transcriptomic, 
epigenetic, and/or phenotypic changes180. Numerous studies have highlighted the 
clinical implications of sub-clonal diversity particularly in the era of targeted therapies. 
In particular, work by Gerlinger and Swanton showed through multi-region sequencing 
and phylogenetic reconstruction, that 63 to 69% of all somatic mutations were not 
detectable across every tumour region in metastatic renal cancer, presenting significant 
challenges to personalized medicine strategies that depend on results from single 
tumour-biopsy samples187. 
Beyond the genetic level, phenotypic and functionally heterogenous populations in 
tumours have been well documented188–191. Different methods have been proposed to 
explain heterogeneity among cancer cells. The first model involves intrinsic differences 
caused by stochastic genetic or epigenetic changes192,193. The second model describes 
how cancers follow a stem cell model in which tumourigenic cancer stem cells 





























Figure 1.4. Schematic of the classical Stochastic and Hierarchical Models of tumour 
heterogeneity 
 24 
1.8.1 Sources of intra-tumour heterogeneity 
1.8.1.1 Stochastic model of tumour evolution 
The field of cancer biology has been dominated by the stochastic model of tumour 
evolution. This model hypothesises that each tumour cell has equivalent replicative 
capacity and that mutations conferring a proliferative or survival advantage result in that 
particular cell and its progeny becoming the dominant clone in the tumour192. According 
to this theory almost every cancer cell could reproduce the whole cancer. Nowell 
formulated this hypothesis based on Darwinian principles describing cancer as an 
evolutionary process driven by stepwise somatic cell mutations with sequential 
selection of sub-clones, all of which are derived from a common progenitor. All surviving 
cells in the population have tumourigenic potential and hence a therapeutic regimen 
must target all cell populations in the tumour191,192,194.  
The very essence of multi-cellular and long-lived animals dictates the requirement for 
properties that, if not tightly regulated result in malignancy, for example, cellular self-
renewal and stabilisation of telomeres195. In the majority of cases, the evolutionary 
progression of cancer is halted as highlighted by the high frequency of asymptomatic 
pre-malignant lesions196. Even advanced malignancies demonstrate Gompertzian 
growth indicating that the vast majority of cancer cells either die before they are able 
to divide, or are restricted from dividing by the tumour microenvironment. As is the case 
in natural selection within species, selection in tumours is driven by competition for 
space and resources. Individual clones evolve via the interaction of selectively 
advantageous “driver” lesions, selectively neutral “passenger” lesions and deleterious 
lesions. Further layers of complexity are introduced by “mutator” lesions which increase 
the rate of other genetic changes and by micro-environmental changes which alter the 
fitness effects of those lesions. Furthermore, the rate of epigenetic change is thought to 
be orders of magnitude greater than that of genetic change and is likely to be a major 
contributor to clonal evolution. Natural selection influences epigenetic variation within 
neoplasms because epigenetic changes are inherited at cell division and affect 
phenotype. Evidence to support the clonal evolution model is seen in cytogenic studies 
where all cells in many primary tumours show the same abnormal karyotype, implying 
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unicellular origin and even when several chromosome patterns are present within a 
single tumour, marker chromosomes in each cell often indicate that the various sub-
populations derive from a common progenitor191. Despite the compelling evidence in 
favour of this theory, this model alone fails to sufficiently explain the cellular diversity 
comprising many tumours. As techniques to study functional tumour cell heterogeneity 
have improved, work involving patient-derived xenograft (PDX) tumour models highlight 
that functional tumour cell heterogeneity accompanies the phenotypic diversity 
observed within tumours. This work led to the emergence of the Cancer Stem cell 
paradigm for tumourigenesis in both haematological and solid tumour 
malignancies197,198.  
1.8.1.2 Cancer stem cell model 
The cancer stem cell (CSC) model dictates that tumours are formed of a cellular 
hierarchy demonstrating some similarity to normal tissue, with a self-renewing, 
multipotent cell at the apex of the hierarchy that no longer responds appropriately to 
environmental cues197,199. This distinct set of stem cells undergo a slow, asymmetrical 
division to produce an identical stem cell while simultaneously producing a more 
differentiated progenitor cell. The progenitors then undergo rapid divisions to generate 
the bulk of the tumour194,200. The idea that tumourigenesis may be analogous to 
embryological development goes back to the 1800s, although it was the culmination of 
many years of research and the development of both xenografting techniques and 
Fluorescent Activated Cell Sorting (FACS) that led to the successful characterisation of 
CSCs in AML by Dick and colleagues197,201. Using FACS analysis of a variety of surface 
markers, they determined that not every AML cell was equal and that most significantly 
only rare cells were capable of tumour initiation. They referred to these cells as tumour 
or leukaemia initiation cells (LICs), the operational term for CSCs; AML is organised into 
a hierarchy with CD34+CD38- cells at the apex. AML supports the hierarchical CSC 
hypothesis as it follows three key characteristics202: 
1. Only a minority of cancer cells is endowed with tumourigenic potential when 
transplanted into immunodeficient mice,                   
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2. Tumourigenic cancer cells are characterized by a distinctive profile of surface 
markers and can be differentially and reproducibly isolated from non-
tumourigenic ones by flow cytometry, and  
3. Tumours grown from tumourigenic cells contain mixed populations of both 
tumourigenic and non-tumourigenic cancer cells, thus re-creating the full 
phenotypic heterogeneity of the parent.  
Clarke et al. added further detail to this definition of CSCs by stating that self-renewal 
must be demonstrated by serial passage in a xenograft assay at clonal cell doses and 
that the non-tumourigenic daughter cells produced may possess proliferative capacity 
but are unable to establish or maintain the tumour clone upon serial passage200. The 
term CSC is reserved for cases where a specific surface marker phenotype can be 
assigned to these cells202. If this is not possible, but the cells meet all other 
requirements of this definition, then they are termed TICs. These seminal studies in 
AML laid the ground work for the identification of CSCs in solid tumours 15 years ago 
with CD44+CD24- cells in breast cancer shown to be responsible for sustaining the 
disease in immunodeficient mice198. Despite the fact that a plethora of studies 
followed supporting the CSC hierarchical model of carcinogenesis, the concept is still 
the subject of significant debate and has not been proven or disproven for many 
cancers including lymphomas. In particular, one of the key debated topics in the field 
of lymphoid malignancies is whether a series of gene alterations occurs in a healthy 
haematopoietic stem cell, or alternatively, a highly committed progenitor de-







1.9 Unified model of heterogeneity 
Recent evidence has highlighted that the stochastic and hierarchical models are not 
mutually exclusive and it has been suggested that CSCs may not have to strictly fit the 
hierarchical model204. A more unified or harmonised model was proposed by John Dick 
et al. which centres on the concept of ‘stemness’202. Stemness is defined as the 
functioning of molecular programmes that govern and maintain the stem cell state. 
Rather than CSC being a static well-defined cell type, cancer genetics, epigenetics and 
the microenvironment are coming together to influence stemness. In this reversible, 
cellular plasticity model, the stochastic and CSC model are unified by postulating that 
cancer cells can interconvert between stem cell and differentiated states known as 
directional interconvertibility205. Intrinsic tumour cell processes and/or stimuli within 
the tumour microenvironment could influence differentiated tumour cells to reacquire 
stem cell characteristics206–208. Conversely, these processes could also drive CSCs toward 











Figure 1.5. Three fields of cancer biology converge to influence stemness202 
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1.9.1 Defining stemness 
The term stemness likely evolved as a result of the difficulty of assigning all 
characteristics of the CSC model to a population. In a review of the literature, Kreso and 
Dick consider the stemness state to consist of a variety of functions that enable cells to 
survive therapy regardless of whether the tumour is organised into a rigid hierarchy or 
not202. The determinants of stemness are the core contributors that affect therapy 
failure, irrespective of whether these determinants are present within a transitory state 
or in well-defined CSC populations. Genetics, epigenetics and the microenvironment all 
drive the stemness phenotype and the focus is on the molecular programmes that 
govern and maintain the stem cell state rather than a distinct cell phenotype. Despite 
these explanation considerable disparity still exists in the CSC field202. A recent book by 
Laplane made significant strides in combining all the relevant experimental literature 
— historical and scientific —  as well as interviews with some of the leading 
international stem-cell researchers and clinicians209. She provided a framework of 
four possible versions of 'stemness': two intrinsic, two extrinsic. Stemness can be 
categorical (an intrinsic property of a stem cell, independent of its environment); 
dispositional (an intrinsic property of a stem cell that emerges only in the right 
environment); relational (an extrinsic property induced in a cell that would otherwise 
be a non-stem cell by its microenvironment); or systemic (an extrinsic property of a 
system such as tissue, rather than an individual cell). The requirement for such a 
framework highlights the complexity of this field and the significant work still 
required to both understand and clinically exploit the stemness population within 
different cancers. 
1.9.2 CSCs and plasticity 
Recent studies have provided evidence for the concept of cancer stem cell plasticity in 
which CSC and non-CSCs may not be definitive, but rather have a transitionary capability 
of shifting from a non-CSC state to a CSC state and vice versa210–215. In vitro, a number 
of TICs from cell lines were shown to be non-static as TIC-enriched populations 
generated non-TICs, and most significantly some studies found that sorted non-TIC 
populations could generate TICs199,214,216. In experimental models of melanoma, 
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tumourigenic cells display considerable plasticity, transiently acquiring stemness 
properties depending on the tumour context. In particular, both CD133+ and CD133- 
melanoma cells have the ability to form tumours, suggesting that CD133 is reversibly 
expressed by tumourigenic melanoma cells rather than identifying cells at a static level 
in a hierarchy217. Further evidence of the complexity of TICs was also described in 
melanoma; JARID1B a histone demethylase, was shown to be essential for continuous 
tumour growth of established melanomas and metastatic progression213. JARID1B 
expression was limited to a small sub-population of melanoma cells, but experiments 
showed that the maintenance of this sub-population was dynamic: while purified 
JARID1B-positive cells generated JARID1B-negative cells, single JARID1B-negative cells 
also gave rise to heterogeneous progeny, including JARID1B-positive cells. This study 
indicates that some cells that are essential for tumour maintenance may not be static 
entities, but rather can acquire tumour maintenance capabilities depending on the 
context. This plasticity is driven by environmental cues that induce reprogramming or 
signalling events that drive stemness. For example, in mouse models of intestinal 
tumour initiation, epithelial non-stem cells can re-express stem cell markers upon Wnt 
activation driven by NF-κB, and are capable of ‘‘de-differentiating’’ to TICs218.  A study 
by Weinberg and colleagues further supported the bi-directional nature of the CSC 
model. They showed the existence of sub-populations of non-CSCs that could readily 
switch to an aggressive CSC state211. This plasticity was induced by the transcription 
factor ZEB1 (a well-characterized EMT transcription factor) and microenvironmental 
stimuli could enhance the rate of non-CSC to CSC conversion210. In order to try to 
determine the reprogramming factors that may be responsible for dynamic stemness, 
Suva et al. introduced developmental transcription factors in a step-wise manner into 
differentiated glioblastoma cells. Remarkably, they showed that a combination of 
POU3F2, SOX2, SALL2 and OLIG2 resulted in cells capable of tumour initiation in 100% 
of animals by binding and activating CSC-specific regulatory elements resulting in the 
recapitulation of the epigenetic and phenotypic properties of CSC219. 
These insights and the potential impact of CSC plasticity towards the treatment of 
cancer dictate further study should be carried out across all cancers including 
lymphomas. B cells in particular inherently display extraordinary plasticity. For example, 
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differentiated B cells can be reprogrammed into macrophages whereby introduction of 
CEBPα/β expression inhibited the B-cell identity gene, Pax5220. Furthermore, studies of 
induced pluripotent stem cells (iPS) showed that terminally differentiated B cells could 
be reprogrammed to pluripotency through ectopic expression of Oct4, Sox2, Klf4 and c-
MYC in conjunction with interruption of the B-specific transcriptional program by 
specific knockdown of Pax5 or exogenous expression of CEBPα/β221. These data suggest 
that B cells may be excellent substrates for reprogramming events causing induction of 
the CSC phenotype.  
1.9.3 CSCs and the microenvironment 
Cancers comprise malignant cells together with inflammatory cells, hematopoietic cells, 
associated stroma and vasculature. In line with the evidence of induced plasticity in the 
CSC phenotype, the microenvironment has been identified as playing an important role 
in providing the signals required for inducing stemness and maintaining the balance 
between CSC and non-CSC. The interaction between CSCs and the tumour 
microenvironment (TME) is often bidirectional; CSCs in glioblastoma have been 
demonstrated to secrete VEGF that modifies the microenvironment and directly 
supports the development of the local vasculature222. In the opposite direction 
endothelial cells secrete nitric oxide that induces Notch signalling in glioma cells and 
drives stemness223. In squamous cell carcinomas, CSCs in the vascular niche establish an 
autocrine loop in which VEGF promotes CSC activity by governing both the 
microenvironment and intrinsic self-renewal pathways in CSCs224. Evidence of the direct 
effect of immune cells on CSCs was provided in a study of colorectal cancer; CD4+ T cells 
were shown to produce IL-22 which acted through STAT3 to induce the stem cell 
genes NANOG, SOX2, and POU5F1. This resulted in increased cancer stemness and 
tumourigenic potential225. Other cytokines that have been shown to have an impact on 
cancer cell stemness and plasticity include TNF and IL-6226. In melanoma, breast and lung 
cancer studies these pro-inflammatory mediators impact the differentiation state of 
tumour cells by up-regulating genes involved in EMT and in breast cancer, activation of 
production of IL-6 induces malignant features in NOTCH3–expressing stem/progenitor 
cells227,228. 
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Most studies have focused on the interactions between CSCs and host stromal and 
immune cells, although recent studies have begun to shed light on the communication 
between CSC and non-CSCs. Zhang et al. identified a positive feedback loop between 
CD29highCD24high CSCs in breast cancer and mesenchymal populations derived from 
them229. The non-CSCs produce signalling molecules including Wnt2, Wnt9a, CXCL12, 
and IL-6 - these molecules then promote self-renewal of the CSCs. Since the 
CD29highCD24low mesenchymal cells were derived from the CD29highCD24high CSC 
population, this data highlights that CSCs are able to generate their own niche. Further 
evidence of communication between CSCs and non-CSCs came from a study of DLBCL230. 
Koch et al. isolated a putative CSC populating using the side population assay. They 
demonstrated that CSC and non-CSC populations could transition from CSC to non-CSC 
as well as from non-CSC to CSC and that the conversion of cells states was modulated 
by exosome-mediated Wnt signalling specifically from the CSC population. 
Similar to the discussions on plasticity, the potential for B-cell lymphoma cells to be 
impacted by their microenvironment is significant. GC and memory B cells, the cells of 
origin of most lymphomas, reside in GCs where they interact with stromal cells and 
differentiate into mature cells that possess self-renewal potential that allows rapid 
lymphocyte division and antigen-specific immunity. Interestingly, as well as sharing self-
renewal capabilities with haematopoietic stem cells (HSCs), memory B cells share a 
transcriptional program of self-renewal with long-term HSCs including expression of 
BMI-1, a stemness related gene in numerous cancers231. The renewal and differentiation 
capabilities of GC B cells upon antigen stimulation make secondary lymphoid organs 
ideal environments to confer stemness through stroma-mediated genetic and 
epigenetic mechanisms. The close physical contact and interactions of lymphoma cells 
and stromal cells in the lymph node and bone marrow microenvironment provides an 
appropriate niche for malignant reprogramming to be achieved through stromal-
mediated regulation of genes controlling stemness pathways. Indeed, studies have 
shown that stromal cells can promote stemness in B-NHL cells by influencing B cell 
differentiation and clonogenicity232,233. Furthermore, stromal cells can also modulate 
key stemness genes including c-Myc, EZH2, Oct-4, Nanog and Sox2234,235. 
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1.9.4 Pathways regulating stemness 
In both the classical unidirectional CSC model and the plastic bidirectional CSC model, a 
number of pathways have been identified as driving the stemness phenotype in CSCs. 
This list is constantly growing and current evidence supports roles for the key 
developmental pathways Wnt, Hedgehog and Notch in mediating key stemness 
properties. Other implicated pathways include JAK/STAT, Hedgehog, Wnt, Notch, 










Figure 1.6. Numerous different pathways have been implicated in promoting stemness 
 
1.9.4.1 Wnt signalling 
The Wnt pathway is a vital, evolutionarily conserved pathway in embryonic 
development and tissue homeostasis, in which Wnt ligands signal through β-catenin for 
their biological functions via binding to the seven-transmembrane receptor, Frizzled 
(FZD) and the single-membrane-spanning low-density receptor-related protein 5/6 
(LRP5/6)238. Wnt has been shown to drive stemness in a range of cancers including 
colorectal, breast, hematologic, skin and lung cancers239–243.  In particular, Wnt signalling 
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has been shown to be a key driver of CSCs in colorectal cancer. Abnormal activation of 
Wnt signalling disrupts the normal growth and differentiation of colon crypt stem cells, 
resulting in a colorectal CSC phenotype by upregulating expression of target genes such 
as MYC and cyclin D244,245. In squamous cell carcinoma, Wnt signalling activation was 
shown to be critical in tumourigenesis of CD34+  CSCs, and knock down of the β-catenin 
gene resulted in depletion of CD34+ CSCs and complete regression in mice243. LEF1, a 
component of the Wnt signalling pathway was recently detected at different levels in a 
large portion of DLBCL samples and it was also identified as a signature gene and 
possible therapeutic target in the molecular BL subtype 246,247. 
1.9.4.2 Hedgehog signalling   
The Hedgehog (HH) pathway has also been shown to be important in the maintenance 
of CSCs in an array of cancers including glioblastoma, lung squamous cell carcinoma, 
breast cancer, pancreatic adenocarcinoma, myeloma, and CML248–251. HH signalling 
plays an important role in plasticity and de-differentiation during the EMT process to 
acquire stem cell-like phenotypes, and inhibition of HH signalling by SMO knockdown in 
pancreatic cancer blocks the self-renewal, EMT, invasion, chemoresistance and 
tumourigenesis of CSCs252. HH signalling components have also been shown to drive 
stemness in lymphoid malignancies. In multiple myeloma, SMO and GLI1 were highly 
expressed in the CSC compartment compared to non-CSCs; Activation of HH signalling 
by ligands induced CSC expansion, while inhibition of HH signalling significantly blocked 
CSC expansion253. In a murine model of CML, deletion of SMO significantly reduced CSCs, 
and overexpression of SMO in a SMO-deficient mouse CML model resulted in a 4-fold 
enhancement of CSCs with simultaneous disease progression251. Interestingly, in BL MYC 
was shown to be able to regulate GLI activity independent of HH ligands or the SMO and 
PTCH signalling molecules254. 
1.9.4.3 Notch signalling 
The Notch pathway is another key evolutionarily conserved pathway in development 
and most significantly it regulates the expression of target genes including some that 
are essential to CSC self-renewal such as MYC, NANOG, OCT-4, and SOX2255–258. Notch 
 34 
signalling has been shown to be instrumental in promoting CSCs of breast cancer, 
pancreatic cancer, and glioblastoma; In a study of 115 breast tumour tissues from 
primary lesions, results showed that Notch-positive tissues were significantly associated 
with the CSC marker ALDH1259. In a study of CSCs from pancreatic patients, Notch ligands 
Notch 1, Notch 3, Jag1, Jag2, and Notch target gene Hes1 were found to be highly 
expressed, and inhibition of γ-secretase (an important protease mediating Notch 
signalling by releasing the Notch intracellular domain) significantly decreased the CSC 
population and sphere formation abilities260. Finally, in Glioblastoma patient CSCs, 
Protein Kinase C Iota (PKCi) was shown to be highly expressed and important for CSC 
survival mediated by Notch signalling, and silencing PKCi caused apoptosis and inhibited 
proliferation of the CSCs both in vitro and in an in vivo PDX model261. 
1.9.4.4 JAK/STAT signalling 
Modulation of the JAK/STAT pathway has been implicated in the enhancement and 
repression of CSCs in several cancers. In AML, analysis of isolated CSCs from 
patients showed constitutive activation of JAK/STAT signalling. In vitro studies 
highlighted that the growth and survival of these CSCs were inhibited following 
treatment with a JAK1/2 inhibitor262. Significant evidence for the impact of this pathway 
on glioblastoma CSCs has also been reported. TGF-β was shown to regulate the self-
renewal and differentiation properties of glioma-initiating cells from patient samples 
and induced activation of the JAK/STAT pathway via leukaemia inhibitory factor (LIF)263. 
Furthermore, inhibition of STAT3 in CSCs prevented proliferation and sphere formation, 
and decreased expression of the neural stem cell genes Olig2 and nestin, while 
simultaneously increasing expression of the neuronal differentiation gene βIII-
tubulin264. Indeed STAT3 has been strongly implicated in promoting the stemness 
phenotype in an array of cancers. In breast cancer, it mediates resistance of 
CD44+CD24−/low breast CSCs to tamoxifen in vitro and also increases the CSC pool in HER2 
overexpressing breast cancer265,266. It was also reported that hepatocellular carcinoma 
could arise from STAT3-driven transformed stem cells with inactivated TGF-β 
signalling267. Importantly, IL-6 has been shown to be important in modulating STAT3-
driven stemness. For example, in breast cancer, activation of an IL-6 inflammatory loop 
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mediates trastuzumab resistance by expanding the CSC population via upregulation of 
STAT3 (as well as AKT and NF-kB)268. IL-11, a less-well studied member of the IL-6 family 
has also been shown to influence breast CSC dynamics through STAT3269. 
1.9.4.5 PI3K/Akt/mTOR signalling 
A wealth of evidence supports the role of the PI3K/Akt/mTOR pathway in modulating 
stemness. Inactivating mutations in PTEN are found commonly in glioblastoma 
multiforme and a recent analysis highlighted the initiating role of PTEN in the 
transformation of neural stem cells into glioblastoma multiforme while retaining the 
ability to express key stemness regulators OCT4, SOX2, and NANOG, and to differentiate 
into multiple lineages270. Another study in AML established a role for the microRNA miR-
126 in the maintenance of stemness through PI3K signalling271. In breast cancer stem-
like cells activation of the mTOR pathway is necessary for colony-formation ability in 
vitro and tumourigenicity in vivo while inhibition of mTOR in colorectal cancer caused a 
decrease in ALDH1 activity, a marker for colorectal CSCs272–274. In both ALL and AML, 
activated PI3K upregulated ABCG2 expression and elevated the percentage of cancer 
stem-like cells275. Bleau also presented similar results in Glioma stem-like cells and 
further elucidated that Akt but not its downstream target mTOR regulated ABCG2 
expression276. This pathway has also been shown to regulate the expression of 
important signalling molecules related to stemness. In studies of NSCLC, abnormal 
activation of the PI3K/Akt/mTOR signalling pathway leads to enhanced expression of 
chemokine (C-X-C motif) receptor 4 (CXCR4), which in turn promotes CXCR4-mediated 
STAT3 signalling that may be responsible for maintenance of stemness277. Chang et al. 
determined that PI3K/Akt/mTOR signalling via the insulin-like growth factor-1 receptor 
(IGF-1R) are attractive targets for therapy directed against breast CSCs278. 
1.9.4.6 NF-κB signalling 
The role of NF-κB in self-renewal and multipotency is less clear although evidence has 
started to emerge. For example, in a breast cancer pre-clinical study using a mouse 
mammary cell line and a mouse mammary model harbouring active ErbB2, investigators 
showed that inhibition of NF-κB reduced the number of progenitor cells and the ability 
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of these cells to form 3D mammospheres in culture. Furthermore they suggest that NF-
κB  is regulating this mammary -initiating cell population via SOX2 and NANOG as 
chemical inhibition of NF-κB  decreased the promoter activity levels of these genes by 
approximately 90% and 50%, respectively279. NF-κB has also been reported to enable 
metastasis of CSCs; A recent study demonstrated that breast CSCs may promote 
metastasis to lungs via LIN28, a stemness factor and downstream effector of IKKβ280.  In 
vitro analysis of breast cancer cell lines highlighted that breast CSCs expressed higher 
protein levels of LIN28 and the activated form of IKKβ than non-CSCs. Genetic silencing 
or chemical inhibition of IKKβ reduced expression of the stemness proteins LIN28, OCT4, 
SOX2 and NANOG. Finally, treatment of breast cancer xenograft-bearing mice with an 
IKKβ inhibitor almost completely eliminated the incidence of lung metastasis, and 
significantly reduced the frequency of CSCs in metastatic foci, compared with vehicle 
control treated cells280. TNF-a was also shown to trigger proliferation of adult neural 
stem cells via IKK/NF-κB signalling281.  
1.10 Cancer stem cells in lymphoma 
The original CSC concept has been fully validated in AML where the initial oncogenic hit 
occurs in a healthy, tissue-specific stem cell282. However, whether CSCs exist in mature 
B-NHL has yet to be determined. Akin to models of leukaemogenesis, potential B-NHL 
stem cells could derive either from HSCs or multipotent progenitors, or alternatively 
reprogramming events induced by cell intrinsic or environmental factors could induce 
stemness in mature B cells.  
In favour of the former model, several case studies report apparent transmission of 
premalignant lymphoid cells from one individual to another. At least  7 cases have been 
reported in which both recipient and donor develop the same lymphoid disease after 
allogeneic transplant283–288. Importantly, each case also demonstrates genetic sequence 
homology between the tumours of the recipient and the donor, thereby excluding a 
chance finding. The cases include T-cell Lymphoma (TCL), Marginal Zone Lymphoma 
(MZL), CLL, FL and Mantle Cell Lymphoma (MCL) although no cases of DLBCL or BL have 
been reported with these observations. In one case of MCL, onset of disease occurred 
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simultaneously in both donor and recipient 12 years after transplant for AML283. The 
malignant clone in the female recipient was found to be derived from the male donor 
(tumour with Y chromosome) supporting the existence of a latent premalignant clone 
and also providing evidence for the important role the TME has in promoting or 
repressing transformation. In one case of FL, a different IgH sequence was found in the 
2 tumours supporting the hypothesis of a common lymphoma progenitor cell existing285. 
Determining what factors promote the development of a putative lymphoma CSC into 
active proliferative cancer remain to be elucidated. 
Sequencing studies in healthy individuals have shed further light on the concept of 
premalignant lymphoma CSC clones. Two seminal papers found that specific somatic 
mutations in peripheral blood cells are detected in healthy adults and precede the onset 
of hematologic malignancy289,290. The frequency increases by age; by age 70, ∼10% of 
healthy individuals have common aberrations.  Some of the common mutations involve 
epigenetic regulator genes which are more common in myeloid cancers, but also occur 
in lymphoid malignancies291–293. In CLL it has been shown that over ∼90% of patients 
harbour the same mutations in their CD34+ stem cells as in their malignant CD19+ bone 
marrow cells294. Furthermore, in Hairy Cell Leukaemia, the BRAF V600E mutation which 
is found in the majority of patients was also discovered in their CD34+ stem cells295. 
Despite these fascinating discoveries no similar results have been reported for BL and 
the data for DLBCL are less conclusive. A recent study of 60 DLBCL patients identified 
copy-number neutral loss of heterozygosity in key lymphoma regions in non-tumour 
control samples296. These regions included 6p21 (HLA, 3% of patients), 9p24.1 (PD-
L1/L2, 5% of patients), and 17p13.1 (TP53, 2.5% of patients). However, in another study 
deep sequencing of genes frequently mutated in DLBCL revealed no mutations in highly 
purified HSCs from 6 DLBCL patients297. Furthermore, sequential sequencing was carried 
out on presentation and relapse samples from these patients and although common 
somatic mutations and clonal IgH VDJ rearrangements were revealed, none were 
identified in the purified patient HSCs. This may suggest that the source of DLBCL 
relapses is of a more mature B-cell type than in low-grade B-cell malignancies. In a 
detailed study of the methylation profile of 83 mature aggressive B-NHL samples, 
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including BL, investigators identified 56 genes de novo methylated in all lymphoma 
subtypes studied, and 22 methylated in a lymphoma subtype-specific manner298. 
Interestingly, the group of genes de novo methylated in all lymphoma subtypes was 
significantly enriched for polycomb targets in embryonic stem cells. De novo methylated 
genes in all cases studied were expressed at low levels in lymphomas and normal 
hematopoietic tissues, but not in non-hematopoietic tissues. These findings, especially 
the enrichment for polycomb target genes in stem cells, indicate that molecular B-NHLs 
with different morphologic, genetic and transcriptional background share a similar stem 
cell-like epigenetic pattern. This provides evidence for two alternative explanations for 
stemness in mature B-NHLs: On one hand these diverse B-NHLs might derive from 
lymphoma precursor cells with similar stem cell-like features that have acquired 
aberrant methylation of PcG target genes, or alternatively an epigenetic footprint of 
stemness could be acquired during lymphomagenesis by epigenetic remodelling with 
common patterns across different lymphomas. Within the molecular reprogramming 
model of stemness in mature B-NHL it is possible that epigenetically aberrant lymphoma 
initiating stem or progenitor cells may retain or reacquire stem cell features. They are 
then susceptible to become fully transformed via the acquisition of translocations such 
as MYC, BCL2 and BCL6. Alternatively the translocation breakpoint product or other 






Figure 1.7. Potential models of stemness in Lymphoma 
Some Lymphomas show evidence of a potential initial oncogenic hit in a HSC while for 
others such as BL and DLBCL it is more likely that genetic and/or epigenetic perturbations 








1.11 Methods of Identifying CSCs 
1.11.1 Xenotransplantation assays 
The gold standard method for identifying TICs is the use of in vivo tumour propagating 
assays. Suspected CSCs are assessed for their ability to serially propagate fully 
heterogenous tumours compared to the CSC-depleted bulk tumour population. 
Furthermore, this assay allows for the transplantation of different numbers of proposed 
CSCs into immunodeficient mice, and the subsequent establishment of a linear 
correlation with engraftment can determine a quantitative estimate for the frequency 
of CSC in the tumour. The first studies by Dick and colleagues determined that 1 in 2.5 X 
105 cells could initiate a leukemic graft197. Because xenografting is such an important 
method involved in defining CSCs it has come under intense examination over the years 
and some of the limitations have been described. One of the most obvious limitations is 
the inability of transplantation methods to faithfully recapitulate the TME. This is 
particularly relevant in the modern era of CSC studies whereby a cell’s environment is 
known to play an important role in dictating stemness features. Many murine growth 
factors are not cross-species reactive (e.g. TNF) and the possibility that some genuine 
TICs in humans may lack the appropriate conditions for growth in animals must be 
considered299,300. Furthermore, the experimental techniques utilised to obtain single 
cells for TIC assays are harsh and can have negative implications for cells. Both chemical 
and mechanical digestion methods are common, during which cells are subject to 
atmospheric 02 as well as sub-optimal pH and nutrient levels. They are then usually 
stained with antibodies and subjected to cell sorting via FACS. The significantly different 
environment that cells encounter for several hours before injection into mice may apply 
selective pressure to the population favouring only the most robust cells and may also 
induce epigenetic changes.  
Despite these complexities over the past several years a number of improvements have 
been achieved in xenotransplantation  including development of more immune-
deficient recipient mice, better methods for transplantation, introduction of basement 
membranes and humanizing recipients with human TME and/or growth factors300,301. 
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Many initial discoveries were made using NOD/SCID (NOD.CB17-PrkdcSCID/J) mice. These 
mice have defective cellular and humoral immunity but the presence of functional NK 
cells has been shown to impact the efficiency of the systems302,303. This was particularly 
evident in studies by Quintana et al. whereby the NOD/SCID model was shown to 
underestimate the CSC frequency304. When more immune-deficient NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NSG) mice were used for xenotransplantation in melanoma, the 
frequency of CSC cells was estimated at 25% compared to the 0.1-0.0001% in the 
NOD/SCID model. The main difference in NSG mice is that the introduction of truncated 
IL2Ry hampers the production of NK cells303,305. This model has become the most 
commonly used in xenotransplantation studies and has shown increased engraftment 
rates across many cancer types. 
The introduction of the basement membrane Matrigel has also had a significant impact 
on efficiency of engraftment in xenotransplantation assays. Matrigel is a solubilized 
tissue basement membrane matrix rich in extracellular matrix proteins that was 
originally isolated from the Engelbreth-Holm-Swarm (EHS) mouse306. In light of the 
important role the TME plays in modulating stemness, the ability of matrigel to apply a 
more tumour specific niche may be particularly important in CSC studies. It is composed 
mainly of laminin, collagen IV, heparan sulphate, proteoglycans and entactin (nidogen), 
although various growth factors such as transforming growth factor-β (TGF-β), fibroblast 
growth factor (FGF), and tissue plasminogen activator are also present which may play 
important roles in CSC progression306. Furthermore, at 37oC matrigel forms a 3D gel 
providing a scaffold for tumour cells307. This may be particularly important in tumours 
where cell to cell physical interaction and communication are important. In melanoma, 
initial estimates of the frequency of CSCs was increased significantly when matrigel was 
used304. The long list of studies that have utilised basement membrane proteins in the 
identification of TICs is evidence of the important role this component has in supporting 
CSCs304,308–316. It is also striking how effective matrigel is at promoting tumour growth 
from very low numbers of cells. In fact, in human melanoma one TIC cell injected with 
matrigel successfully produced a fully heterogenous tumour304. Similar results were 
seen for human squamous cell carcinoma with TGF-B shown to be involved in controlling 
the TIC phenotype308. 
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1.11.2 Cell surface phenotyping 
The use of flow cytometry to identify putative CSCs has been a very powerful technique 
over the years, particularly due the ability to integrate FACS to separate cell 
compartments based on a combination of cell surface markers. Surface marker 
expression can be hugely informative regarding the differentiation state of cells within 
defined lineages. In the normal stem cell field, HSCs were shown to have a surface 
phenotype denoted originally by CD34+CD38- and further extended to include Thy-1 
(CD90), IL7Ra and Flk2317. It was knowledge of the CD34+CD38- phenotype that 
contributed to the seminal studies by Dick et al. in identifying leukemic stem cells in 
AML282. However, as research in the area has developed some discrepancies with the 
original findings were identified. Initially LICs were thought to reside exclusively in the 
CD34+CD38- fraction of AML282. However, following the use of NSG rather than 
NOD/SCID mice, LICs were identified in other cell fractions too318. Thorough 
investigations were carried out using larger sample numbers and the original conclusion 
was validated – in all cases the CD34+CD38- fraction denoted a CSC population although, 
contrary to previous knowledge, in at least half of the more than 100 samples analysed, 
LICs were also found in other fractions319. In a study of 16 AML patients, 13 patients had 
tumour initiating capacity in fractions other than CD34+CD38- (CD34+CD38+, CD34-CD38+ 
or CD34-CD38-).  However, strong evidence for a hierarchical structure still remains as in 
the vast majority of cases, populations devoid of leukaemia initiating capacity exist. 
Furthermore, only gene signatures from functionally validated LIC populations were 
prognostic for patient survival319. 
Similar results regarding cell surface protein expression exist in other cancers. The 
original identification of the CD44+CD24- phenotype as the CSC population in breast 
cancer has been contested and other populations have been identified that possess 
stemness characteristics including cells expressing ALDH, CD133 and CD49F198,315,320,321. 
A number of cell surface proteins in ovarian cancer have been reported as denoting CSCs 
including CD44+, CD24+, CD133+, CD117+ and CD44+CD117+322–325. However Stewart et 
al. report significant instability of the ovarian TICs and determined that CD44+CD117+ 
cells were absent in most ovarian cancer patients or were found not to be 
tumourigenic326 .  
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These studies highlight some interesting situations – there appears to be significant 
interpatient heterogeneity with respect to CSC cell surface phenotype, a daunting 
concept in terms of targeting these populations for therapy. Furthermore, it appears 
that cell surface markers may be uninformative and may not represent a valid approach 
to determine hierarchical organization in some cases. Alternative methods of identifying 
and isolating cells with stemness may be required based on functional characteristics. 
Two potential options which have only recently been investigated include the use of 
sorting based on differential expression of miRNA, or the use of reporter assays that 
measure cellular signalling pathway activity327. Vermeulen et al. used this latter method 
in colon CSCs that were defined by Wnt signalling and regulated by the TME328. 
1.11.3 Side population assay 
Another approach that focuses on functional characteristics to identify CSCs is the Side 
Population (SP) Assay which is based on the differential ability of cell populations to 
efflux Hoechst dye. The ability to expel this dye is mediated by the ATP-binding cassette 
(ABC) family of transporter proteins expressed within the cell membrane. It is estimated 
that between 500 to 1200 genes encode drug transporters but ABCB1 (P-glycoprotein, 
multidrug resistant protein 1, MDR1), ABCC1-5 (multidrug resistant-associated proteins, 
MRP1-5), and ABCG2 (breast cancer resistance protein, BCRP1) are the most well 
characterized transporter proteins that function to denote the SP phenotype329–333. The 
SP phenotype was first described by Margaret Goodell and colleagues in 1996 using 
mouse bone marrow cells334. The SP did not exclusively encompass the stem cell 
population although it overlapped with the phenotypically defined CD117+ Sca-1+ Lin-
Thy1lo HSC population, and most significantly when surface marker expression and the 
SP phenotype are combined, the resulting isolated cells are one of the most pure and 
potent adult stem cell populations available335,336. Since its discovery over 20 years ago, 
this powerful assay has been implemented in identifying stem cells and progenitor cells 
in an array of tissues including umbilical cord blood, skeletal muscle, kidney, liver, 
mammary glands and lung337–342. The field of cancer stemness then began to utilise the 
SP assay as a means of isolating this therapy-resistant population and indeed 
successfully identified SP cells have been implicated in chemotherapy resistance in a 
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large number of cancers343–348. Importantly, SP cells have also been shown to possess 
the other key characteristics of TICs – self-renewal and tumourigenicity in 
xenotransplantation assays in a plethora of malignancies276,343,348,349. Important 
considerations when employing the SP assay are that SP cells do not exist in every 
tumour. Reports have shown that dye efflux is not a defining property of all stem cell 
populations and hence if an SP phenotype is not present it does not mean that the 
tumour does not contain populations with stemness350,351. Furthermore, ABC 
transporter expression is not exclusive to the SP and indeed, as discussed above in 
relation to multidrug resistance, ABC transporters are expressed by specialized cells 
within several organs, including the small intestine, liver, kidney, brain and 
placenta331,352–355. Taken together it is important to emphasize that the term ‘SP cell’ 
and ‘CSC’ are not interchangeable. Rather, the SP phenotype offers a useful assay to 
enrich for cells with CSC potential and should be combined with cell surface phenotyping 
and xenotransplantation in order to further characterise the true CSC population. 
Operationally, the SP is identified by staining cells with Hoechst dye and then visualising 
the Hoechst profile simultaneously in two distinct channels of a flow cytometer 
equipped with a UV laser. Hoechst 33342, when excited by UV light, emits fluorescence 
that can be detected in two distinct channels on the flow cytometer: the ‘‘Hoechst Blue’’ 
and the ‘‘Hoechst Red’’) channel, while a dichroic mirror is used to split the emission 
wavelengths. As the ‘‘Hoechst Red’’ channel is more sensitive to small changes in dye 
concentration, the so called ‘‘side population’’ cells emerge as a distinct dim ‘‘tail’’ 
extending first on the left side of G0/G1 cells (often referred to as the main population) 
toward the lower ‘‘Hoechst Blue’’ signal. This population is lost upon inhibition of ABC 
transporter activity with drugs such as verapamil and this offers a useful control for 
experiments334,356. 
Functionally, the SP phenotype is dynamic and is regulated by many growth factors, 
signalling pathways and micro-RNAs357. One example of this is seen in the 
haematopoietic system where the SP phenotype is acquired or reactivated in Lin- cells 
following interaction with mesenchymal stromal cells through VLA-4/α4β1 integrin and 
CD44358. Another study demonstrated that TGF-β reduced the SP in a dose-dependent 
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manner in hepatic cancer cell lines while Liu et al. reported that in NSCLC and colon 
cancer cell lines glucose induces a reversible upregulation of the SP fraction through ATP 
mediated suppression of AMPK and activation of the Akt pathway359,360. As well as this, 
ABCG2 transcription is regulated by several transcription factors that bind to the 
promoter region including Hif-1α, the oestrogen receptor, progesterone receptor 
isoform β, GLI, NRF2, SP1 and SP2357. Interestingly, several studies have also shown that 
a number of MicroRNAs negatively regulate the translation of the ABCG2 protein 









Figure 1.8. Identification of a side population by Hoechst staining 
Following staining of cells with Hoechst 33342 dye the dye fluorescence signal can be 
detected in two distinct channels on the flow cytometer. As the ‘‘Hoechst Red’’ channel 
is more sensitive to small changes in dye concentration, the so called ‘‘side population’’ 
(SP) cells emerge as a distinct dim ‘‘tail’’ extending first on the left side of G0/G1 cells 





1.12 Aims of the investigation 
The introduction to this thesis has given an overview of our current understanding of 
the biology of paediatric B-NHL as well as treatment options and the significant 
challenge relapse and refractory disease still poses. There is an unmet need for novel 
therapeutics to improve salvage rates of these patients as well as attempt to reduce the 
toxic doses of chemotherapy currently used. This thesis will investigate the potential 
importance of intra-tumour heterogeneity in paediatric B-NHL and in particular 
determine if a population with stemness properties exist which may contribute to 
therapy resistance. We will also utilise novel in vitro and in vivo methods to investigate 
resistance mechanisms and attempt to identify novel targets that may be effective in 
these difficult to treat cases. 
 
Specifically, the aims of this thesis are to: 
- Establish the first comprehensive paediatric B-NHL Patient Derived Xenograft 
(PDX) resource and determine if these offer a good model to investigate 
heterogeneity. 
- Investigate both inter- and intra-tumour heterogeneity within the PDX resource 
and identify populations that may have therapeutic relevance. 
- Determine if a population with stemness characteristics exists in paediatric B-
NHL by xenotransplantation assays, cell surface phenotyping and functional 
assays and investigate the characteristics of this population both in vivo and in 
vitro. 
- Investigate resistance mechanisms in vivo by attempting to mimic relapse in PDX 
models. 
- Investigate resistance mechanisms in vitro utilising a CRISPR-Cas9 genome-wide 
over expression screen to provide rational targets for investigation in PDX 
models. 
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Chapter 2. Materials and Methods 
2.1 Cell lines 
Bjab, DG-75, Raji and Ramos cell lines were obtained from a validated collection at the 
DSMZ German Collection of Microorganisms and Cell Cultures (Braunschweig, 
Germany).  Cells were grown in Roswell Park Memorial Institute (RPMI) 1640 (Gibco) 
with 10% Fetal Bovine Serum (FBS) (Labtech) and 1% Penicillin-Streptomycin 
(Invitrogen). All cells were grown in a humidified 5% CO2 incubator at 37°C. 
2.2 Primary Patient Samples 
2.2.1 Patient sample acquisition 
Paediatric B-NHL primary patient samples were obtained following informed consent on 
enrolment of patients to the Inter B-NHL Ritux Clinical Trial or following local ethical 
approval (granted to Dr. Suzanne Turner; Research Ethics Committee Reference: 
07/q0104/16). Two samples were kindly provided by Dr. Simon Bomken from the 
Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, 
Newcastle University once they had been passaged through a mouse and hence not 
under the regulations of the Human Tissue Act. 
2.2.2 Patient Sample Processing 
Mononuclear cells (MNCs) were isolated from pleural effusion, peripheral blood or bone 
marrow by gradient centrifugation over Lymphoprep™ (STEMCELL Technologies). 
Depending on the volume of material received, the sample was mixed with PBS 











Table 2.1. Lymphoprep and PBS volumes utilised for isolation of MNCs 
 
Sample was collected by centrifugation at 800 x g for 20 minutes at room temperature 
(15 - 25°C) with the brake off. The upper plasma layer was removed and discarded 
without disturbing the plasma:Lymphoprep™ interface. The MNC layer was removed at 
the plasma:Lymphoprep™ interface, by pipetting, without disturbing the 










Figure 2.1. Gradient centrifugation of biopsy samples 
Liquid biopsy samples from patients underwent gradient centrifugation over lymphoprep 
to isolate the MNCs.  
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2.3 In vivo experiments 
2.3.1 Mice 
JAX™ NSG Mice (NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ) were obtained from Charles River, UK 
and housed in individually ventilated cages (IVCs) under sterile pathogen-free conditions 
at the University of Cambridge, Central Biomedical Services (CBS) animal facilities, 
Addenbrooke’s Hospital, Cambridge. At the end of procedures mice were culled by the 
Schedule 1 method of cervical dislocation in accordance with Home Office guidelines 
under project licence numbers 80/2630 (2014-2017) and P4DBEFF63 (2018) and 
personal licence IB70151AE.  
2.3.2 Injection of primary patient samples into NSG mice 
Matrigel® Basement Membrane Matrix (Corning) was stored at -200C and thawed on ice 
for a minimum of 4 hours before use. Isolated MNCs were counted following trypan blue 
exclusion (Thermo Fisher Scientific) and 5X106 (or the maximum number of cells 
available if the biopsy sample was limited) were suspended in 200ul of PBS and mixed 
with 200ul of Matrigel. Cells were kept on ice and 300ul of suspension injected 
subcutaneously or interperitoneally into NSG mice using a 30 gauge hypodermic needle 
(VWR). Mice were monitored for health and tumour size by animal technicians daily. 
When precise tumour volume was part of a study plan, tumours were measured daily 
by both a technician and myself. Animals were shaved around the tumour area to assist 
with precision of measurement and callipers used to measure both the length and width 
of the tumour. 
2.3.3 Harvesting of tumours 
Once tumours reached 12mm in any dimension, animals were culled and the tumour 
removed using sterile scissors and tweezers. Tumours were immediately placed in PBS 
on ice and returned to the lab for disaggregation. Tumours were disaggregated in a petri 
dish using a 70µM nylon cell strainer (BD Falcon) and the plunger of a 5ml syringe (BD 
Plastipak), applying light to medium mechanical force. Single cell suspensions were then 
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counted following trypan blue exclusion and diluted with PBS for serial passage as 
described above and/or utilised in further experiments. 
2.3.4 Fluorescent in-situ Hybridization  
Fluorescent in-situ Hybridization (FISH) was carried out to determine the presence of 
the MYC translocation. Single cell suspensions were collected by centrifugation at 200 X 
g for 5 minutes and resuspended in Carbonyl’s Fixative (3:1 Methanol: Glacial Acetic 
Acid). Samples were then sent to Cambridge haematopathology & oncology diagnostic 
service (HODS), Addenbrooke’s Hospital. FISH was performed using a Vysis LSI 
IGH/MYC/CEP 8 Tri-Color Dual Fusion Probe Kit (Abbott Diagnostics), which detects the 
fusion between IGH and MYC. Results were reported as the percentage of cells positive 
for IGH-MYC rearrangement as well as the signal pattern. 
2.3.5 Tumour Histology 
Following extraction of tumours, either the whole tumour or a section was immediately 
placed in 10% neutral-buffered Formalin (Sigma-Aldrich). After 24 hours the tumour was 
removed and placed in 70% Ethanol/PBS. Tumours were submitted to the Histology 
laboratory at the Department of Pathology, University of Cambridge to be made into 
Formalin Fixed, Paraffin Embedded (FFPE) blocks. Slides were also cut and Haematoxylin 
and Eosin staining carried out using standard procedures.  
2.4 Flow Cytometry  
Cells were counted following trypan blue exclusion, washed with PBS and collected by 
centrifugation at 250 X g for 5 minutes. Supernatant was discarded and cells 
resuspended in Flow Cytometry buffer (PBS, 0.05% Bovine Serum Albumin (Thermo 
Fisher) at a concentration of 1X106 cells/ml. Cell suspension (100µl) was added to each 
well of a 96-well plate and appropriate antibody was added. Volume of antibodies varied 
depending on the specific antibody titration and all antibodies used and their associated 
isotype controls are listed in Table 2.2. Cells were incubated for 40 minutes at 40C, 
protected from light before a further wash in PBS and resuspension in 2ml of flow 
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cytometry buffer in 5ml polystyrene FACS tubes (BD Falcon™) before immediate analysis 
on a BD Accuri C6 or a LSR Fortessa Flow Cytometer at the NIHR Cambridge BRC Cell 
Phenotyping Hub, Addenbrooke’s Hospital. At least 10,000 events were recorded and 
data analysed with FlowJo v9.1 Flow Cytometric Analysis Software. 
When separation of cells based on cell surface protein expression was required, 
Fluorescence Activated Cell Sorting (FACS) was carried out on cells stained as described 
above using a BD FACSAria™ Fusion at the Cell Phenotyping Hub. Cells were suspended 
































Source Fluorochrome Isotype Control 
ABCG2 Pharminogen APC Mouse IgG2b, κ 
CD10 Pharminogen PE Mouse IgG1, κ 
 CD117 Pharminogen PE-Cy5 Mouse IgG1, κ 
CD117 Pharminogen PE Mouse IgG1, κ 
 CD133 Miltenyi Biotec  
 
PE Mouse IgG2bκ 
 CD150 Pharminogen PE Mouse IgG1, κ 
 CD184 Biolegend PE Mouse IgG2a, κ 
 CD19 Pharminogen PE-Cy5  
 
Mouse IgG1, κ 
 CD20 Pharminogen  FITC Mouse IgG2b, κ 
CD21 Biolegend FITC Mouse IgG1, κ 
 
Mouse IgG1, κ 
 
CD24 Biolgened PE-Cy7 Mouse IgG2a, κ 
 
Mouse IgG2a, κ 
 
CD27 Biolegend APC Mouse IgG1, κ 
 CD34 Biologend PE Mouse IgG1, κ 
 
Mouse IgG2a, κ 
 
CD34 Pharminogen PE Mouse IgG1, κ 
 CD38 Biolegend FITC Mouse IgG2a, κ 
 CD40 Pharminogen FITC Mouse IgG1, κ 
 CD44 Biolegend PE Mouse IgG1, κ 
 CD45 Pharminogen PE Mouse IgG1, κ 
 CD45 Pharminogen APC Mouse IgG1, κ 
 CD49D Pharminogen FITC Mouse IgG1, κ 
 CD49F Pharminogen FITC Mouse IgG2a, κ 
 
 
CD59 Biolegend PE Mouse IgG2a, κ 
 CD9 Pharminogen FITC Mouse IgG1, κ 
 CD90 Pharminogen PE Mouse IgG1, κ 
 CD90 Pharminogen APC Mouse IgG1, κ 
 Oct3/4 Pharminogen PE Mouse IgG1, κ 
 
 
Table 2.2. Details of antibodies used in flow cytometry 
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2.5 Side Population analysis 
SP analysis was carried out on both cell lines and cells isolated from PDXs. Cell lines were 
cultured in 2% FBS containing media for 7 days before SP analysis whereas SP analysis 
of PDX samples was performed on cells immediately after extraction from mice. Live 
cells were counted following trypan blue exclusion and 1X106 live cells suspended in 1 




Table 2.3. FACS buffer components 
 
Hoechst 33342 dye (Sigma-Aldrich) was added at the appropriate concentration (Table 
2.4) and cells incubated at 370C in a thermomixer set to 200rpm in a dark room for the 
appropriate time (Table 2.4) Controls were prepared following incubation with 100µM 
verapamil (Sigma-Aldrich) for 20 mins before the addition of Hoechst dye. In order to 
determine the correct Hoechst dye concentration and incubation time, all cell lines and 
PDXs were incubated with concentrations of dye ranging from 2-10ug/ml for 60, 90 or 
120 mins until a reliable side population, that was eliminated by verapamil, was 
identified. Following incubation, cells were collected by centrifugation at 250 X g in a 
centrifuge at 40C and resuspended in ice cold FACS buffer with 1 µg/ml propidium iodide 
(Sigma-Aldrich). Sample was transferred to 5ml polystyrene FACS tubes (BD Falcon™) 
and stored on ice before analysis. Analysis was carried out on BD LSRFortessaTM  
equipped with an Ultraviolet (UV) laser at the NIHR Cambridge BRC Cell Phenotyping 
Hub. Hoechst 33342, when excited by UV light, emits fluorescence that can be detected 
in two distinct channels on the flow cytometer: the “Hoechst Blue” (450/50 nm band-
pass filter) and the “Hoechst Red” (610/20 nm long-pass filter) channel, while a dichroic 
mirror (LP600 nm) was used to split the emission wavelengths. At least 50,000 events 
were recorded and data analysed with FlowJo v9.1 Flow Cytometric Analysis Software. 
 
Cell Type Media/Buffer Hepes FBS 
Cell Line RPMI 10mM 2% 
PDX PBS 10mM 2% 
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When separation of MP and SP populations was required, FACS was carried out on the 
Hoechst stained cells using a BD FACSAria™ Fusion at the Cell Phenotyping Hub. Cells 
were suspended at 30 million per ml and passed through a 50µm cell strainer before 
sorting. The BD FACSAria™ Fusion is equipped with a UV laser and the machine was set 




Table 2.4. Incubation conditions for SP analysis of PDXs and cell lines 
2.6 In vitro experiments  
2.6.1 Transwell assay 
Cell lines - Raji, Ramos, Bjab and DG-75, were incubated with Hoechst 33342 at the 
optimal concentrations and times as determined above and sorted by FACS using 
stringent gating based on verapamil-treated control samples. Unsorted whole cell 
populations were also passed through the cell sorter so all populations experienced the 
same conditions. Live cell populations were counted following trypan blue exclusion and 
plated in 24 well plates (10,000 cells per well). The transwell assay was set up using a 









PDX sample   
1 2 120 
2 2 120 
3 2 120 
4 5 120 
5 2 120 
   
Cell Line   
Bjab 2 90 
DG-75 2 120 
Ramos 5 90 
Raji 2 120 
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cell were placed in the bottom well (400µl) and SP cells (100µl) placed in the well insert. 
Cells were counted every second day following trypan blue exclusion. 
2.6.2 Measurement of cytokine levels in cell culture media 
SP and whole cell populations were grown in media for 5 days before the supernatant 
was isolated following centrifugation at 200 X g for 5 minutes. Cytokine levels in 
supernatants was quantified by BioLegend’s LEGENDplex™ bead-based immunoassay as 
indicated by the manufacturer’s instructions in a 96 well V-bottom plate. Standards 
were first produced by serial dilution of the supplied Human Immunoglobulin Isotyping 
Panel Standard Cocktail. This resulted in 8 standards ranging from 0-400,000pg/mL. 
Assay buffer (25µl) was added to each well followed by 25µl of sample or standard 
followed by 25µl of capture beads. The plate was then sealed with a plate sealer, 
wrapped in tin foil and incubated for 2 hours at room temperature while shaking at 
800rpm in order to keep beads in suspension. Cells were then collected by 
centrifugation of the plate at 250 X g for 5 minutes using a swinging bucket rotor with 
microplate adaptor. Immediately after centrifugation, the supernatant was disposed of 
by quickly inverting and flicking the plate in one continuous and forceful motion. The 
plate was washed by dispensing 200μL of 1X Wash Buffer into each well and incubating 
for one minute before disposal as described above and before addition of 25µL of 
Detection Antibody to each well, the plate resealed and covered with aluminium foil for 
1 hour incubation at room temperature while shaking at 800 rpm. Without washing, 
25µL of SA-PE was then added to each well before re-sealing, wrapping in aluminium 
foil and incubating at room temperature for 30 minutes with shaking at 800rpm. The 
plate was subject to centrifugation and supernatant discarded as above before washing 
and repeating the centrifugation process again. Wash Buffer (150µL)  was added to each 
well and the beads resuspended by pipetting. Samples were read on a BD LSRFortessaTM 
and data analysed using LEGENDplexTM Data Analysis Software. 
2.6.3 Exosome isolation 
SP cells from Bjab and DG-75 were grown in media for 3 days. Cells were transferred to 
15ml Falcon tubes and collected by centrifugation at 1000 X g for 15 minutes at 4°C in a 
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bench top centrifuge. Supernatant was collected into new 15ml tubes and the cell pellet 
discarded. Supernatant was subject to centrifugation at 2000 X g  for 15 minutes at 4°C 
in a bench top centrifuge to remove any remaining cells and was then transferred into 
50ml polycarbonate tubes with caps (Beckman Coulter). The volume of supernatant was 
increased to 20ml with PBS. Tubes, buckets and lids combined were weighed and the 
values recorded to ensure samples positioned opposite one another in the 
ultracentrifuge were balanced (max 0.1g weigh difference) with PBS was added 
dropwise to balance weights. Centrifugation was conducted at 17000g (14500rpm) for 
15 minutes at 4°C in an Avanti J-20 centrifuge using a JA20 rotor (17000g = 14500rpm). 
Supernatant was transferred into 38.5ml polycarbonate tubes  with caps (Beckman 
Coulter) and the remaining pellet (apoptotic bodies) was discarded. Following balancing 
as described above, centrifugation at 100,000 X g for 80 minutes at 4°C (centrifuge + 
buckets cooled in advance) in an Optima L-100 XP Centrifuge was performed using a SW-
28 rotor (100000g = 27000rpm). Supernatant was discarded and the pellet (exosomes) 
resuspended in 1ml PBS. Sample was transfer to ½ *2 inch ultra-clear tubes (Beckman 
Coulter) before balancing volumes to 3ml with PBS and centrifugation at 100000 X g for 
40 minutes at 4°C in an Optima L-100 XP Centrifuge with a SW-55Ti rotor (100000g = 
32700rpm). As much supernatant as possible was carefully removed using a pipette, 
with the tube held at head height under light to visualise the exosome pellet and to 
avoid disturbing it.    
2.6.4 Determination of Effective Dose (ED)50 values for individual drugs utilised in 
experiments 
BL cell lines were plated in flat-bottom 96-well plates, (Corning) at a density of 0.5X106 
cells/ml and before treatment with a range of 8 concentrations of drug as indicated in 
the results for 72 hours. Methotrexate, Doxorubicin and Vincristine were purchased 
from Sigma-Aldrich; Dactolisib, JQ1 and Ibrutinib were obtained from MedChemExpress. 
Drugs were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at a concentration of 
2mM then stored at -20⁰C until use.  Rituximab was purchased from Roche in solution 
and was stored at 4⁰C at a concentration of 10mg/ml.  
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Cell viability for each condition was determined using the CellTiter-Blue® (CTB) Cell 
Viability Assay according to manufacturer’s instructions. Briefly, reagent was added 
directly to cells and incubated for 1 hour at 37⁰C after which fluorescence was measured 
on a SpectraMax i3 plate reader (Molecular Devices).  
Normalized dose-response curves were generated with GraphPad Prism software364 
using non-linear regression methods that employ the following model (Equation 1), with 
𝑥	being defined as dose value concentration in log scale and 𝑦 being defined as the 




 Equation 1 
Other ED values were calculated using the determined ED50 value by employing the 






∗ 	ED50 Equation 2 
2.6.5 Determination of synergy  
In order to identify potential synergistic interactions of drugs, BL cell lines were plated 
at 5X106 cells/ml in 96-well plates and treated with single agent or combinations of 
drugs. The CTB assay was utilised to determine viability and the Bliss combination index 
(BCI) calculated based on the Bliss Independence model365. The BCI was calculated with 
the following equation: B𝐶𝐼 = 	 /01/2#/0∗	/2
/02
, where Ea indicates the viability effect of 
drug A, Eb indicates the viability effect of drug B and Eab indicates the viability effect of 
being treated with drug A and drug B together. BCI < 1 indicates synergism, BCI = 1 
indicates additive effect, BCI > 1 indicates antagonism.  
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2.7 RT-qPCR quantification of gene expression 
All kits were used according to the manufacturer’s instructions. To compare gene 
expression levels, total RNA was isolated with the RNeasy Plus Mini Kit (Qiagen) before 
RNA (1 ug) was reverse transcribed using the ProtoScript II First Strand cDNA Synthesis 
Kit (NEB). RT reactions were diluted (1/10) and 10 ng equivalent (to input RNA amount) 
was used as the template DNA for qPCR using Power SYBR Green PCR Master Mix 
(ThermoFisher) with standard reaction conditions on the QuantStudio™ 6 Flex Real-Time 
PCR System (ThermoFisher). Primers used are described in Table 2.5. Data were 
analysed using the double delta Ct (∆∆Ct) method conducted with normalization to 
GAPDH (∆Ct) before relative expression level comparison to the control sample (∆∆Ct). 















Gene Forward primer (5’ - 3’) Reverse primer (5’ - 3’) 
MYC GGCTCCTGGCAAAAGGTCA CTGCGTAGTTGTGCTGATGT 
BCL2 GGTGGGGTCATGTGTGTGG CGGTTCAGGTACTCAGTCATCC 
BCL6 ACACATCTCGGCTCAATTTGC AGTGTCCACAACATGCTCCAT 
GNA13 CCCAAGGAATGGTGGAAACAA ACCCAGTTGAAATTCTCGACG 
ARID1A CCAGCAGAACTCTCACGACC CTGAGCGAAGGACGAAGACG 
ID3 GAGAGGCACTCAGCTTAGCC TCCTTTTGTCGTTGGAGATGAC 
TCF3 CCGACTCCTACAGTGGGCTA CGCTGACGTGTTCTCCTCG 
ALDH1A1 CTGCTGGCGACAATGGAGT CGCAATGTTTTGATGCAGCCT 
VEGFA AGGGCAGAATCATCACGAAGT AGGGTCTCGATTGGATGGCA 
PIM1 GAGAAGGACCGGATTTCCGAC CAGTCCAGGAGCCTAATGACG 
CDK4 ATGGCTACCTCTCGATATGAGC CATTGGGGACTCTCACACTCT 
CDC7 AGTGCCTAACAGTGGCTGG CACGGTGAACAATACCAAACTGA 
TERT CCGATTGTGAACATGGACTACG CACGCTGAACAGTGCCTTC 
SMARCA4 GACCAGCACTCCCAAGGTTAC CTGGCCCGGAAGACATCTG 
SOX2 GCCGAGTGGAAACTTTTGTCG GGCAGCGTGTACTTATCCTTCT 
GAPDH GGAGCGAGATCCCTCCAAAAT GGCTGTTGTCATACTTCTCATGG 
PTEN TTTGAAGACCATAACCCACCAC ATTACACCAGTTCGTCCCTTTC 
COL1A1 GAGGGCCAAGACGAAGACATC CAGATCACGTCATCGCACAAC 
PAX5 ACTTGCTCATCAAGGTGTCAG TCCTCCAATTACCCCAGGCTT 
MTOR TCCGAGAGATGAGTCAAGAGG CACCTTCCACTCCTATGAGGC 
Table 2.5. RT-qPCR primers used to measure expression of genes in PDXs at different 
passages 








Table 2.6. RT-qPCR primers used to measure expression of genes in SP and MP from 
PDXs. 
All primers were retrieved from PrimerBank366,367 and synthesized by Sigma-Aldrich. 
 
2.8 RNA-sequencing analysis 
2.8.1 Library preparation and sequencing 
All kits were employed according to the manufacturer’s instructions. Total RNA was 
extracted from control and relapse tumours using the RNeasy Plus Mini Kit (Qiagen). 
RNA was quantified by Qbit and submitted to the NGS library facility, Wellcome Trust - 
Medical Research Council Stem Cell Institute, University of Cambridge for library 
preparation. RNA integrity for each sample was determined using an Agilent 
Bioanalyzer. High quality total RNA was verified with a RNA Integrity Number (RIN) value 
of >9.2 for each sample. mRNA was enriched from total RNA using NEXTflex™ Poly(A) 
Beads (Bioo Scientific) and libraries then produced using the NEXTflex™ Rapid 
Directional RNA-Seq Kit (Bioo Scientific), which is designed to prepare directional, strand 
specific RNA libraries for sequencing using Illumina® sequencers. Briefly, this process 
involved fragmentation of mRNA which was subjected to first-strand cDNA synthesis 
with random hexamers. AMPure XP bead clean-up was performed and barcoded DNA 
Gene Forward primer (5’ - 3’) Reverse primer (5’ - 3’) 
NANOG TTTGTGGGCCTGAAGAAAACT AGGGCTGTCCTGAATAAGCAG 
ABCG2 ACGAACGGATTAACAGGGTCA CTCCAGACACACCACGGAT 
ABCB1 TTGCTGCTTACATTCAGGTTTCA AGCCTATCTCCTGTCGCATTA 
OCT4 GGGAGATTGATAACTGGTGTGTT GTGTATATCCCAGGGTGATCCTC 
SOX2 TACAGCATGTCCTACTCGCAG GAGGAAGAGGTAACCACAGGG 
AKT1 AGCGACGTGGCTATTGTGAAG GCCATCATTCTTGAGGAGGAAGT 
MCL1 GTGCCTTTGTGGCTAAACACT AGTCCCGTTTTGTCCTTACGA 
PIM1 GAGAAGGACCGGATTTCCGAC CAGTCCAGGAGCCTAATGACG 
FZD6 GATTTTGGTGTCCAAGGCATCT GCGCACACTGGTCAATTCC 
BMI1 CGTGTATTGTTCGTTACCTGGA TTCAGTAGTGGTCTGGTCTTGT 
SOX2 GCCGAGTGGAAACTTTTGTCG GGCAGCGTGTACTTATCCTTCT 
GAPDH GGAGCGAGATCCCTCCAAAAT GGCTGTTGTCATACTTCTCATGG 
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adapters were ligated to both ends of the double-stranded cDNA followed by PCR 
amplification. Library size was then validated using an Agilent Bioanalyzer and libraries 
submitted to the CRUK Cambridge Institute Genomics Core where they were 
multiplexed and single-end sequenced (1 X 50 base pairs) on one lane of an Illumina 
HiSeq 4000. Samples were demultiplexed based on sample specific barcodes and the 
raw sequencing data produced. 
2.8.2 Data Analysis 
Quality Control was performed on the raw reads using FastQC368 and high quality 
sequencing data were uploaded to the Galaxy web platform, with the public server at 
usegalaxy.org used to analyse these data369. HISAT2370, a sensitive spliced alignment 
program, was used to map RNA-seq reads to the latest version of the human genome, 
GRCh38, with a minimum alignment rate of 93% for each sample. The BAM files 
produced were then input into HTSeq-count371 along with a feature file in GFF format, 
and a table of counts for each gene was produced as the script output.  DESeq2372 was 
then utilised to determine differential gene expression (DGE). This method takes count 
tables generated from HTSeq-count as input and tests for differential expression based 
on a model using the negative binomial distribution with an output of differentially 
expressed genes with corresponding Log2FC, p and FDR values produced. Hierarchical 
clustering and principal component analysis (PCA) were performed using ClustVis373, a 
web tool for visualizing clustering of multivariate data with normalised read counts from 
DESeq2 utilised as the input.  In order to carry out Gene Set Enrichment Analysis (GSEA; 
Broad Institute)374 normalized read counts were re-formatted to Gene Cluster Text 
(GCT) file format and a Categorical class (CLS) file was generated 
(http://software.broadinstitute.org/cancer/software/gsea/wiki/index.php/Data_forma
ts). Both files were used as the input files for GSEA on its javaGSEA Desktop Application. 
GSEA was performed to compare the expression profile of relapse and control samples 
using all gene sets from the Molecular Signatures Database (MSigDB) with the 




Gene Forward primer (5’ - 3’) Reverse primer (5’ - 3’) 
MALAT1 TCACCAGCGGAAAACTCAAG GCTGTAGGCCCCAAAGATGTC 
COL1A1 GTGCGATGACGTGATCTGTGA CGGTGGTTTCTTGGTCGGT 
ABCB1 TTGCTGCTTACATTCAGGTTTCA AGCCTATCTCCTGTCGCATTA 
CDC25B GGCTGAGGAACCTAAAGCCC CTTTCCGTCTACTGTCTGTAGGA 
NFATC4 CTTCTCCGATGCCTCTGACG CGGGGCTTGGACCATACAG 
HDAC10 CAGTTCGACGCCATCTACTTC CAAGCCCATTTTGCACAGCTC 
CDK10 CGGAGGCTCAGGTCAAGTG CACACAACCCTTGTCGGTCA 
MAD2L2 ACCGCCCAGTGGAGAAATTC CATCGCACACGCTGATCTT 
STXBP6 GGATTCGGCAGAGTTTGATTTGT CCTCCCATAATTTTGGATTGGCA 
CD9 TTCCTCTTGGTGATATTCGCCA AGTTCAACGCATAGTGGATGG 
CFL1 TTCAACGACATGAAGGTGCGT TCCTCCAGGATGATGTTCTTCT 
TGFB1 CAATTCCTGGCGATACCTCAG GCACAACTCCGGTGACATCAA 
DBN1 CAACTGGGTGGGCGAAGAT TGCTGGCGTTCACGATCAC 
BID ATGGACCGTAGCATCCCTCC GTAGGTGCGTAGGTTCTGGT 
PTPRCAP TTGAGCGACAGGAGGATGAG GACGCCTCTCCACATTGCT 
CD27 CAGAGAGGCACTACTGGGCT CGGTATGCAAGGATCACACTG 
GAPDH GGAGCGAGATCCCTCCAAAAT GGCTGTTGTCATACTTCTCATGG 
Table 2.7. RT-qPCR primers to validate expression of differentially expressed genes 
identified from RNA-seq. 
All primers were retrieved from PrimerBank366,367 and synthesized by Sigma-Aldrich. 
 
2.9 Genome-wide Cas9 transcriptional activation screen 
For genome-wide Cas9 transcriptional activation screens, a three plasmid (Figure 2.2 B-
D) system - human CRISPR activation library v1 (Addgene, cat. no. 1000000057, kind gift 
from Feng Zhang, MIT) - was used375. 
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Figure 2.2. Genome-scale Cas9 transcriptional activation screen employed to identify 
resistance mechanisms to chemotherapy and Rituximab 
(A) Programmable transcriptional activation can be achieved by using dCas9 and 
activation domains (e.g., VP64/p65/HSF1) to recruit transcriptional machinery to the 
transcriptional start site (TSS) of the desired target gene, resulting in upregulation of the 
target transcript. PAM: protospacer adjacent motif, Pol II: RNA polymerase II. (B-D) 
Vector-system used for the Genome-scale Cas9 transcriptional activation screen. The 
library (lenti sgRNA(MS2)_Zeo) must be combined with additional SAM effectors in a 3-
vector format. Blast: Blasticidin, Hygro: Hygromycin, Zeo: Zeocin. Figure modified from 
Joung et al., 2017376. 
 
This library is based on a dCas9-VP64 fusion protein (Figure 2.B) that recruits 
transcriptional complexes to the transcriptional start site (TSS) of target transcripts as 
well as an altered sgRNA (Figure 2D) to recruit accessory transcriptional co-activators 
(MS2-p65-HSF1) (Figure 2C) to synergistically interact with the transcriptional complex. 
Specifically, a hairpin aptamer that selectively binds to MS2 phage protein was 
appended to the tetraloop and stem loop no. 2 regions377. Then a separate vector 
(Figure 2C) was constructed to express MS2 protein fused to the p65 transcription factor 
and heat shock transcription factor 1 (HSF1). This allows for additional recruitment of 
transcriptional activators to the TSS, leading to >500-fold enhanced overexpression in 
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2.9.1 Generation of a dCas9 and MS2 expressing Raji cell line 
To conduct the genome-scale Cas9 transcriptional activation screen, a stably expressing 
lenti dCAS-VP64_Blast (Addgene, cat. no. 61425) and lenti MS2-P65-HSF1_Hygro 
(Addgene, cat. no. 61426) Raji cell line was engineered375. Briefly, the lentiviral plasmids 
(kind gifts from Feng Zhang, MIT) were individually packaged into lentivirus and 
subsequently used for viral transduction of the Raji cell line. First, the expression 
plasmids were co-transfected into log-phase growth 293FT cells (Invitrogen) with 
second-generation lentiviral packaging plasmids (kind gifts from Didier Trono, EPFL) – 
psPAX2 (Addgene, cat. no. 12260) and pMD2.G (Addgene, cat. no. 12259) at a ratio of 
1:1:1 with TransIT-293 (MirusBio) in OptiMEM reduced serum medium (Thermo Fisher 
Scientific) at 32°C. After 24 hours, the medium was replaced with fresh Dulbecco’s 
Modified Eagle Medium (DMEM; Gibco) supplemented with 10% FBS, DNAse I (Thermo 
Fisher Scientific, 1 U/mL), 20 mM HEPES pH 7.4 and 5 mM MgCl2. Viral supernatant was 
collected 48 and 72 hr post-transfection, pooled, subject to centrifugation at 360 x g for 
5 min, the resulting supernatant filtered (Minisart 0.45µm filter, Sartorius Stedim) and 
stored at -80⁰C if not used immediately.  
Following these procedures, Raji cells were transduced with viral particles of lenti dCAS-
VP64_Blast at a Multiplicity of Infection (MOI) of < 0.7 then selected in blasticidin S HCl 
(5 μg/mL) (Thermo Fisher Scientific) 24 hrs post viral transduction for seven days or until 
0% survival was observed in uninfected cells. Then lenti MS2-P65-HSF1_Hygro particles 
at an MOI of < 0.7 were applied and stable cells were selected in hygromycin B (300 
µg/mL) (Thermo Fisher Scientific) 24 hrs post viral transduction for seven days as before. 






2.9.1.1 Western Blot to confirm the presence of dCas9 
Protein lysates were prepared by incubating 5 million cells in RIPA buffer (Sigma Aldrich, 
cat. no. R0278) supplemented with Halt Protease and Phosphatase Inhibitor Cocktails 
(ThermoFisher) for 30 min on ice. Cellular debris were removed by centrifugation at 
16,000 X g for 20 min at 4°C and the supernatant stored at -20°C until usage. Proteins 
were quantified with a PierceTM BCA Protein Assay Kit (ThermoFisher) following the 
manufacturer’s protocol and analyzed on a SpectraMax i3 plate reader (Molecular 
Devices). Protein lysate (50 µg) was solubilized in SDS solution (250 mM Tris pH 6.8, 10% 
SDS, 5% beta-mercaptoethanol (BME), 0.02% bromophenol blue, 30% Glycerol) and 
boiled for 5 mins at 95°C. Samples were resolved by SDS-PAGE with a 4% stacking gel 
and a 10% running gel for 1 hr at 100 V in running buffer (25 mM Tris, 190 mM glycine, 
0.1% SDS). Proteins were transferred to a 0.45 μM Immobilon-P PVDF membrane (Merk 
Millipore) using a Mini Trans-Blot Cell apparatus (Bio-Rad) at 100 V for 1 hr in transfer 
buffer (25 mM Tris, 0.01% SDS, 1.92 mM Glycine). Following transfer, membranes were 
first blocked in buffer (5% milk powder in TBST (20 mM Tris-HCl pH 8, 150 mM NaCl, 
0.1% Tween-20)) for 1 hr at room temperature and subsequently incubated with 
polycloncal anti-Cas9 antibody (Abcam, 1:2000 dilution in blocking buffer) at 4°C 
overnight. Afterwards the membrane was incubated with goat anti-rabbit 
immunoglobulin/HRP (Agilent technologies, 1:2000) for 1 hour at room temperature. 
Washing of membranes was performed in TBST (3 X 5 minute washes), protein bands 
were visualized by Immobilon Western Chemiluminescent HRP Substrate (Merck 
Millipore) and detected by a LAS-4000 Image Analyzer (Fujifilm/Raytek). 
2.9.1.2 Validation of dCas9-VP64 overexpression activity 
To confirm the dCas9-VP64 overexpression activity in the transduced Raji cell line, 30 
guide sequences (Table 2.8) were designed with the Cas9 activator tool378 and 
introduced into the lenti sgRNA(MS2)_Zeo backbone vector (Addgene, gift from Feng 
Zhang, MIT). The genes – encoding for growth factors, guanine nucleotide exchange 
factors, transcription factors, kinases and adapter proteins were targeted with two 
sgRNAs per gene. 
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Gene sgRNA Forward ssDNA element (5’ - 3’) Reverse ssDNA element (5’ - 3’) 
ARHGEF9 1 CACCgCGCAAGCGCCCGCAGTCGCT AAACAGCGACTGCGGGCGCTTGCGc 
2 CACCgGGCGGGTATGTCAGTGGCTC AAACGAGCCA`CTGACATACCCGCCc 
BCL10 1 CACCgAGGTACTGACAAGCCCAGAC AAACGTCTGGGCTTGTCAGTACCTc 
2 CACCgCAGGGTCTGGGAAAAGGGG AAACCCCCTTTTCCCAGACCCTGCc 
CRK 1 CACCgACGCGCTCCCTGCCCAGGG AAACCCCTCGGGCAGGGAGCGCGTc 
2 CACCgGGCTGCCGGGAAGGGGCCCG AAACCGGGCCCCTTCCCGGCAGCCc 
EREG 1 CACCgGGTGCTGCGAACTTTATACT AAACAGTATAAAGTTCGCAGCACCc 
2 CACCgGAGCCCCTCCCGGGCCCTAA AAACTTAGGGCCCGGGAGGGGCTCc 
FOS 1 CACCgAAACGTCACGGGCTCAACCA AAACTGGTTGAGCCCGTGACGTTTc 
2 CACCgGGCGCCAGAGGGGTGGCGCG AAACCGCGCCACCCCTCTGGCGCCc 
NR4A2 1 CACCgCAGCGCGGCGATTGGGCGGC AAACGCCGCCCAATCGCCGCGCTGc 
2 CACCgGGCCAGGAGTCCAGGGAGCG AAACCGCTCCCTGGACTCCTGGCCc 
PLEKHG6 1 CACCgCAGTAATGAGGGCTGAGTAA AAACTTACTCAGCCCTCATTACTGc 
2 CACCgGGGCGGGCGCCGCCGGGGG AAACCCCCCGGCGGCGCCCCGCCCc 
PRKACA 1 CACCgTGCGGGGGCGTCACAGACAG AAACCTGTCTGTGACGCCCCCGCAc 
2 CACCgGGCCTAGGCCAATGAGCGGC AAACGCCGCTCATTGGCCTAGGCCc 
PSD2 1 CACCgGGGACGGACGGCAGGAGGGA AAACTCCCTCCTGCCGTCCGTCCCc 
2 CACCgGGAGCGGAGCCGTGAGCTGG AAACCCAGCTCACGGCTCCGCTCCc 
PTGES 1 CACCgCTGCAGGGAAAGCACAAAGT AAACACTTTGTGCTTTCCCTGCAGc 
2 CACCgGGGCGGTGCTGGCTGCAGGA AAACTCCTGCAGCCAGCACCGCCCc 
RORC 1 CACCgCCCCCAGTGCTTCTGGACTG AAACCAGTCCAGAAGCACTGGGGGc 
2 CACCgGTTTAAGCTGTGCTGCACCACAC AAACGTGTGGTGCAGAGCTTAAACc 
SAMD4A 1 CACCgCTCCCCCCTTCTTGCAGCTT AAACAAGCTGCAAGAAGGGGGGAGc 
2 CACCgGATGGTGATTTCCGGCGTCC AAACGGACGCCGGAAATCACCATCc 
SPDEF 1 CACCgTATAATGGGAAATCAGGCCC AAACGGGCCTTGATTTCCCATTATAc 
2 CACCgTTTGTTCAGGTAAATAAGGA AAACTCCTTATTTACCTGAACAAAc 
UBIAD1 1 CACCgGCCGGCGGCGCGGGCTGGAC AAACGTCCAGCCCGCCGCCGGCc 
2 CACCgCCGCCCTCCAGCCCACCCTC AAACGAGGGTGGGCTGGAGGGCGGc 
YAP1 1 CACCgGGCGAGTTTCTGTCTCAGTC AAACGACTGAGACAGAAACTCGCCc 
2 CACCgCAAACGCCAAAACTAAAGTT AAACAACTTTAGTTTTGGCGTTTGc 
NT  CACCgGGTCCCTCAGGGTGCAACTT AAACAAGTTGCACCCTGAGGGACCc 
Table 2.8. Oligonucleotides used to generate dsDNA fragments containing the 20 bp 
target sequence. 
Previously cloned into the lenti sgRNA(MS2)_zeo vector. ARHGEF9: RhoA guanine 
nucleotide exchange factor 9 (TF), BCL10: B-Cell CLL/Lymphoma 10 (GF), CRK: CRK Proto-
Oncogene (Adapter Protein), EREG: Epiregulin (GF), FOS: Fos Proto-Oncogene (TF), 
NR4A2: Nuclear Receptor Subfamily 4 Group A Member 2 (TF), PLEKHG6: Pleckstrin 
Homology And RhoGEF Domain Containing G6 (GNEF), PRKACA: Protein Kinase CAMP-
Activated Catalytic Subunit Alpha, PSD2: Pleckstrin And Sec7 Domain Containing 2, 
PTGES: Prostaglandin E Synthase (GF), RORC: RAR Related Orphan Receptor C (nucleic 
acid binding protein), SAMD4A: Sterile Alpha Motif Domain Containing 4A (TF), SPDEF: 
SAM Pointed Domain Containing ETS Transcription Factor, UBIAD1: UbiA 
Prenyltransferase Domain Containing 1, YAP1: Yes Associated Protein 1 (TF). NT is a 
scrambled 20 bp sequence that is predicted to not target any region of the human 
genome. Orange nucleotides indicate the overhangs while black nucleotides represent 
the 20 bp target sequence. 
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Following this, the cloned lenti sgRNA(MS2)_zeo backbone was transduced into library-
ready stably expressing lenti dCAS-VP64_Blast and lenti MS2-P65-HSF1_Hygro Raji cells 
and selected for integration of the vector in zeocin-containing media (300 µg/mL) 
(Invivogen). Total RNA was collected seven days after the final transduction with the 
RNeasy Plus Mini Kit (Qiagen) and quantified by Nanodrop 1000 (ThermoFisher) with 
RT-qPCR carried out as described in section 2.7. All qPCR reactions were performed in 










Table 2.9. RT-qPCR primers used for the validation of the dCas9-VP64-system based 
overexpression of target genes in the Raji cell line 
All primers were retrieved from PrimerBank366,367 and synthesized by Sigma-Aldrich. 
 
 
Gene Forward primer (5’ - 3’) Reverse primer (5’ - 3’) 
ARHGEF9 AATGAGCACTGAGCGTCACTA AGCAGGGTCCTATCTCGCTG 
BCL10 TCTGGACACCCTTGTTGAATCT TGGAAAAGGTTCACAACTGCTAC 
CRK GCGGAGTAGCTGGTACTGG GCGCGAGTTCTCTGAGACG 
EREG GTGATTCCATCATGTATCCCAGG GCCATTCATGTCAGAGCTACACT 
FOS GGGGCAAGGTGGAACAGTTAT CGGCTTGGAGTGTATCAGTCA 
NR4A2 ACCACTCTTCGGGAGAATACA GGCATTTGGTACAAGCAAGGT 
PLEKHG6 CCGCCCTACAGAAGCTGAAG GGATAATGGTCGAGAACTCAGGA 
PRKACA ACCCTGAATGAAAAGCGCATC CGTAGGTGTGAGAACATCTCCC 
PSD2 GGATGGCCTGTCAGACTCAGA CAGCCTGCTAAACTCGTTGTT 
PTGES TCCTAACCCTTTTGTCGCCTG CGCTTCCCAGAGGATCTGC 
RORC GTGGGGACAAGTCGTCTGG AGTGCTGGCATCGGTTTCG 
SAMD4A TCGAGGCTTTGGGCAATCC GAGCTGACGAATCCACTGGT 
SPDEF CAGTGCCCGGTCATTGACA CAGCCGGTATTGGTGCTCT 
UBIAD1 AGTGTGCCTCCTACGTGTTG CAGGACACCGTGGGATCTG 
YAP1 TAGCCCTGCGTAGCCAGTTA TCATGCTTAGTCCACTGTCTGT 
GAPDH GGAGCGAGATCCCTCCAAAAT GGCTGTTGTCATACTTCTCATGG 
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2.9.2 CRISPR screen of Chemotherapy and Rituximab resistance 
2.9.2.1 Transformation, amplification and preparation of lentiviral sgRNA libraries 
Aliquots of the Human CRISPR Activation Library v1 (~1000 ng at 50 ng/μl) (SAM - 3 
plasmid system) (Addgene) were acquired. Each library (100 ng) was transformed into 
ElectroMAX Stbl4 Competent Cells (ThermoFisher) via electroporation with the Gene 
Pulser II Electroporation System (BioRad) according to the protocol supplied with the 
Stbl4 cells. This process was carried out with 4 replicate reactions. Cells were recovered 
in SOC Outgrowth Medium (NEB) and cultured for 1.5 hrs at 30 °C before being plated 
onto ampicillin lysogeny broth (LB) agarose bioassay dishes (Nunc), which were 
incubated overnight at 30 °C. The bacterial colonies were then harvested and the CRISPR 
plasmid libraries were isolated using the EndoFree Plasmid Maxi Kit (Qiagen). 
To prepare lentivirus libraries, log-phase HEK293FT cells (Invitrogen) were seeded at 
~50% confluence the day before transfection in reduced (5%) FBS supplemented DMEM 
to obtain ~80% confluence at transfection. For each T175 flask, 18 μg of sgRNA plasmid 
library, 16 μg of psPAX2 and 10 μg of pMD2.G were incubated in 4.5 mL of Opti-
MEM/TransIT-293 (110 µL of TransIT-293) for 15 min at room temperature. After 
transfection (60 hrs), the media were collected and subject to centrifugation at 500 X g,  
4°C for 15 mins to remove the cellular debris. Aliquots of the supernatant were stored 
at –80 °C. 
2.9.2.2 Transduction of Raji cells using lentiviral CRISPR libraries 
To determine optimal virus volumes for achieving a MOI of 0.3, trial infections to 
determine effective MOI were set up with Raji cells. Briefly, 1 million cells per well were 
seeded into 6-well plates (Corning) in 10% FBS RPMI 1640 and the virus libraries mixed 
with fresh media were added to the cells. Each well received a different volume of the 
viruses (10 μl up to 500 μl) along with a mock (no virus) transduction control. Cells were 
incubated with the virus for 24 hours and cells from each well were then split into 2 
wells in a 6-well plate. One well received 300 μg/mL of zeocin. After 5 days, when no 
viable cells remained in the no-transduction control, live cells in duplicate wells 
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containing zeocin were counted following trypan blue exclusion. The effective MOI was 
calculated as the average cell count from the triplicate wells (with zeocin selection) 
divided by the average cell count from the triplicates with no selection reagent. The virus 
volume yielding a MOI of 0.3 was selected for scaling up for the screens. The virus 
transduction protocol for the actual screens was scaled up to 20 million cells per T175 
flask with a total of 500 million cells being transduced. Cells were selected in zeocin and 
the effective MOI of the cells transduced for the screens were verified once again as 
described above. 
2.9.2.3 SAM (GOF) enrichment screen 
Raji cells (2 billion) were transduced as described above to maintain ~500 X 
representation of the sgRNA libraries. Zeocin was added to the cells 24 hr after 
transduction and maintained for 7 days replacing the selection media every 2 days. On 
day 7, media on the cells was replaced with media not containing zeocin and maintained 
for 3 days before dividing them into four different conditions in duplicates with a 
minimum of 50 million cells per replicate and a separate 50 million cells frozen down in 
duplicate to be used as the day 0 sample for genomic DNA analysis. The four conditions 
employed were: Chemotherapy treated cells, Rituximab treated cells, Chemotherapy + 
Rituximab treated cells and the DMSO control. ED concentrations used were: 
Chemotherapy = ED70, Rituximab = ED70, Chemotherapy + Rituximab = ED85 which 
were determined based on the results of the synergy experiments detailed in chapter 7. 
Cells were either counted and divided or had their media replaced every 2-3 days, 
depending on their confluence. Cell pellets with a minimum of 50 million cells per 
replicate were taken 13 days after the addition of drugs at which point the screen was 
terminated and the cell pellets were frozen at -80 °C.  
2.9.2.4 Preparation of HiSeq libraries  
Frozen cell pellets were lysed and their gDNA extracted with the QIAamp DNA Blood 
Maxi Kit (Qiagen) according to the manufacturer’s instructions. PCR of the virally 
integrated guides was performed on gDNA at the equivalent of 500 cells per guide using 
Herculase II Fusion DNA Polymerase (Agilent) (Table 2.10). Oligonucleotides (Sigma) 
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included the Illumina adapters, a staggered region, and the barcodes (Table 2.11). The 
amount of input gDNA for each sample to achieve 500 X coverage of the SAM library 
was calculated to be approximately 230 μg DNA per replicate, assuming 6.6 μg of gDNA 
is the yield of 1 million cells. Therefore, 23 parallel 100 μl PCR reactions with 10 μg of 
input genomic DNA in each reaction were completed in an ABI Veriti Thermal Cycler 
(Applied Biosystems) in a single-step reaction of 24 cycles (Table 2.12). 
Component Amount per reaction (μl) Final concentration 
UltraPure water 61  
5 x Buffer 20 1x 
100% DMSO 2 2% 
100 mM dNTP 1 1 mM 
10 μM F Primer Mix 2.5 0.25 μM 
10 μM R Primer 2.5 0.25 μM 
Herculase II Fusion DNA Polymerase 1  
1 μg/mL gDNA 10 0.1 μg/mL 



























































Table 2.11. Oligonucleotides used for HiSeq library preparation. 
All forward oligonucleotides were mixed at equal molar concentrations, introducing 
artificial diversity to the library from the varied staggered sequences, then used with one 
reverse primer (unique 8 bp molecular barcode) per sample. Illumina P5 adaptor, 
Illumina P7 adaptor, sequencing forward, sequencing reverse, stagger (varied) 







Cycle number Denature Anneal Extend 
1 95 °C, 20 sec   
2-25 95 °C, 20 sec 60 °C, 20 sec 72 °C, 40 sec 
26   72 °C, 3 min 
Table 2.12. PCR cycle conditions used to amplify the sgRNAs’ guide sequence region 
and to append the Illumina (HiSeq) compatible adapters and barcodes. 
 
PCR products from all 23 reactions were pooled, purified using the Zymo DNA Clean and 
Concentrator-5 kit (Zymo research) and a small amount of sample separated on a 2% 
agarose gel in 1 x TAE at 100 V for 2.5 hrs to confirm the removal of excess primers. The 
isolated amplicons were then quantified by qPCR reactions using kapa Kit 
(ThermoFisher), mixed at equal molar concentrations and submitted for HiSeq high 
Output v4 x 100 reactions with PhiX spike at Bauer Core (Harvard University). 
2.9.2.5 Bioinformatics-based analysis of CRISPR screen results 
Raw fastq files were downloaded from the Bauer Core’s server using FileZilla. Initial QC 
was conducted with FastQC (Babraham Bioinformatics) to assess the general quality of 
the sequence runs. The following steps were executed on Terminal of a MacBook Air 
laptop. First, multiple fastq files for each of the replicates were merged into a single 
fastq file with the concat function. All nucleotides preceding the 20bp guide sequence 
of the sgRNAs were removed using CutAdapt 1.12379. Resulting merged and trimmed 
files were used as the input files for analysis on a turn-key bioinformatics script, named 
the Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK)380. A 
subsequent version of the script, MaGECK-visualization framework (VISPR) was used to 




2.9.2.6 Viability assay based validation of candidates identified from the screen 
To validate the top candidates identified from the screen, 2 guide sequences per 
candidate gene (Table 2.13) were individually cloned into the aforementioned sgRNA 
vector. Once cloned and the sequence verified, each were co-transfected with psPax2 
and pMD2.G into 1 million 293FT cells per individual well of a 6-well plate using TransIT-
293. Viruses were collected 60 hours post-transfection and frozen at -80°C. 
CRISPR-ready Raji cells (with stable expression of dCas9-VP64 + MS2-cofactors) were 
transduced with the sgRNA containing viruses to generate individual stable cell lines for 
each sgRNA. Cells were selected (300 µg/ml zeocin) and passaged for 5 days before 
splitting them into 96-well plates for drug treatment and CTB-based viability assay. Each 
stable cell line was plated at 5X106 cells/ml and treated with concentrations of 
chemotherapy and Rituximab as utilised in the screen. Further analysis of the shift in 
ED50 induced by each sgRNA for single drugs was performed by treating cells with 5 












Table 2.13. Oligonucleotides used to introduce guide sequences into sgRNA vectors 
for the genes identified to induce resistance in the SAM screen against 
chemotherapeutics and/or Rituximab. 
 
2.10 Statistical Analysis 
This project involved several different approaches of statistical analysis and all statistical 
tests were performed with Prism 7, unless otherwise indicated.  
Gene sgRNA Sequence (5’ - 3’)  Sequence (5’ - 3’) 
ABCC1 1 CACCGCAGCCGGACCAGCCACCTCT AAACAGAGGTGGCTGGTCCGGCTGC 
2 CACCGCGCCCCACCCCGCCCCGCCC AAACGGGCGGGGCGGGGTGGGGCGC 
PIM1 1 CACCGCGGGACTGGGCGACTCCCCT AAACAGGGGAGTCGCCCAGTCCCGC 2 CACCGGGCCGAGGGAGGAGAGGGGG AAACCCCCCTCTCCTCCCTCGGCCC 
IRAK1 1 CACCGGAGGGGGCGCGAGGGACAGC AAACGCTGTCCCTCGCGCCCCCTCC 
2 CACCGGCGCAAGATGGCGGCGGGCC AAACGGCCCGCCGCCATCTTGCGCC 
PEG10 1 CACCGCTGAACTGGCCAAGCTGGGA AAACTCCCAGCTTGGCCAGTTCAGC 2 CACCGGGGGATGGGGGATGGGGGTG AAACCACCCCCATCCCCCATCCCCC 
BRCC3 
1 CACCGGGGAAACGCCCGCGCGGTTT AAACAAACCGCGCGGGCGTTTCCCC 
2 CACCGGGGCTGTGGGGGCGGGGCTG AAACCAGCCCCGCCCCCACAGCCCC 
ATG10 1 CACCGGGTGGTCGCGGGCGGCGGGG AAACCCCCGCCGCCCGCGACCACCC 2 CACCGGCGGGGGAGAGCTGCCCGCC AAACGGCGGGCAGCTCTCCCCCGCC 
NFKB1 
1 CACCGCTAGGGGCGCTGTGCGCCCC AAACGGGGCGCACAGCGCCCCTAGC 
2 CACCGGTGCGGGCTTCCCCCACCCC AAACGGGGTGGGGGAAGCCCGCACC 
KRAS 1 CACCGCGTACGAGAGGGAGCGGCTG AAACCAGCCGCTCCCTCTCGTACGC 
2 CACCGGCGGTGTGGGAAGAGGGAAG AAACCTTCCCTCTTCCCACACCGCC 
ALCAM 
1 CACCGGTTAGTCCCAGGGCTCTCCC AAACGGGAGAGCCCTGGGACTAACC 
2 CACCGGTTGCAGCGCCCCAGTGATA AAACTATCACTGGGGCGCTGCAACC 
ITGB1 1 CACCGAGCACTTAAAGCCGCCGGCC AAACGGCCGGCGGCTTTAAGTGCTC 
2 CACCGCCGGGGCTAGGAGGAGGCGG AAACCCGCCTCCTCCTAGCCCCGGC 
ABCB1 
1 CACCGCACATATTTCTTCAATGCTT AAACAAGCATTGAAGAAATATGTGC 
2 CACCGGGATAAGTTTGGGTGGAGGA AAACTCCTCCACCCAAACTTATCCC 
LIN7B 1 CACCGCAGTGGGAGGGGTCGCCAAC AAACGTTGGCGACCCCTCCCACTGC 
2 CACCGGGGCGCGGCTGGCGCGCGGC AAACGCCGCGCGCCAGCCGCGCCCC 
CITED2 1 CACCGCCGGAACACCGCGAACACCC AAACGGGTGTTCGCGGTGTTCCGGC 2 CACCGCGTCTTGGCGCCGCCCGCCC AAACGGGCGGGCGGCGCCAAGACGC 
MAPK13 1 CACCGGAAGCGCGGGAGCGCAGGGC AAACGCCCTGCGCTCCCGCGCTTCC 
2 CACCGAGGCCCGGGCGTGGCGGCCC AAACGGGCCGCCACGCCCGGGCCTC 
SOX14 1 CACCGTCTGCTGCTGATTGGCGCCC AAACGGGCGCCAATCAGCAGCAGAC 2 CACCGTGTTGGCAGGTGCGCCCCCT AAACAGGGGGCGCACCTGCCAACAC 
ADAM9 
1 CACCGCACCGCTAGTGCTGGTTGCCACCGC AAACGCGGTGGCAACCAGCACTAGC 
2 CACCGCACCGGTCGGGCGCGCGTGCTCGTC AAACGACGAGCACGCGCGCCCGACC 
DDB2 1 CACCGCACCGAAAAAAAATCCATAAAGCCG AAACCGGCTTTATGGATTTTTTTTC 2 CACCGCACCGTGACCTCCCTGGAGCAAAGA AAACTCTTTGCTCCAGGGAGGTCAC 
DKK3 
1 CACCGAGAGGAGGGCGTGGGGCGTG AAACCACGCCCCACGCCCTCCTCTC 
2 CACCGGCGGGGCGGGGTGGGCCTGG AAACCCAGGCCCACCCCGCCCCGCC 
JARID2 1 CACCGCGGTCGGCACCAGGCTAAGC AAACGCTTAGCCTGGTGCCGACCGC 
2 CACCGGCGCCTGGCGGCTGAGCGGT AAACACCGCTCAGCCGCCAGGCGCC 
HAX1 
1 CACCGTTTAGGAGGAAGGCGGTCAT AAACATGACCGCCTTCCTCCTAAAC 
2 CACCGAAACTGGTCTCTGAAAGGTG AAACCACCTTTCAGAGACCAGTTTC 
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Chapter 3. Establishment of Patient Derived Xenografts 
3.1 Introduction 
The standard toolkit for cancer researchers for decades has been the use of clonal cell 
lines cultivated in vitro. However, this resource is lacking in its ability to allow for 
investigation of heterogeneity within a patient’s tumour. Data has highlighted that the 
behaviour of these cell lines diverges largely from the original tumour. In particular, gene 
expression patterns show significantly reduced complexity in cultured cell lines as forced 
selection by in vitro conditions reduces the heterogeneity of the sample with 
subsequent loss of important biological properties382. Furthermore, mouse xenografts 
using these cell lines have had minimal success when it comes to predictive power in 
translational research, which contributes to the high failure rate of most novel therapies 
in phase III clinical trials383. Patient derived Xenografts (PDXs) have evolved as a powerful 
pre-clinical tool capable of bridging the gap between established cell lines and primary 
tumour samples. PDXs better maintain the heterogeneity of patient tumours and hence 
allow for a more clinically relevant examination of tumour evolution, response to 
therapy and development of chemo-resistance.  
Mature paediatric B-NHL (pB-NHL) presents in three main forms - BL, DLBCL and PMBL384 
and despite advances in the understanding of the different pathologic and genetic 
features of these separate entities the current standard of care for all is still high dose 
chemotherapy with the addition of Rituximab being currently formally evaluated, with 
positive outcomes102. Within the most common subtype, BL, recent studies have shown 
that it may not be as homogeneous as previously thought, i.e. there are distinct 
subpopulation with unique genotypes and phenotypes within tumours. Love et al. 
found, in the largest sequencing study of BL, that there was considerable heterogeneity 
in the number of mutated genes across samples. Out of a total of 70 mutated genes the 
range of mutation in the sample cohort was 2 to 16, highlighting diversity across patient 
samples52. This study did not report variant allele frequency of mutations although 
research in our own lab, carrying out high coverage multi-region whole exome 
sequencing has identified a large amount of low frequency, sub-clonal heterogeneity 
within primary presentation BL samples. Given this evidence of heterogeneity, 
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preclinical model systems such as PDXs that capture the genetic and functional 
heterogeneity of primary pB-NHL are necessary. This will enable us to enter the next 
stage of research where we try to identify targeted therapies for individual patients as 
well as decipher the clonal dynamics leading to resistant disease in 5-10% of patients. 
PDX models of B cell lymphoma exist, although those published are adult samples and 
consist mainly of the DLBCL subtype as this is most common in adults385. To our 
knowledge no other comprehensive pB-NHL PDX resource exists. 
Of course, the PDX model does not come without its challenges; studies of PDXs have 
indicated that histology386 and gene expression profiles are retained387, along with 
single-nucleotide polymorphism388 and copy number variants389, although conflicting 
data exits regarding the presence of genetic alterations in the engrafted tumours 
compared with their parental cancers390–392. Genes associated with stromal gene 
ontology annotations are the most altered, most likely due to loss of the human stromal 
compartment and interactions with the mouse stromal microenvironment. For these 
reasons, careful investigations at each passage are important to ensure the PDX is 
faithfully recapitulating the original tumour sample. Most authors advocate using PDX 
models with a low passage number (<10) to preserve the genetic integrity of the 
parental tumor393, although most PDX models in use have not been extensively 
genetically profiled, something that should become common practice going forward. 
Another consideration when establishing PDX models is the location of implantation 
with subcutaneous (SC), intraperitoneal (IP), intravenous (IV) and orthotopic 
implantation all commonly used. Given the “semi-solid” nature of pB-NHL careful 
consideration is necessary to determine the most relevant and reliable site for the 
establishment of PDXs in this study. Numerous types of immunodeficient mice can be 
used to establish xenograft models - athymic nude mice, SCID, NOD-SCID, and 
recombination-activating gene 2 (Rag2)-knockout mice,303 although primary malignant 
cells often require more robust immunodeficiency for effective engraftment. The use of 
NOD/SCID mice with IL2rg mutations (NSG) has proven to be effective across a range of 
cancers including those with lymphoid origin and was chosen for use in this model. Of 
course, the use of NSG mice results in replacement of human stromal components (such 
as cancer-associated fibroblasts, endothelial cells, immune and inflammatory cells) by 
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murine elements as well as a lack of interaction between immune cells and tumour cells. 
Transgenic mouse models would provide these tumour-stromal-immune interactions 
but the fact that they do not represent a human origin is a major limiting factor. For 
example, transgenic MYC mouse models show delayed onset of lymphomagenesis and 
result in tumours with of a clonal nature eliminating the ability to examine tumour 
heterogeneity59. The utilisation of humanised PDX models in the future, if costs reduce, 
will help to combine all the important elements of tumour modelling but for now the 
use of PDXs in NSG mice offers the best method to examine heterogenous populations 
of pB-NHL. 
Chapter Aims 
- Establish Patient Derived Xenografts of samples obtained from the Inter B-NHL 
Ritux Clinical Trial for paediatric B-cell non-Hodgkin lymphoma 
- Determine the optimal engraftment route  
- Determine the ability of the PDX model to maintain tumour characteristics 
through passage with respect to histology, genetic features, cell surface protein 











3.2.1 Patient biopsy sample details 
Due to the rarity of pB-NHL, ethics constraints and standard practice to take fine needle 
aspirates for diagnosis, acquiring samples of the required quality and quantity for PDXs 
has been difficult (i.e. fresh frozen disaggregated tumour or effusion). Samples were 
received from various biopsy sites including a solid tumour mass, pleural effusion, bone 
marrow and peripheral blood (Table 3.1). 







Biopsy site Diagnosis Stage 
1 Needle biopsy of 
abdominal mass 
Burkitt Lymphoma III 
1 Bone Marrow Burkitt Lymphoma III 
2 Pleural Effusion Burkitt Lymphoma III  
3 Peripheral blood Burkitt Lymphoma/Leukaemia with 
CNS involvement 
IV 
3 Bone Marrow Burkitt Lymphoma/Leukaemia with 
CNS involvement 
IV 
4 Peripheral Blood Burkitt Lymphoma IV 
4 Bone Marrow Burkitt Lymphoma IV 
5  Bone Marrow Burkitt Lymphoma/Leukaemia IV   
6 Bone Marrow Burkitt Lymphoma III  
7 Pleural Effusion Burkitt Lymphoma III 
8 Bone Marrow Originally Burkitt Leukaemia. Changed 
to Pre-B-ALL with MYC translocation 
IV  
9 Bone Marrow Burkitt Lymphoma/Leukaemia IV 
9 Pleural Effusion Burkitt Lymphoma/Leukaemia IV 
10  Peripheral Blood Burkitt Lymphoma IV 
10 Bone Marrow Burkitt Lymphoma IV 
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3.2.2 Successfully engrafted tumours maintain the surface phenotype of biopsy 
tumour cells 
PDXs were successfully established from pleural effusion, bone marrow and peripheral 
blood in this study. All samples were treated identically upon receipt with mononuclear 
cells (MNCs) isolated by gradient centrifugation over lymphoprep. When sufficient 
biopsy material was available cells were analysed by flow cytometry using forward 
scatter (FSC) and side scatter (SSC) to identify the MNC population reminiscent of 
lymphocytes. In addition, CD20, CD19 and CD10 expression was assessed and the main 
population in which these cells resided was used as an indicator of the tumour cell 
population. B cell surface proteins are indicative of the presence of tumour cells, 
specifically CD20 which is a membrane-embedded surface molecule that plays a role in 
the development and differentiation of B cells into plasma cells. It appears after CD19 
and CD10 expression which are other characteristic markers in BL394. Some interesting 
observations regarding engraftment and maintenance of tumour cell characteristics 
were noted in successfully engrafted tumours. The first PDX was produced from a 
pleural effusion of patient 2. Flow cytometry to determine cell size and granularity 
identified a small population of cells (approximately 5%) consistent with a lymphoid cell 
profile (Figure 3.1A). Following isolation of the MNCs by gradient centrifugation over 
lymphoprep, this increased to 55% (Figure 3.1B). These cells had a B-NHL phenotype, 
with over 99% being CD10, CD19 and CD20 positive, a population not usually present in 
pleural effusion (Table 3.2). Interestingly, surface proteins associated with stemness 














Figure 3.1. Gradient centrifugation of a pleural effusion from patient 2 increases the 
ratio of lymphoid cells detected by flow cytometry. 
(A). Whole pleural effusion from the biopsy was analysed by flow cytometry. The 
lymphocyte gate was approximately 5% of the whole population, based on the normal 
FSC and SSC for this population. (B). MNCs were separated from the pleural effusion by 
gradient centrifugation and this results in an increased lymphocyte gate of 55.8% 
 
Table 3.2. Cell surface phenotype of lymphocytes within the pleural effusion taken 
from patient 2. 



























Given the identification of a clear population with a B-NHL phenotype the possibility of 
sorting this population before injection into mice was considered. However, due to the 
limited sample size as well as the potential that FACS sorting may induce stress in these 
primary patient samples, the whole MNC population was injected into mice. 
Furthermore, the presence of accompanying healthy cells may provide a 
microenvironment more similar to that of the patient and hence could be beneficial for 
initial growth of the tumour cells in mice. This method of sample preparation led to 
successful tumour engraftment after SC injection of mice with cells (5X106) in matrigel. 
Importantly, phenotyping of the tumour produced at passage 1 (P1) highlighted the 
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Figure 3.2. The cell surface phenotype of all markers is maintained in patient sample 
2 between biopsy and passage 1. 
MNCs were isolated from pleural effusion sample and cells analysed by flow cytometry. 
The lymphocytes were gated on as shown in the FSC and SSC graph. Cells were single 
stained for high, low and medium expressed surface markers. Following injection of 
tumour cells in mice and extraction of the tumour produced this process was repeated 
and the expression profiles compared, showing maintenance of marker expression. Data 
is representative of 2 replicates as biopsy cells were injected into 2 different mice. 
 
The second successful engraftment was of a peripheral blood sample from patient 3. 
Following gradient centrifugation to isolate MNCs, cells were labelled with anti-CD20 
and a back-gating strategy identified the population with highest CD20 expression. 
(Figure 3.3B). The percentage of CD20 positive cells constituted 84% of the pre-
determined lymphocyte gate of the primary sample (Figure 3.3C) which increased to 
96% following successful engraftment. The percentage of cells expressing other BL 
associated surface proteins also increased following the first passage (Table 3.3) 
suggesting that in vivo, malignant CD20+ cells are selected for growth over other cells 
within the sample such as untransformed lymphocytes. In contrast, the percentage of 
CD117+ cells disappears after the first passage suggesting that either these cells were 
not tumour cells or were not selected for growth in vivo. In support of the former, these 
cells were negative for CD20 in the biopsy sample (Figure 3.4A). Furthermore ABCG2 
expression was maintained on 1% of the population after passage and this cell 
population was positive for CD20 in the initial biopsy (Figure 3.4B). 
Results of the first passage of patient samples 2 and 3 highlight some noteworthy 
observations. The presence of healthy cells within the injected population does not 
hamper engraftment and these untransformed cells do not survive. The surface protein 
expression profile of tumour cells is maintained after passage in the mouse, including 
populations present at very small percentages. Finally, cell surface proteins associated 
with stemness such as CD34 and ABCG2 were present in the biopsy samples and were 











Figure 3.3. Gating strategy to identify lymphocyte gate with CD20 positive cells 
Peripheral blood sample underwent gradient centrifugation to isolate MNCs. (A). Cells 
were analysed by flow cytometry and the FSC and SSC plot identified three clear 
populations of cells. (B.) The lymphocyte gate was chosen based on the highest 













Table 3.3. Cell surface phenotype of 
lymphocytes from patient sample 3 
peripheral blood before engraftment 
and after P1 highlights the preferential 
survival of certain cells 
MNCs were isolated from peripheral 
blood sample and single stained for an 
array of surface markers before analysis 
by flow cytometry. Following injection of 
tumour cells in mice and extraction of 
the PDX this process was repeated and 
the expression profiles compared. Data 
is representative of 2 replicates as biopsy 











Figure 3.4. CD20+CD117+ cells were not present in patient 3 biopsy sample but 
CD20+ABCG2+ cells were 
MNCs were isolated from peripheral blood and double stained for (A). CD20 + CD117 and 
(B). CD20 + ABCG2. Cells were then analysed by flow cytometry and the presence of 
double positive cells in the biopsy sample determined. 
 
3.2.3 Not all biopsy samples led to successful engraftment 
Successful PDXs were formed from pleural effusion, bone marrow and peripheral blood 
during this study, suggesting that the site of biopsy may not be important in the 
establishment of PDXs from BL samples. Despite this, not all biopsies gave rise to tumour 
formation. In fact, the only biopsy sample received from a solid mass (patient 1) did not 
engraft. Bone marrow with tumour involvement was also received from this patient and 
also did not lead to successful engraftment. Importantly, the patient had not received 
any treatment before the biopsy was taken. The tumour biopsy was limited in size hence 
all cells were injected, although analysis was carried out on the bone marrow sample. 
Three clear populations of MNCs were present after collection by centrifugation; gates 
L1, L2 and L3 (Figure 3.5, Table 3.4). L1 had no CD20 positive cells while L2 had the 
highest proportion of CD10, CD19 and CD20 positive cells and hence it was deemed most 











samples from this patient suggests that the environment in which cells were injected 
was not appropriate for growth of these particular tumour cells. An overview of 
engraftment outcome for each biopsy sample received is given in Table 3.5. In most 
cases sufficient material was available to perform a limited amount of phenotyping on 
the original biopsy and the percentage of cells expressing BL associated markers (CD10, 
















Table 3.4. Cell surface expression of the indicated proteins on distinct cell populations 
within the bone marrow of patient 1. 
 
Marker L2 % L3 % 
CD5 0.82 61.3 
CD7 0.28 59.1 
CD9 13.2 9.25 
CD10 77.6 3.74 
CD19 90.3 20.1 
CD20 35.2 19.1 
CD34 0.62 0.26 
CD38 93.7 28.5 
CD40 36.3 4.65 
CD44 10.7 82 
CD45 59.7 93.9 
CD49D 6.76 20.2 
CD49F 0.71 11.7 
CD90 0 0.16 
CD105 0.31 0 
CD133 0.31 0.38 
OCT3/4 0 0 
CD117 0.46 0.2 
Figure 3.5. Multiple cell populations were 
present within the isolated MNC fraction 
from bone marrow of patient sample 1 
Following gradient centrifugation of patient 
sample 1 bone marrow biopsy, MNCs were 
isolated and analysed by flow cytometry. 
Forward and side scatter identified three 


































































































































































































































































































































































































It is difficult to form any conclusive insights from the above data regarding factors that 
are important for engraftment of BL PDXs. It appears pleural effusion is the biopsy 
material most likely to engraft with three out of three injected samples forming PDXs. 
Bone marrow and peripheral blood each produced one successful PDX but other 
samples from these biopsy sites did not engraft. The tumour cell burden may also be an 
important factor in determining if a sample of MNCs engrafts or not. The first four 
successful engraftments all had a high burden of tumour cells (based on 
CD20+CD19+CD10+ phenotype) although the fifth successful engraftment from a pleural 
effusion had a relatively low burden of CD20+CD10+CD19+ cells and the bone marrow 
sample from this patient did not produce a PDX, suggesting again that pleural effusion 
is the material most likely to engraft. Other factors also likely influence engraftment 
rate. For example, although each biopsy was processed identically, some samples were 
received more quickly than others and the sub-optimal conditions that may have been 
experienced by samples may have impacted the probability of engraftment. 
Nonetheless, five PDXs were formed from a total of ten patients giving a 50% 
engraftment rate. Alternatively, when considering each of the 14 individual biopsies 
received across these patients, all of which had tumour involvement, the engraftment 
rate was 35.7%. A frozen aliquot of a further established BL PDX sample were received 
from another investigator. This pleural effusion-derived PDX successfully engrafted 
bringing the total number available to us to six. The PDX from patient 9 was established 
later in the project and is not included in further studies. 
3.2.4 Subcutaneous or intraperitoneal injection of tumour cells but not the 
intravenous route leads to successful engraftment 
When sufficient patient material was available, samples were injected SC, IP and IV. 
Interestingly, even for samples obtained from bone marrow and peripheral blood, the 
IV route did not lead to tumour formation or the detectable presence of human cells in 
the animal peripheral circulation. However, all samples that engrafted SC also 
developed tumours via the IP route (Figure 3.6) and both these routes led to tumours 











Figure 3.6. Tumours form from both subcutaneous and intraperitoneal injections 
MNCs were isolated from patient sample 7 pleural effusion and suspended in PBS. Cells 
were injected with matrigel (5X106) in both the SC and IP route. (A). SC tumours are easy 
to palpate and measure and form tumours outside the peritoneal membrane. (B). IP 

















                                           





                   





Figure 3.7. Cell surface expression of tumours is the same whether formed in the 
subcutaneous or intraperitoneal cavity. 
MNCs were isolated from patient sample 7 pleural effusion and suspended in PBS. 5X106 
cells were injected with matrigel in both the SC and IP route. When tumours reached 
maximum size they were excised, disaggregated into single cell suspension and analysed 
by flow cytometry for surface protein expression. The same results were seen for the 
other PDX samples, with no significant difference in phenotype based on SC or IP 
injection.    
SC 
IP 
CD9 CD19 CD20 CD27 
CD21 CD24 CD40 CD34 
CD9 CD19 CD20 CD27 
CD21 CD24 CD40 CD34 
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The fact that tumour engraftment was successful via the SC and IP route but not IV, 
highlights the potentially important role matrigel has in establishing tumours in the 
mouse, possibly due to the range of extracellular matrix proteins and growth factors 
present. Furthermore, the failure of IV injections may hint towards the importance of 
tumour cell-to-cell interaction, with matrigel providing a 3D matrix. As tumours 
propagated by IP and SC routes had no significant phenotypic surface expression 
variability, the SC method was employed throughout these studies to allow easier 
measurement and monitoring of tumour growth. 
3.2.5 Monitoring of tumour characteristics through passage 
To ensure that PDX tumours are a robust and reliable model for studying tumour 
heterogeneity it is imperative to monitor tumour characteristics through passage to 
ensure they are maintained. Comprehensive phenotyping by histology, FISH, flow 
cytometry and gene expression was conducted on all PDXs at passage one and again at 
subsequent passages. 
3.2.5.1 Tumours maintain their histopathological appearance over multiple passages 
Due to defective macrophages in NSG mice the starry sky appearance associated with 
solid BL masses is not fully recapitulated. Despite this, histopathological analysis of H 
and E stained slides from each tumour after passage 1 and 5 were examined and the 
maintenance of a high-grade lymphoma histology was verified along with tumour cell 

























Figure 3.8. Tumour histology is maintained in PDXs between passage 1 and 5 
PDX tumours were extracted when they reached 12mm and formalin fixed. H and E 
staining was performed and slides examined by a clinical histopathologist. 













3.2.5.2 Tumours maintain their cell surface protein expression profile over multiple 
passages 
The average numbers of days for the injected primary cells to first produce palpable 
tumours when engrafted SC was 33 (range 28-48). Following tumour growth the cells 
were reinjected as outlined in Figure 3.9. Subsequent passages, for the most part, led to 
palpable masses of 12mm in any one direction by an average of four weeks. At each 
passage tumours were analysed for cell surface protein expression and each tumour 
faithfully maintained its expression profile over passage, highlighting the existence of an 







Figure 3.9. Mechanical disaggregation of tumour for serial passage 
Once initial engrafted biopsy samples had formed tumours of 12mm, animals were 
euthanised and tumours extracted. Tumours were mechanically disaggregated into 























































Figure 3.10. Cell surface protein expression of 5 PDXs was maintained over 4 passages. 
Biopsy tumour cells were injected into NSG mice with matrigel. When the tumour 
reached 12mm (Passage 1) it was extracted, disaggregated into single suspension and 
labelled with antibodies before flow cytometry analysis. Cells were also serially 
passaged. The process was repeated at P2, P3 and P4. Plots show the maintenance of 
surface marker expression over 4 passages. 
 
3.2.5.3 PDXs maintain key genetic features with passage 
FISH was employed to investigate the presence of the MYC translocation in tumour cells 
after multiple passages through mice. This important feature was maintained in the five 
PDXs between passage 1 and passage 5 (Figure 3.11).  
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Figure 3.11. MYC translocation is maintained after five passages in mice 
Following passage 1 and 5 in mice, tumours were disaggregated and the presence of the 
MYC translocation signal investigated by FISH. Images represent one DAPI stained 
nucleus of a cell. 100 cells were counted per sample and reported. Aqua (A) signal = 
centromere of chromosome 8, red (R) signal = MYC, green (G) signal = IgH, F = fusion.  





































However, tumour cells are genetically distinct with sub-clonal variation and so gene 
expression profiling for 20 genes on RNA isolated from tumour cells after passages 1 and 
3 was conducted (Figure 3.12). These 20 genes were chosen based on studies of 
expression profiles of BL and also included genes associated with stemness and genes 
identified as important in other PDX studies58,395. A close correlation was detected 
whereby the correlation coefficient between P1 and P3 for each PDX was greater than 














Figure 3.12. Expression levels of 20 genes were maintained in PDXs between passage 
1 and 3. 
RNA was extracted from PDXs after passage 1 (P1) and 3 (P3). RT-qPCR was carried out 
on both samples using the same reference cDNA from the Raji cell line as the control. 























Taken together, comprehensive phenotyping by histology, FISH, flow cytometry and 
gene expression highlighted the successful maintenance of tumour properties in the 
PDX models. Each of these 5 successfully engrafted tumours retain their MYC 
translocation through passage as well as their histology and gene expression profile for 
a sample of genes. Importantly, analysis of cell surface protein expression highlighted 
heterogeneity at both the inter- and intra-tumour level (Figure 3.10). Each tumour 
faithfully maintains its cell surface protein expression profile over passage, highlighting 
the existence of an intricate population equilibrium within individual samples.  
Comparison with the starting tumour population was not made as, for many cases, there 
was insufficient material to conduct detailed flow cytometry and in addition, the starting 
















We have successfully established PDX models of paediatric B-NHL and demonstrated 
their ability to faithfully maintain molecular and phenotypic characteristics through 
multiple passages. This ability to maintain tumoural heterogeneity ensures the model 
possesses a high level of clinical relevance and can be used for identifying populations 
with chemo-resistant potential as well as to investigate targeted therapies. 
The utilisation of cell lines has been shown to be lacking in terms of their ability to 
translate results to the clinic, mainly due to their clonal nature which hinders the study 
of intra-tumour heterogeneity as well as inter-patient heterogeneity. As survival rates 
in pB-NHL approach 90% but salvage rates in relapse remain at <30%, it is necessary for 
us to develop a greater understanding of the different populations within tumours to 
not only try to reduce the use of toxic chemotherapy but also to develop targeted 
therapies for the difficult to treat chemo-resistant relapse and refractory cases. The 
well-established Paediatric Preclinical Testing Program supported by the National 
Cancer Institute established 51 solid tumours (including sarcomas, neuroblastoma, brain 
tumours, osteosarcoma) and 10 ALL models and has shown that prediction of response 
in the clinic is significantly higher when a PDX model is used as opposed to cell line 
xenografts19. Due to the genetic heterogeneity of B-NHL, several different pathways 
leading to drug resistance have been identified in the adult disease and recent data 
highlights that this is likely to be the same in paediatric cases62. Successful treatment of 
chemo-resistant pB-NHL may therefore require the rational design of combinatorial 
drugs targeting multiple populations and pathways specific to different subtypes of B-
NHL as well as the development of personalized approaches to address patient-to-
patient genetic heterogeneity.  
One of the initial considerations in the establishment of a PDX model is the genotype of 
immunodeficient mouse to use. Several types of immunodeficient mice can be used to 
establish xenograft models: athymic nude mice, SCID, NOD-SCID, and recombination-
activating gene 2 (Rag2)-knockout mice. These strains have been shown to be 
appropriate for establishment of B-NHL cell line xenografts396, although they are often 
not sufficiently immunodeficient for the establishment of PDXs from primary cancer 
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cells due to their functional innate immune system397. With this in mind and with 
personal knowledge that other researchers have had difficulty establishing B-NHL PDXs 
we chose to use the NSG model which has enhanced immunodeficiency through a lack 
of NK cells and has been shown to increase the take rate of numerous human cancers in 
PDX models398. An engraftment rate of 35.7% was observed when considering all 
specimens with tumour involvement received, increasing to 50% if just considering 
individual patients. These rates are comparable to many other similar studies with one 
review of existing data highlighting that engraftment rates typically vary between 23% 
and 75% depending on the tumour type399. Pleural effusion samples had the highest 
engraftment success rate although PDXs also developed from peripheral blood and bone 
marrow via the IP and SC routes. In contrast, no cells engrafted via the IV route, 
regardless of the biopsy origin site. Possible explanations for the failure of the IV 
engraftment route include the absence of matrigel as well as the less protective niche 
the IV route might offer. NSG mice have no mature B or T cells or NK cells although 
leakiness in this phenotype is possible. Furthermore,  they contain defective dendritic 
cells and so tumour cells may be better protected from any potential residual immune 
functions of the animal when injected into the IP or SC cavities. 
Despite the importance of an absent immune system to enable tumour engraftment, 
this is also one of the limitations of the NSG mouse model given the emerging evidence 
in recent years of the important role the TME plays in cancer. This area has not been 
well-studied in BL with traditional views that there is not a strong dependence on the 
microenvironment for stimuli in BL due to the fact that malignant cells harbour a MYC 
translocation and cooperating mutations that confer strong cell-autonomous survival 
and proliferation signals400. However, more recent data has shed light on the potentially 
important role of the TME in mature B-NHL and in DLBCL the importance of non-
malignant cells, particularly macrophages and dendritic cells has been reported401. Apart 
from immune cells the TME is made up of stromal cells including resident fibroblast-like 
cells, endothelial cells and extracellular matrix. Recently the role of stromal components 
of the TME in mature B cell malignancies has been highlighted and in particular they 
have been shown to regulate sustained MYC activation facilitating lymphoma cell 
growth and proliferation402,232. Upon adhesion to stromal cells, malignant cells as well 
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as stromal cells produce and secrete a host of soluble factors associated with malignant 
B cell growth403–405. Medina et al. showed that B-cell lymphoma adhesion-induced BAFF 
expression by bone marrow stromal cells promoted cell growth in B cell lymphomas via 
activation of NF-κB signalling406. IL-6 which is another prototypical growth and survival 
factor in B cell lymphomas407 is also produced by the TME and initiates ERK1/2, PI3K and 
JAK/STAT3 signaling408. Numerous other cytokines have also been shown to contribute 
to the cross talk between stromal and lymphoma cells including IL-7, IL-4, IL-8, VEGF, 
CXCR4, MIP-1, Jagged-1, and insulin growth factor (IGF)-1409–413. 
Importantly, emerging evidence has shown that TME also has a critical role in supporting 
stemness properties in B-NHL. The renewal and differentiation capacity of germinal 
centre lymphocytes upon antigen stimulation has suggested that secondary lymphoid 
organs are ideal niches to confer lymphocyte stemness features through stroma-
mediated genetic and epigenetic means402. Given the close contact of lymphoma cells 
and stromal cells in the lymph node and bone marrow microenvironment, malignant 
reprogramming may be achieved through stroma-mediated regulation of genes 
controlling a stemness pathway232. Recent studies on TME have revealed that stromal 
cells can modulate stemness by influencing B cell differentiation and enhancing 
lymphoma cell clonogenicity232,233. 
Due to the emerging evidence of the role of the TME in B-NHL as well as the introduction 
of Rituximab and potentially the future use of other immune therapies for the treatment 
of pB-NHL further investigation in this area is required. It will be necessary for PDX 
models to possess a human immune system component to facilitate the study of 
immune-cancer cell interactions and preclinical assessment of cancer immune 
therapies. Several different methods exist to develop humanized mice including the 
transplantation of total peripheral blood or tumour-infiltrating lymphocytes into 
immunodeficient mice, or the transplant of CD34-positive human hematopoietic stem 
cells or precursors, either alone or in combination with additional human immune 
tissues (e.g. human thymic tissue) into immunodeficient mice301.  Each method has its 
complexities and with the high expense these are not in common use currently. 
However, now that we have established and characterised a PDX resource that will 
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continue to expand, exploring human immune system-conditioned PDX models is a 
likely direction to improve pre-clinical studies of pB-NHL. 
The most important consideration when utilising PDXs as a model for cancer is how well 
it represents the original patient disease. Due to insufficient biopsy material we used 
passage 1 compared to later passage tissue to monitor the effect of serial passage on 
the tumour cell characteristics at the histological, gene expression and surface protein 
level. However a number of lines of evidence in our study also highlight that it is likely 
changes did not occur to tumour properties between biopsy and passage 1. All tumours 
were almost 100% MYC translocation positive after passage 1 and in the two cases 
where the exact initial translocation signal was available from the diagnostic report, this 
signal was maintained after passage 1. Furthermore patient sample 2, which produced 
PDX1 from a pleural effusion, showed that surface marker expression in the biopsy 
sample MNC population was maintained after passage 1 and in patient sample 3 
peripheral blood sample (PDX2), any cell populations that were lost from the biopsy 
sample were shown not to be CD20+ cells and hence most likely healthy immune cells 
that fell into the same forward and side scatter gate. Of course, it is not possible to 
categorically conclude this from our data so it is also possible they may have been 
tumour cells that did not adapt to the in vivo environment. Several studies in the 
literature also support the maintenance of properties between biopsy and passage 1 
including a study of MCL PDXs which sequenced 1,212 cancer-associated genes and 
found no mutations introduced after passage 1392. Furthermore in a study of adult DLBCL 
PDXs, a comparison of the mutant allele fraction in primary specimens and the 
associated PDXs indicated that these models retained the complex genetic signature of 
primary samples385.  
Analysis of tumour properties between subsequent passages from P1 onwards in our 
model was also an encouraging indicator of the ability of this model to maintain the 
biological and molecular heterogeneity of the tumours. Nearly every cell at passage 5 
was MYC translocation positive with maintenance of the exact signal from passage 1, 
highlighting that tumour cells are not losing this key BL characteristic. Furthermore, the 
correlation coefficient for gene expression levels between P1 and P3 was greater than 
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0.94 for all 5 PDXs. However, we acknowledge that this was a limited set of genes and 
going forward to further validate the PDXs we would examine expression of a broader 
array of genes as well as carry out SNP arrays or whole exome sequencing to get an 
overview of the mutational landscape of the tumours through passage.  At the cellular 
level, the histology of each tumour was maintained over five passages and significantly 
the heterogenous surface protein expression profile was also maintained highlighting 
the potential importance of a tightly controlled population equilibrium within the 
tumours. 
Overall, the first well-characterised PDX resource for pBL has been established showing 
that, at least for some of the PDXs, initial tumour heterogeneity is maintained between 
the biopsy and the first passage. Furthermore, the characteristics of the tumours in 
terms of cell surface protein expression, morphology and the presence of the driving 
MYC translocation are maintained through multiple passages in the mice and provide us 
with a valuable resource to investigate the functional and clinical significance of the 
heterogenous populations in these BL tumours. PDXs offer a greatly improved route 
towards personalised medicine. A notable example is a pilot clinical study in which 
pancreatic PDX models were used to guide treatment for 11 patients with advanced 
cancers. 17 treatment plans were devised with 15 of these resulting in durable partial 
remissions414. This type of modelling is beneficial in cases where few established 
treatments exist such as in the case of relapsed of refractory pB-NHL. The existence of a 
PDX that represents the full heterogenous nature of the patient disease would allow for 
the development of targeted therapy plans, focusing on the correct population of cells.  
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Chapter 4.  Heterogenous populations exist in paediatric B-NHL 
including a side population 
4.1 Introduction 
With evidence generated thus far highlighting that the PDX model accurately maintains 
tumour properties through passage, the heterogeneity of tumour cell populations 
within these PDX tumours was investigated utilising limiting dilution assays, cell surface 
phenotyping and functional assays. The fact that malignancies, both epithelial-derived 
and haematological, show morphological and physical heterogeneity has been known 
for many years, since the first pathological assessments were conducted204. However, 
more recently this knowledge has been expanded upon by increasing awareness of 
variation in both molecular and functional biology, as assessed by in vitro and in vivo 
assays. These developments have led to the search for populations within heterogenous 
malignancies that are capable of maintaining disease and most importantly are 
responsible for clinical relapse. 
The stochastic model of cancer was proposed by Nowell et al. in 1976 and utilises the 
concept of clonal evolution to explain heterogenous populations present in tumours192. 
This model proposes that each cell in the whole tumour population has the ability to 
produce a malignancy. Mutations arising in tumour cells confer a selective growth 
advantage and hence lead to the observed heterogeneity. Both endogenous and 
exogenous factors can result in this selective pressure. Endogenous effects include 
variation in growth, apoptosis, metabolism, and other “hallmarks of cancer.” Non-cell 
autonomous factors causing selective pressure include cytokine concentrations, cell–
cell interactions and the niche TME206.  
Alternatively, the CSC model suggests a hierarchical organization of cells, whereby a 
small subset has the ability to sustain tumorigenesis and generate heterogeneity 
through differentiation415. The term CSC is generalized to define a distinct population of 
cells with stem cell-like properties and not necessarily a transformed tissue-specific 
stem cell. These cells have self-renewal properties and can undergo differentiation to 
give rise to a transient-amplifying (TA) cell population with limited replicative potential. 
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The TA cells are responsible for forming the bulk of the tumour416,417. CSCs by definition 
must be able to give rise to tumours upon injection into immunocompromised mice and 
the tumours they produce should be serially transplantable as a demonstration of long-
term repopulation capacity202.  
Until recently these two models, i.e. stochastic versus CSC, were considered mutually 
exclusive. However recent advances in knowledge have highlighted the blurred lines in 
this area of study and it is proposed that the two models of cancer heterogeneity can 
be harmonized202. Greater knowledge of cancer genetics, epigenetics and the tumour 
microenvironment has highlighted the important role each of these has in defining 
stemness and less focus is placed on tumours strictly fitting either model of 
heterogeneity. This theory compliments the findings discussed in a review by Visvader 
in which CSCs were described to have variable phenotype, to be present as multiple 
clones within individual tumours and to undergo genetic evolution415. Finally, it is not 
incomprehensible that non-CSCs may have the potential to transition to CSC-like cells415.  
The CSC model has become more accepted and its therapeutic implications realised, 
although its study has been hampered both by a lack of consistency in the terms used 
for these cells and by how they are defined. A study of the literature has identified a lack 
of clarity in the use of the terms CSC, tumour-initiating cell (TIC) and tumour-
propagating cell (TPC). Reviews by Visvader and Lindeman as well as Kreso and Dick have 
addressed this and I will utilise their definitions throughout this thesis415,202. 
Contributing to a lack of clarity is the fact that not all tumours harbour CSCs. For 
example, in melanoma, the high proportion of tumorigenic cells (as many as 50%) 
assayed under more permissive conditions and with a wide spectrum of markers (e.g., 
CD271), argues against a CSC model of heterogeneity212. Cells that form tumours in this 
case cannot be deemed CSCs but are more appropriately called TPCs. Conversely, the 
term TIC has been reserved for cells with characteristics closer to CSCs. In the case of 
primary colorectal cancers, three different cell types were all assigned the title of TICs 
on the basis of clonal sphere cultures derived from individual patient tumours418. These 
included a rare subset of CSC-like cells that maintained tumour growth on serial 
transplantation, a TIC with limited self-renewal capacity (therefore not defined as a 
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CSC), and a more latent CSC that was activated only in secondary or tertiary 
transplantation assays. Dick bases his definition of a CSC on the defining characteristics 
laid out by Clarke et al. in 2006 and Nguyen et al. in 2012, whereby CSCs represent a 
distinct population that can be prospectively isolated from the remainder of the tumour 
cells and can be shown to have clonal long-term repopulating and self-renewal 
capacity194,200. Because prospective identification and isolation is difficult, they and 
others refer to populations which cannot be prospectively isolated but have CSC 
properties as TIC or leukaemia-initiating cells. Hence, TICs are defined by their ability to 
(1) generate a xenograft that is representative of the parent tumour, (2) self-renew as 
demonstrated by serial passage in a xenograft assay at clonal cell doses, and (3) give rise 
to daughter cells that may possess proliferative capacity but are unable to establish or 
maintain the tumour clone upon serial passage. Their only difference compared to a CSC 
is that they cannot be prospectively isolated202. 
The study of heterogeneous tumour cell populations and in particular the identification 
of CSCs is a difficult task and researchers have used a range of techniques over the years. 
Xenotransplantation has been widely used for both the identification and quantification 
of cells capable of propagating tumour growth. As mentioned earlier, the importance of 
identifying these cells in order to be able to separate them and class them as CSCs is 
important and hence flow cytometry and FACS became powerful tools in this area. Early 
research focussed on distinguishing heterogenous populations by examining cells for 
the presence of cell surface proteins typically associated with differentiation status on 
the assumption that CSC might express proteins associated with stemness419. FACS was 
used in the seminal studies published by Lapidot et al. in the late 90s when CSCs in AML 
were identified by expression of CD34, a cell surface protein associated with HSCs197. 
Over time these studies were expanded to a whole host of proteins, not just those 
associated with tissue-specific stem cells. Indeed, several of the proteins present on 
varying percentages of tumour cells in our PDXs have previously been implicated in CSC 
studies including CD24 in breast, gastric and pancreatic cancer420,421, CD9 in ALL422 and 
CD44 in a large array of cancers421,423,424.  
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The process of identifying CSCs by cell surface phenotyping can be challenging as a large 
number of surface proteins are often expressed and the CSC compartment could be a 
population identified by expression of a combination of any number of these proteins. 
For this reason, I focussed on identifying CSC-like cells based on their ability to fulfil 
functional criteria. One such assay is the Side Population (SP) assay; this technique 
developed by Margaret Goodel identifies a fraction of cells with the ability to efflux the 
Hoechst dye334. These cells were later shown to express ABC transporters likely 
evolutionarily conserved on cells with stemness properties as a protection 
mechanism333.  
Aims of this chapter  
- Conduct limiting dilution assays with PDXs to estimate the proportion of cells 
within the bulk tumour capable of propagating tumours 
- Investigate whether heterogeneous cell surface protein expression within the 
PDXs can be employed to identify cells with CSC properties 
- Determine the optimal conditions for the detection of a SP in these PDXs 
- Investigate the potential of the SP to meet the characteristics of a CSC population 
- Attempt to phenotype the SP by examining them for the expression of defining 











4.2.1 Limiting Dilution Assays show the frequency of tumour propagating cells to 
range from 1 in 159, to 1 in 1120 in different PDXs 
Traditionally, the existence of a distinct tumour propagating population has been 
demonstrated through limiting dilution assays whereby the lowest number of cells from 
which it is possible to generate a tumour is indicative of the percentage of TPCs within 
a bulk tumour. This technique is not without its caveats, but was employed in this study 
as a crude method to identify heterogeneous populations of tumour cells, particularly 
given the presumed homogeneity of BL. Quantifying the frequency of cells with tumour 
propagating ability is useful as it can give an estimation of whether all cells within the 
tumour can produce further tumours or if there is a distinct population alone with this 
ability. A range of tumour cell numbers from PDX1-3 inclusive were injected into cohorts 
of mice and Poisson statistics used to calculate the frequency of cells capable of initiating 
xenografts425,426. Cells were isolated from a tumour grown in an NSG mouse after 
passage 2, disaggregated and re-injected suspended 1:1 in Matrigel, in limiting dilutions 
into NSG mice. When as few as 25 cells from PDX1 were injected into recipient mice, 1/3 
developed a tumour although when 100 cells were injected into each of three mice no 
tumours formed (Table 4.1).  Following ELDA (Extreme Limiting Dilution Analysis)427 of 
the experimental data using a confidence interval of 95%, the predicted TPC frequency 
for PDX1 was determined to be 1/285 (range = 1/79 to 1/1032). Identical analysis of 
PDX2 and PDX3 tumours yielded predicted TPC frequencies of 1/1120 and 1/159 
respectively. Interestingly, although this is a broad estimate, it does highlight an 
important observation – not all cells in any of the PDXs are capable of propagating 


























Table 4.1. Limiting Dilution Assays using ELDA analysis estimate the frequency of 





No. of cells 
injected 
No. of mice 
injected 
No. of mice 
developing 
tumours 
PDX1    
1000000 1 1 
100000 2 2 
10000 2 2 
1000 3 3 
100 3 0 
25 3 1 
5 3 0 
PDX2   
1000000 1 1 
100000 2 2 
10000 2 2 
1000 3 2 
100 3 0 
25 3 0 
5 3 0 
PDX3   
1000000 1 1 
100000 2 2 
10000 2 2 
1000 3 3 
100 3 1 
25 3 1 
5 3 0 
 
Confidence intervals for 
1/(TPC frequency) 
Lower Estimate Upper 
1032 285 79.2 
 
Confidence intervals for  
1/( TPC frequency ) 
Lower Estimate Upper 
4456 1120 282 
 
Confidence intervals for  
1/( TPC frequency ) 
Lower Estimate Upper 
611 159 41.5 
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4.2.2 Cell surface protein expression profiling indicates tumour cells with varying 
levels of tumourigenic potential 
Flow cytometry is a powerful technique that has been utilised to identify heterogeneity 
within tumours by examining the cell surface expression of a whole host of proteins 
indicative of lymphoid cell developmental stages and functions; for example, in humans 
CD34+CD38- is the immunophenotype identifying HSCs with other proteins including 
CD90 (Thy-1) and IL7Ra refining this phenotype further428. Other proteins are indicative 
of later developmental stages such as CD21 and CD24 expressed on immature B cells, 
while CD27 and CD40 are expressed on activated germinal centre B cells. The variable 
expression levels of these and many other cell surface proteins within the PDX tumours 
is displayed in Figure 3.10 in chapter 3 and provided the basis for experiments to assess 
the functional properties of these distinct cell compartments, specifically their ability to 
seed new tumours. 
Initial experiments were conducted using paediatric BL cell line xenografts as opposed 
to patient-derived tumours. In particular, Ramos cells which have a broad array of 
proteins expressed on sub-populations of cells including CD9, CD40, CD44 and CD49D 
were investigated. Cells were sorted into positive and negative fractions for each specific 
protein by FACS. Positive and negative cells (5X105) were then injected into separate 
NSG mice in triplicate and tumour growth monitored until the maximum size limit was 
reached (12mm in any one dimension). The tumours were then resected and the size 
verified. All cellular fractions produced tumours that reached the size limit within a 
maximum of 41 days (Figure 4.1). However, there were significant differences in the 
tumour forming capacity of the CD9, CD44 and CD49D-expressing cell populations; the 
CD9-, CD44+ and CD49D+ fractions reached the tumour size limit significantly faster than 
their opposite cell populations (i.e. CD9+, CD44- or CD49D-). This highlights that each of 
these populations, positive or negative for each surface protein, can be termed TPCs 
although it does lend support to the concept of multiple subclones existing within the 










Figure 4.1. Differential tumorigenic potential of sorted cell fractions in Ramos cell line 
xenografts.  
Cells were stained with antibody and sorted by FACS into positive and negative 
populations before 5X105 cells were injected with matrigel into 3 NSG mice for each cell 
population. The time taken for the tumours to reach the maximum allowed size was 
determined. * p<0.05, **p<0.005, ***p<0.001 
 
Once experiments had been conducted and optimised with the cell lines, and given the 
particularly striking significance associated with CD9, positive and negative populations 
were sorted from each of the four PDXs that also contained CD9-expressing subclones 
of cells (Table 4.2). This was conducted with PDX tumours isolated after passage 2 and 
cells injected into two further mice for each cell population. The tumours were 
measured on a daily basis and the time to produce maximum allowable tumour size 
recorded. Interestingly, the CD9 negative population again had significantly increased 





Table 4.2. Proportion of CD9 positive and negative cells in 4 PDXs (PDX1 is CD9 
negative) 
PDX # CD9+ Cells (%) CD9- Cells (%) 
2 91 9 
3 98.2 1.8 
4 71 29 
5 87.3 12.7 









































Figure 4.2. Differential tumorigenic potential of sorted CD9 positive and negative 
fractions isolated from PDX tumours. 
Cells were labelled with antibody and sorted by FACS into CD9 positive and negative 
populations before 5X105 cells were injected with matrigel into two NSG mice each. The 
time taken for the tumours to reach maximum allowed size was measured. (A) 
Representative data for PDX2 highlights the significant difference in growth rate at each 
time point. (B) Data show the times taken for tumours to reach the maximum size, 
comparing populations either positive or negative for CD9. *p<0.05, **p<0.005, 
***p<0.001 





















































CD9 expression is just one example of a surface phenotype that resulted in differential 
growth rates amongst tumour populations. Further examples of increased tumourigenic 
potential based on cell surface protein expression are presented in Table 4.3. Both the 
intra-tumoural and inter-tumoural heterogeneity of these cell surface proteins within 
our PDX resource highlight that the landscape of pBL is likely more complex than 
previously thought.  
 
PDX Fraction with greater 
tumourigenic potential 
Proportion of cells (%) p-value  
1 CD44+ 89 0.008 
2 CD24+ 86 0.009 
3 CD49D+ 15 0.007 
4 CD90+ 88 0.0009 
 
Table 4.3. Cell surface protein expression identifies tumour cell populations with 
significantly increased tumourigenic potential in vivo. 
Tumour cells of each cell fraction, positive or negative for the indicated proteins, were 











4.2.3 Cells expressing primitive surface proteins are present in PDX tumours  
As well as examining the cell surface proteins that characterise BL and those identified 
in other CSC studies, a broad array of antibodies were utilised to identify populations of 
cells expressing markers associated with HSCs and ‘stemness’. In particular, the 
primitive cell surface proteins CD34, CD90, CD117 and ABCG2 were investigated. CD34 
is a HSC marker and identification of cells expressing this protein may indicate a CSC 
population that originated from an early progenitor cell. Like CD34, CD90 is a protein 
expressed on pluripotent HSCs429. Cell surface proteins associated with early stem and 
progenitor cells were identified in each of the PDXs. Of particular note is CD90 positivity 
for almost all cells in PDX4 (Figure 4.3). The expression of proteins associated with 
stemness on tumour cells with a presumed mature B cell origin is an interesting 
observation and these data suggest that further characteristics of stemness in the PDXs 
should be explored. Representative graphs are shown for PDX4 (Figure 4.3) with 











































Conjugated antibody Isotype Control 
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Figure 4.3. Stemness associated cell surface proteins including CD34, CD90, CD117 and 
ABCG2 are expressed on PDX4 
Cells from PDX4 tumours were labelled with stem cell associated surface proteins. Gates 
were assigned using unstained negative controls and the absence of non-specific binding 




PDX % CD34+ % ABCG2+ % CD90+  % CD117+ 
1 1.34 1.13 0.7 0 
2 0.84 1.09 0 0 
3 0.42 0.82 0 0.35 
4 1.10 1.43 88.5 0.48 
5 0.67 1.35 1.13 0 
 
Table 4.4. Proportions of cells with each stemness associated surface protein marker 
in five PDXs 
 
4.2.4 A side population (SP) is present in all 5 PDXs 
Based on the difficulty of prospectively identifying a CSC population by cell surface 
phenotyping alone, the SP functional assay was used to determine the presence of cells 
with stemness features based on their ability to efflux the Hoechst dye. It has been 
noted that in order to identify the SP, technical parameters such as cell density, dye 
concentration, time of incubation, data analysis and correct gating must first be carefully 
optimised356. Optimisation was initially carried out using PDX-derived tumour cells 
harvested from mice at passage 1 or 2 when the tumour was at maximal size. In the first 
stage, incubation time and concentration of Hoechst dye was optimised. The presence 















Figure 4.4. Optimisation of the protocol for the detection of SP cells in PDX1 
The SP assay was carried out at the indicated times and Hoechst dye concentrations. 
Data are representative of technical triplicates. A Verapamil control (+V) was included 
for each condition.  
 
 
Following 60 minutes incubation with 2µg/ml Hoechst dye, there is a large SP of 7.7% 
which is not significantly diminished on verapamil co-incubation, implying that this is 
not a true SP and rather is likely due to the short incubation time whereby not all cells 
had sufficient time to take up the Hoechst dye. Other combinations of dye 
concentration/incubation time including 5µg/ml for 90 minutes and 5µg/ml at 120 
minutes led to the detection of small SP fractions. However, the largest SP (1.05%) that 
was diminished following co-incubation with verapamil was seen with 2µg/ml dye 
incubated for 120 mins. Optimisation was also carried out for the other four PDX 
tumours, all showing similar results, except PDX4 which required a stronger 
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concentration of Hoechst dye and incubation for 120 mins to identify the SP. The optimal 
conditions for detection of a SP in each PDX are shown in Table 2.4 of chapter 2. Figure 













Figure 4.5. A Side Population is detectable in tumours derived from all five PDX models 
Following optimisation of the staining protocol for all 5 PDXs, cells were incubated with 
Hoechst dye at the optimal concentration and time, with and without verapamil. Data 






















At times the exact positioning of the SP gate was difficult to determine, especially if a 
small number of cells remained in this gate in the verapamil control. Viewing the plot in 
density mode made it simpler to distinguish the overall populations and hence was often 









Figure 4.6. A density view of SP plots was used to assign the SP gate 
In cases where a small number of assumed SP cells were still present in the verapamil 
control, density view made it easier to assign the location of the SP gate. 
 
Sufficient material was available from initial biopsy sample of PDX5 to enable SP analysis 
to be performed on the original sample. Significantly, a SP was identified in the isolated 
MNCS from this patient pleural effusion sample (Figure 4.7) highlighting that this 
population is not an artefact of engraftment and, similar to the data in chapter 3, 
provides strong evidence that the PDX model is an excellent representation of the 
























Figure 4.7. A Side Population was present in the biopsy sample from which PDX5 was 
derived 
MNCs were isolated from a pleural effusion biopsy sample and stained with Hoechst dye 
with and without verapamil control and the presence of a SP was determined by flow 
cytometry.  
 
4.2.5 The SP fraction of the bulk tumour population cannot be identified by a distinct 
cell surface protein expression profile  
Each of the PDX tumours contain cells expressing cell surface proteins indicative of a 
primitive origin (Figure 4.3, Table 4.4). The maintenance of these minute populations of 
cells over time is an interesting observation and suggests they may have an important 
role in the tumour dynamics. As ABCG2 expression is a defining feature of the SP 
phenotype, co-expression of this surface protein with all other markers identified within 
the PDX4 tumour population was investigated to try and refine the SP phenotype. PDX4 
shows expression on subpopulations of cells within the whole tumour of CD9, CD24, 
CD49D, CD34, CD133, CD117 and CD44 as well as strong expression of CD90 (Figure 3.10) 
and many of these have been associated with characteristics of stemness. Interestingly, 
although for most surface proteins ABCG2 was expressed within the positive and 













CD90 positive (Figure 4.8). Furthermore, CD133+ cells were exclusive to the ABCG2 
positive fraction. These data suggest that it may be possible to assign a cell surface 





















Figure 4.8. ABCG2 positive cells express cell surface proteins associated with cells 
having properties of stemness 
PDX4 cells were incubated with antibodies against ABCG2 and a range of different 






















However, whilst significantly enriched in the SP compartment of PDX4, cells expressing 
ABCG2 were not exclusive to the SP (Figure 4.9). Furthermore, proteins shown to be 
specific to the ABCG2 compartment in PDX4, such as CD133 (Figure 4.8), were also found 
in both MP and SP fractions (Table 4.5). Regardless, a change in the percentage of SP 
cells expressing certain proteins was observed, for example, CD9 was expressed by a 
considerably lower percentage of SP cells in PDX4 (Figure 4.9). Similar results were seen 
for all five PDXs whereby expression of stemness-related cell surface proteins was 
increased in the SP fractions (Table 4.5). ABCG2 was enriched in the SP of all 5 PDXs and 
CD90 which is expressed in PDX 1, 4 and 5 was present on a higher percentage of SP 
cells, indeed all tumour cells from PDX4 SP are CD90+. CD34 positive cells are also 
increased in the SP of all five PDXs. Apart from proteins traditionally associated with 
stem cells, other interesting results were noted. For example, CD9 expression is greatly 
decreased on the SP of four PDXs while CD49D is on a significantly higher fraction of the 
SP of 3 out of 5 PDXs. CD24 is already highly expressed in four PDXs although in PDX4 
the percentage of cells expressing CD24 in the MP is 57%, compared to 83% of SP cells 
expressing this protein. Finally, CD44 which is only expressed in PDX1 and 2 is also 
significantly higher in the SP fraction than the MP. Whilst it is not possible to identify 
any cell surface protein specific to either MP or SP, these data offer an interesting insight 
into the expression profile of the SP. It is likely that the SP enriches for the CSC 
population but may not in its entirety constitute the CSC compartment. The CSC could 
still be identifiable by a specific cell surface protein profile but this may be a combination 
























Figure 4.9. ABCG2 is expressed on a higher proportion of SP cells while the CD9 
population is decreased in the SP 
PDX4 tumour cells were incubated with Hoechst dye and the SP and MP separated by 
FACS. Both populations were incubated with antibodies against a range of surface 










 PDX1 PDX2 PDX3 PDX4 PDX5 
 MP SP MP SP MP SP MP SP MP SP 
CD9 0 0 89.4 52.1 99 63.9 64.7 27.7 88 41.2 
CD10 99.7 89.3 94 95.2 100 81.6 94 94.8 99.9 96.2 
CD19 98 98.3 99.4 99.8 98.9 99 99 100 99.9 100 
CD20 98.9 99.1 96.1 95.2 94.4 93.8 97 96.6 96 97.3 
CD21 22.4 22.9 0 0 3.2 2.9 2.6 3.1 3.5 4.2 
CD24 99.9 100 89 99.6 99 100 57 83.4 100 100 
CD27 32.3 29.9 98 99.4 10.2 9.2 99.1 95.6 98.6 99.2 
CD34 1.34 3.9 0.84 5.9 0.4 4.8 0.39 4.2 0.5 3.8 
CD40 15 18.7 0.6 0.71 4.6 4.3 10.2 9.8 50.6 55.9 
CD44 89 97.9 0.5 2.2 0 0 0 0 0 0 
CD45 99.7 100 96.7 98.2 100 100 98.5 99.2 99.1 99.4 
CD49D  44 76.8 92.4 91.2 15 42.8 59.9 73.1 44 45.8 
CD49F 0 0 0 0 0 0 0 0 0 0 
CD59 83.6 80.1 99.5 87.2 40 42.3 100 100 95.6 95.1 
CD90 0.7 4.1 0 0 0 0 88.9 99.9 1.13 5.23 
CD117 0 0 0 0 0.3 0.87 0.4 0.59 0 0 
CD133 0 0 0 0 0 0 0.3 2.2 0.16 0.21 
CD150 0 0 0 0 0 0 0 0 0 0 
CD184 99.7 99.9 99.2 100 100 100 99.8 97.1 93.2 91.4 
ABCG2 1.13 23.9 1.09 18.1 0.82 9.7 1.17 23.3 1.35 14.1 
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4.2.6 SP cells are much more likely than MP cells to give rise to tumours in NSG mice. 
SP and MP cells were isolated from each PDX and collected using the Aria Fusion Cell 
sorter as detailed in Figure 4.10A. Whilst a small proportion of MP cells were sometimes 
present in the SP fraction, importantly no SP cells were present in the MP sorted fraction 
(Figure 4.10B). Tumour formation from isolated SP and MP fractions sorted from all 5 
PDXs was monitored and all but one of the 15 SP cell injections resulted in tumour 














Figure 4.10. SP cells produce tumours in NSG mice. 
(A.) Following incubation of PDX cells with Hoechst dye, SP and MP cells were sorted by 
FACS into separate tubes before re-analysis on a Fortessa to determine the sample purity 
(B.). (C.) The number of NSG mice that developed tumours following injection of SP or 












4.2.7 Tumours formed from SP or MP cells in vivo give rise to tumours with a 
minority SP fraction recapitulating the dynamics of the original PDX 
An important characteristic of a true CSC population is that they can give rise to 
heterogeneous populations, composed of both CSCs and differentiated progeny202. 
Tumours produced from SP injected cells were not composed of SP cells alone but also 
MP cells (Figure 4.11A). Furthermore, the SP fraction in the newly established tumours 
reached an equilibrium of less than 2% of the bulk tumour despite having been injected 
as 100% SP cells. In the three mice that produced a tumour from injected MP cells, the 
tumour that developed contained a SP, although smaller than the SP fraction detected 












Figure 4.11. Tumours formed from SP and MP injected cells give rise to tumours with 
a minority SP fraction 
Once tumours from SP and MP cells had reached maximum size, cells were incubated 
with Hoechst dye and analysed for the SP phenotype. The SP fraction in a SP (A) or MP 









PDX % SP in SP-
derived tumour 
% SP in MP-
derived tumour 
2 1.78 0.49 
3 1.23 0.22 
4 2.78 0.65 
Table 4.6. Overview of SP fractions in tumours formed from MP cells. 
 
4.2.8 SP cells have increased expression of stemness related genes 
If the SP constitutes a CSC population then a difference in gene expression profile 
compared to MP cells may be expected. Indeed, in the majority of studies where a SP 
fraction has been isolated, increased expression of genes associated with stemness 
related pathways have been reported275,430–432.  In this study, SP and MP cells isolated 
after passage 1 from each of the five PDXs were analysed by RT-qPCR for expression 
levels of genes associated with stem cell activity as well as genes involved in B cell 
development and survival pathways. A number of genes were shown to be significantly 
increased in SP cells compared to MP cells (Figure 4.12). Of note, there was significant 
heterogeneity across the five PDXs. Only ABCG2 and ABCB1 were upregulated in the SP 
of all five PDXs (Figure 4.12). Most genes were only upregulated in some of the PDXs but 





















Figure 4.12. Transcript levels of genes associated with stemness and/or survival are 
increased in the SP compared to the MP fraction of PDX-derived tumours. 
After passage, RNA was isolated from SP and MP sorted cells and RT-qPCR carried out 
for a range of genes. GAPDH was used as a reference control and the fold change in 
expression levels between SP and MP was determined by calculating 2-DDCt. Data 
represent the means and standard deviations of technical triplicates. Representative of 











Intratumor heterogeneity caused by genetic, phenotypic or functional differences 
between cancer cell sub-populations is a considerable clinical challenge and may explain 
why many cancer therapies fail. Understanding sub-population dynamics is therefore 
central for both optimization of existing therapy and for the development of new 
treatment options. Different models have been proposed to explain this heterogeneity 
including the stochastic model and the cancer stem cell model and in this chapter a 
number of different methods that have been traditionally used to identify CSCs were 
explored. PDXs provide an excellent model to carry out these studies as they were 
shown in chapter 3 to maintain the intrinsic heterogeneity within each tumour.  
The initial limiting dilution assays showed that only a small proportion of cells within 
PDX1-3 could propagate tumours in vivo. In PDX2 this was as low as less than 1 in 1000 
cells. This clearly highlights that not all cells within the population are capable of 
propagating the tumour. These cells represent TPCs but further analysis is necessary to 
determine if they meet all the requirements of a CSC. Limiting dilution assays and 
xenotransplantation in general has several caveats that must be considered when 
interpreting data. Cells are being injected into an environment that may not be 
conducive to tumour growth, even if a cell is a true TIC, and hence cells may be selected 
for on the basis of their ability to adapt to an environment rather than their TIC 
potential. The use of the most immunodeficient mice available is an important factor in 
xenotransplantation and Quintana et al. highlighted that the NOD/SCID model 
underestimated the CSC frequency304. They showed that when more immune-deficient 
NSG mice were used for xenotransplantation in melanoma, the frequency of CSCs was 
estimated at 25% compared to the 0.1-0.0001% in the NOD/SCID model. NSG mice were 
used in our study, although the potential for some residual NK cell function as well as 
defective macrophage and dendritic cell function could impact on engraftment. 
Furthermore, we utilised matrigel and selected the sub-cutaneous compartment for 
injection so we may be selecting populations that are conducive to these conditions. 
Therefore, despite the power of xenotransplantation assays, results should always be 
considered in the context of these caveats. 
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The idea of varying levels of tumourigenic potential within the tumour cells was then 
examined based on cell surface protein expression. Data in chapter 3 outlined the 
significant level of heterogeneity with respect to cell surface protein expression both 
within and between the PDX samples. Initial experiments on cell lines indicated that the 
varying surface protein expression was not just random and rather had significant 
growth implications. This was translated to the PDXs. The heterogeneity was identified 
at a phenotypic and functional level rather than genetic but did translate to differential 
in vivo tumourigenic potential of distinct sub-populations. No surface expressed protein 
alone could identify a population with unique tumour propagating potential although 
the results seen for CD9+ versus CD9- populations for both the Ramos cell line and for 
four PDXs show that CD9- cells constitute a compartment with significantly increased 
tumourigenic potential in BL. This agrees with previous studies which have shown that 
expression of CD9 inhibits the tumourigenicity of human colon carcinoma cells433 and is 
inversely associated with cancer metastasis434 yet contrasts with a study in B-ALL which 
suggests that CD9+ cells may be candidates for CSCs435. The CD9+ and CD9- populations 
both have tumour propagating potential hence it is unlikely CD9 negative cells constitute 
a CSC, although their contrasting growth properties compared to the CD9+ population 
provide evidence of distinct clones within tumours with variable functional properties. 
This idea of clones with varying levels of fitness was further validated in the other PDX 
models. For example, the CD24+ population was significantly more tumourigenic in PDX2 
as was the CD44+ population in PDX1. CD24 has been identified as a candidate for a CSC 
marker in human nasopharyngeal carcinoma436 and in ovarian cancer a population 
enriched for ovarian CSCs was defined by a CD24+ phenotype323. In contrast, the 
CD44+CD24- cell phenotype has been widely reported to define the CSC population in 
breast cancer highlighting how identifiers of CSCs can vary across cancer types, 
increasing the complexity of this study area198,437. Other cancers that have identified 
CD44 as a CSC marker include gastric322,438, colon439, lung440 and adult T-cell 
leukaemia/lymphoma441. The CD49D+ fraction which made up the minority of PDX3 had 
increased tumourigenic potential in mice. CD49D (integrin alpha 4) plays a critical role 
in leucocyte trafficking, activation, and survival, and also facilitates interactions between 
leucocytes and stromal cells found in the marrow or germinal centre442. In human breast 
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sarcoma, CD49D+ identifies TICs with greater resistance to doxorubicin and in CLL its 
expression is a negative prognostic indicator for overall survival442,443. These are just an 
example of some of the proteins that showed heterogeneity within and between the 
PDXs, resulting in varying levels of fitness in tumours and highlight that the 
heterogeneity within pB-NHL is significant and potentially clinically relevant.  
The identification of primitive and stemness-related cell surface proteins on tumour 
cells in all five PDXs is a particularly interesting observation for BL, a cancer considered 
to derive from mature germinal centre B cells. CD34 and ABCG2 were expressed on 
around 1% of cells in all 5 PDXs. CD90 was also expressed on a small fraction of cells in 
different PDXs except for PDX3 which was almost completely CD90 positive, which is 
particularly striking. CD34 can be expressed on more differentiated cells such as pro-B 
cells but CD90 is usually only expressed on CD34+CD38- haematopoietic stem cells and 
multipotent progenitor cells429. Its expression on cells that also express the 
characteristic BL proteins such as CD20 as well as CD27, a memory B cell marker is of 
particular note444. CD90 is a 25–37 kDa glycosylphosphatidylinositol (GPI)-anchored cell 
surface protein. Apart from being expressed in haematopoietic precursor cells it is also 
present on fibroblasts, ovarian cancer cells, endothelial cells and neurons and is involved 
in MAPK and PI3K siganlling445.  In gastric cancer and differentiated AML subtypes, CD90 
was proposed as a marker to identify CSCs as CD90 expression was high in cells that 
expressed self-renewal or drug-resistance genes446,447. Very little data exist regarding 
CD90 in BL apart from one study by Ishiura et al. which identified strong expression of 
CD90 in the Akata BL cell line and determined that treatment with anti-Thy1 antibody 
inhibits their proliferation more strongly than Rituximab448. A study of expression of 
CD90 antigen on pre-B cell ALL with t(9;22) indicated that it correlated with the 
proliferative status of the leukaemia cells, not their phenotypic immaturity449. The 
mechanisms and significance of CD90 expression in mature pB-NHL remains to be 
elucidated although its expression, and the increased fitness of CD90+ cells versus CD90- 
cells in PDX4, again highlight an intriguing level of heterogeneity both within and 
between patient samples. The expression of ABCG2 in the PDXs is another significant 
result as this protein has been associated with CSCs, malignant behaviour and drug 
resistance in a broad array of cancers147,450–452. ABCG2 is expressed in several normal 
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tissues but its expression is sharply down-regulated during hematopoietic stem cell 
differentiation and is expressed at a very low level in mature cells compared with 
progenitor cells333. ABCG2 expression is detected in several cancers and generally this 
expression is associated with negative prognosis and multi-drug resistance in tumours, 
for example lung, oesophageal and breast cancers333,453,454. A study by Kim et al. 
evaluated ABCG2 expression in 67 cases of DLBCL. High levels of ABCG2 on tumours 
correlated with shorter OS as well as Sonic Hedgehog protein levels – a key stem cell 
associated signalling pathway455.  
The identification of progenitor and stem related markers in the PDXs leads to numerous 
hypotheses and requires further study. The initiation of carcinogenesis in BL could be in 
a more primitive cell than previously thought and, akin to models of leukaemogenesis, 
potential pB-NHL stem cells could derive either from HSCs or multipotent progenitors. 
Even though advances have been made in the understanding of CSCs in leukaemias and 
solid tumours, this theory has not been studied in mature lymphoid malignancies until 
recently. Evidence has emerged of apparent transmission of premalignant lymphoid 
cells from 1 individual to another in at least seven cases including FL, MCL, T-cell 
lymphoma, mucosa-associated lymphoid tissue lymphoma and CLL283–288. Despite these 
advancements in knowledge, few studies have been conducted in this area for DLBCL 
and BL and for those that exist, the evidence is not as conclusive296,297. Alternatively, the 
existence of stem-related characteristics could be due to epigenetic changes during 
tumorigenesis whereby more differentiated cells are reprogrammed to acquire stem cell 
features; in evidence epigenetic regulation of ABCG2 has been widely reported456,457.  
Regardless as to whether any of these proteins identifies a CSC in pB-NHL, their presence 
are important observations in the study of intra-tumour heterogeneity. 
Due to the level of heterogeneity between our samples with regards to cell surface 
expression of proteins and the difficulty in pinpointing a CSC population by surface 
phenotyping alone, a functional assay that has been shown to denote cells with 
stemness was employed. Following development of the SP assay by Goodell et al. in 
1996 this technique has been employed in a whole host of studies to identify stem-like 
cells in healthy and malignant tissue. Despite a lull in the study of SP cells in the early 
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part of this decade, a study in 2016 by Boesch et al. which identified SP cells in 12/13 
unrelated human cancers, renewed interest in this area458. After careful optimisation of 
the assay in this study we were able to detect a SP fraction in all five of our PDXs. The 
first evidence that these may indeed constitute a CSC population was the ability of the 
SP cells to propagate tumours in NSG at a much higher rate than MP cells. The tumours 
formed from SP cells also underwent asymmetric division with the presence of both SP 
and MP cells in the ensuing tumour. Interestingly, the population of SP cells in the newly 
developed tumour reduced from 100% SP when injected, to approximately 2% after 
tumour formation. Hence, not only do these cells produce non-SP cells but the tumours 
also evolve towards a state where SP cells make up the minority of the tumour. 
However, some injected MP cells (one in three of three different PDXs) produced 
tumours. If the SP fractions represented a true CSC compartment then the non-SP cells 
should not have long-term replicative capabilities.  The possibility that some SP cells 
passed into the MP fraction during sorting cannot be disproven although the gates were 
stringently applied to avoid this occurring and doublets were eliminated in the gating 
strategy. Alternatively, the MP population may be contaminated with some SP cells due 
to the very sensitive incubation technique. It is possible that some cells, with the ability 
to, had not yet effluxed dye and hence were present in the ‘MP gate’. Interestingly the 
3 tumours formed from MP cells had a small fraction of SP cells present on tumour 
formation and this population was able to produce a tumour on further passage, 
highlighting long-term propagating potential. A further interpretation of this result 
draws on an idea mentioned above whereby the CSC population may be more transient 
than previously thought. Non-SP cells may be able to acquire stemness characteristics 
due to epigenetic changes. An unstable CSC phenotype can lead to phenotypic 
conversions due to cell-intrinsic or microenvironmental cues415. Indeed, as discussed in 
chapter 1, numerous studies have highlighted the ability of the TME to induce a stem 
cell phenotype in mature B cell malignancies, in particular it has been shown that 
stromal cells activate MYC, EZH2, OCT4, NANOG and SOX2, key drivers of the stem cell 
phenotype234,235. Some other studies also support the hypothesis of inter-conversion of 
phenotype if conditions are correct459. In particular, a study in DLBCL highlighted that 
conversion of cell states between SP and non-SP cells was possible and was mediated 
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by exosome-mediated Wnt signaling230. It is therefore possible that in this study, cells 
within the MP injected population were able to convert to SP cells due to a particular 
environmental or cell-intrinsic cue that influenced the transition. Mitsutake et al. 
reported a similar finding in their study of thyroid cancer; 6/8 of their non-SP injected 
mice produced tumours, and although the SP cells were more clonogenic than non-SP 
cells, the clonogenic ability of non-SP cells was not zero. Their interpretation was that 
CSCs are enriched in the SP but not exclusively present460. In fact similar results have 
been seen in a whole host of recent studies including those in cervical cancer, laryngeal 
squamous cell carcinoma, mantle cell lymphoma and hepatocellular carcinoma432,461–463. 
In all these studies, some tumours formed from non-SP cells, although they were 
reported to be significantly less frequent or tumourigenic than their SP counterparts.  
Kreso and Dick consider the prospective identification and isolation of the cells as a 
requirement for a population to be considered a CSC202. After identifying a SP fraction 
in each of the PDXs studied here and determining their tumour initiating capabilities, a 
more specific cell surface phenotype was investigated to enable identification of the SP 
fraction. As ABCG2 expression is a defining feature of the SP fraction we initially looked 
at co-expression of this surface protein with other stem cell associated cell surface 
proteins in PDX4. These data highlighted that ABCG2+ cells were all CD24, CD90 and 
CD49D positive. Identifying distinct expression profiles associated with the ABCG2+ cells 
in PDX4 provided evidence that it may be possible to determine a specific phenotype for 
the CSC-like cells in BL. However, when phenotyping of the separated SP and MP 
fractions was conducted for all five PDXs, although ABCG2 expression was significantly 
higher in the SP cells, it was not exclusive to the SP compartment. In addition, markers 
determined as being specific to the ABCG2 compartment in PDX4, such as CD133, were 
also found in both MP and SP fractions. Despite this, there were significant increases or 
decreases in the proportion of cells expressing certain proteins in the SP of all five PDXs. 
CD9 expression is on a lower percentage of cells in the SP of all PDXs that express it 
which is particularly interesting considering the increased tumourigenic potential of 
CD9- PDX cells in vivo. Studies have shown that there is an inverse correlation between 
CD9 expression level and tumour metastasis in solid tumours434 and Yoon et al. also 
showed that down-regulation of CD9 expression correlates with tumour progression in 
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B cell lymphomas464. CD90 which is expressed on tumour cells of PDXs 1,4 and 5 is 
expressed on a higher proportion of SP cells, indeed all cells in the PDX4 SP are CD90+. 
CD49D expression was expressed on a higher fraction of the SP of three out of five PDXs 
which is particularly interesting considering that CD49D+ cells from Ramos and PDX3 had 
significantly increased tumourigenic potential in vivo. The increase in primitive cell 
marker expression is also an important observation and in particular CD34 is expressed 
on more cells in all SP fractions. The fact that ABCG2 and other primitive cell markers 
are increased in SP cells suggests that the SP phenotype is enriching for CSCs, but may 
not encompass the entire CSC population – the previous discussed growth of three 
tumours from MP cells may support this theory. Alternatively, the CSC population may 
indeed lie specifically within the SP but be defined by a certain cell surface phenotype 
involving a combination of markers. Nonetheless, the fact that cell surface expression 
phenotypes determined earlier in our studies to confer increased fitness in vivo are 
associated with the SP in the PDXs, is an encouraging indicator that we are successfully 
prising apart the heterogeneity within these PDXs and most importantly identifying 
populations with functional importance. 
 To determine further characteristic features of the SP fractions that may be 
contributing to their increased tumourigenic potential, RT-qPCR expression analysis of a 
host of genes was carried out. Genes chosen included ones associated with stemness 
properties, as well as anti-apoptotic and therapy resistance genes which have been 
shown to be upregulated in SP cells in other studies230,459,465.  As expected, ABCG2 and 
ABCB1 were both expressed by a higher percentage of SP cells for all 5 PDXs. The 
primitive cell-associated gene NANOG was only upregulated in the SP of PDX1 while 
OCT4 was only expressed in two PDXs and its increased expression in the SP was minor. 
SOX2 was expressed by all PDXs and was upregulated in the SP fraction for three of 
them.  Apart from ABCG2 and ABCB1, no single gene was differentially expressed in all 
5 PDX SP fractions compared to the MP although the anti-apoptotic proteins MCL1 and 
PIM1 were upregulated in the SP of three and four different PDXs, respectively. Both of 
these have been shown to be important in B-NHL with PIM1 known to cooperate with 
BCL6 to promote the development of lymphoma466 while targeting of MCL1 kills MYC-
driven mouse and human lymphomas even when they bear mutations in TP53467. 
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Furthermore, targeted genomic sequencing of paediatric BL has identified recurrent 
alterations in the MCL1 gene and other anti-apoptotic genes468. FZD6 was upregulated 
in the SP of two PDXs; this gene is a member of the 'frizzled' gene family, which encode 
receptors for Wnt signalling proteins. In liver cancer, SMARCA4, a SWI/SNF family 
member mediates transcriptional activation of FZD6 initiating self-renewal of TICs and 
SMARCA4 is commonly mutated in BL52,469.  
Finally, expression levels of AKT, a member of the PI3K pathway, were increased in the 
SP fractions of 4 PDXs. This is an interesting insight as the PI3K pathway has been 
reported to have a role in regulating ABCG2 expression276. The fact that there is 
heterogeneity with respect to the expression profile of the SP fraction in the five PDXs 
is again an interesting observation – although they all have signatures associated with 
upregulation of stemness and anti-apoptotic programs at the transcript level, there is 
no overlapping signature in all five, at least with respect to this gene set. In a recent 
study by Wagener et al., a PluriTest algorithm was used to investigate traces of 
pluripotency in germinal centre derived B cell lymphoma and determined that BL cells 
more closely resemble human pluripotent stem cells than non-molecular BLs and 
intermediate lymphomas do, arguing for a greater role of stemness in BL compared to 
other mature B-NHLs470. Given that the main characteristic that distinguishes BL from 
these other entities is deregulated MYC expression it suggests a possible role for this 
gene in promoting stemness.  In the context of our data this is plausible as the 
expression analysis above highlighted that cell cycle progression and proliferative 
activity are important signatures of the SP.  
The observed heterogeneity in expression levels across the PDXs may allude to the fact 
that the identification of a distinct CSC with the same features in each patient may not 
be possible. As outlined by Kreso and Dick in their unified model of cancer - genetics, 
epigenetics and the microenvironment can each influence stemness and hence may not 
converge on the same characteristics in all tumours - which will in turn influence clinical 
outcome202.  Indeed, in a study of the TICs in 16 AML samples, it was shown that the cell 
fraction(s) that contained TICs, identified by xenotransplantation assays, were variable 
for each sample319. However, the expression profile for all samples converged on a 
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stemness signature with the TIC signature prognostic for overall survival across a wide 
spectrum of AML patients. The idea that the CSC compartment might not be the same 
across patients is another daunting prospect when it comes to translating the CSC model 
to patient therapies. However, by adapting a personalised medicine approach, with the 
use of PDXs, the drivers of stemness in individual tumours can be elucidated and 
targeted. For example, BMI1, which was upregulated in one of our PDX SP fractions, has 
been strongly linked to self-renewal and implicated in the maintenance of stem cells in 
several tissues471–473. It was found that human colorectal TIC function is dependent on 
BMI1 and down-regulation of its expression inhibited the ability of colorectal TICs to 
self-renew, resulting in abrogation of their tumorigenic potential474. Treatment of 
primary colorectal cancer xenografts with a small molecule BMI1 inhibitor resulted in 
colorectal TIC reduction with long-term and irreversible impairment of tumour growth. 
Hence, utilising PDXs to determine the CSC or other populations driving relapse or 
resistance in pB-NHL and devising targeted treatment options may be a rational 
approach in these difficult to treat cases. 
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Chapter 5. Investigating SP growth dynamics in vitro and potential SP-
targeting therapeutics  
5.1 Introduction 
The CSC hypothesis states that within a given tumour cell population a small subset of 
cells are capable of propagating the tumour and importantly can give rise to both 
tumourigenic and non-tumourigenic cells200. Hence, by definition, if the SP 
compartment denotes the CSC then these characteristics should be met, whether this 
SP population is in a primary tumour or a cell line.  Whilst a SP has been identified in all 
5 PDXs, the inability to grow these tumour cells ex vivo meant further analysis of the 
growth dynamics of these populations was difficult. Therefore, the presence of a SP 
within paediatric BL cell lines was investigated to determine if they meet the 
characteristics of a CSC. Most of the literature on the SP assay has been conducted using 
cell lines, with a recent study showing the presence of SP fractions in cell lines 
representing 12 different cancer types458. In addition, many studies have highlighted the 
increased tumourigenic potential of cell line-derived SP cells in vivo compared to SP-
depleted  cell lines475,476,477,478. Moreover, in vitro studies have demonstrated that SP 
cells have increased viability compared to MP in cell lines derived from hepatocellular 
carcinoma, squamous cell carcinoma, cervical cancer, osteosarcoma and Anaplastic 
Large Cell Lymphoma430,431,461,462,465,478. 
In the previous chapter, the differential expression of potentially targetable proteins 
associated with stemness, anti-apoptotic pathways and PI3K signalling in the SP fraction 
of PDXs was determined. In the literature, a host of signalling pathways have been 
shown to be involved in maintenance of the CSC phenotype. For example, the Notch 
signalling cascade is a major pathway involved in numerous critical cellular processes 
including stem cell maintenance, progenitor cell proliferation and differentiation255. 
Furthermore, activation of Notch4 and Notch1 has been noted in breast CSCs, and 
inhibition of these receptors, particularly Notch4, leads to significantly decreased 
mammosphere formation in vitro and complete inhibition of tumour initiation in vivo479. 
Wnt signalling is another highly deregulated pathway in cancer and it has been shown 
to be involved in self-renewal and maintenance of stem cells and CSCs in several tissues 
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including skin, intestine and mammary gland480. A minor subpopulation of breast TICs 
associated with drug resistance was identified in human breast cancer; in vitro and in 
vivo studies showed that suppression of Wnt signalling inhibited sphere- and colony-
formation of primary breast tumour cells and blocked tumour growth in murine 
models481. Several studies also suggest the involvement of the PI3K/AKT/mTOR pathway 
in maintenance of CSC features. For example, in breast cancer, inhibition of PI3K or AKT 
activity reduced generation and growth of CD44/CD24 mammospheres, leading to stem 
cell/mesenchymal phenotype loss and recovery of epithelial-like markers482. In prostate 
cancer, PI3K/AKT/mTOR pathway deregulation is associated with CSC maintenance; 
moreover, prostate CSCs are resistant to selective mTOR inhibitors483. As such, there are 
potentially many therapeutically-actionable targets for the elimination of populations 
with stemness in cancer. Given the inability to grow and assay primary patient tumours 
in vitro, SP fractions were isolated from paediatric BL cell lines in order to conduct in 
vitro studies of the growth dynamics of these cells and their response to drugs.  
Aims of this chapter 
- Determine if a SP is present in paediatric BL cell lines and optimise the procedure 
for its identification 
- Determine if cell line SP cells have CSC properties 
- Compare the growth potential of SP and MP cells in vitro 
- Compare the sensitivity of SP and MP cells to conventional chemotherapies 








5.2 Results  
5.2.1 A Side Population exists in BL cell lines 
Optimisation was carried out in the same way as described for the PDXs as detailed in 
chapter 4. Briefly, DG-75, Ramos, Raji and BJAB cell lines were incubated with increasing 
concentrations of Hoechst dye (2-10ug/ml) for varying time intervals (60, 90, 120 mins). 
Initial optimisation was conducted with cells cultured in 10% FBS revealing very small SP 
fractions of 0.2% or less (data not shown). Several studies have identified the 
importance of different culture conditions to the SP phenotype and the possibility for 
variation in the population depending on confluency, serum levels and hypoxia484. When 
the FBS concentration was altered to 2% for seven days culture before analysis, the SP 
fraction was much more abundant, a feature that has been noted in other SP 
optimisation studies356.  As these conditions may better represent the tumour 
microenvironment in vivo where it is known that nutrient starvation, hypoxia and poor 
blood supply are common, 2% FBS containing media was used in subsequent SP 
experiments485,486. To maintain consistency between experiments, other variables such 
as cell density and assay conditions were kept constant. Each of the four cell lines had 
an SP of between 0.8-1% (Figure 5.1A) although there was slight variation in the exact 
percentage with each assay. The average of five separate experiments per cell line 
identified Raji to have the greatest variation in SP percentage with an average SP value 



















































Figure 5.1. BL cell lines contain a SP 
(A.) Data representative of the SP detected in each of the cell lines compared to 
Verapamil-treated control cells. (B.) The SP ranges in quantity for each cell line in 
independent assays. Data represent the means and standard deviations of five 
independent experimental replicates conducted for each of the indicated cell lines. 
 
5.2.2 SP cells have greater proliferative capabilities than MP cells in vitro and 
support the growth of the MP; SP-derived soluble factors drive MP growth 
In order to investigate the proliferative properties of SP and MP cells in vitro, 10,000 of 
each cell type were sorted and cultured over a 10 day period. A gating strategy for 
sorting of the cell populations was developed in order to minimise contamination within 
cell populations (Figure 5.2). Unstained, whole cell populations were also passed 
through the cell sorter to ensure they experienced the same conditions of stress. 
Importantly, cell viability analysis was carried out on the SP, MP and unsorted 
population, which had also passed through the sorter, and there was no significant 
difference in cell viability in the 3 populations. This suggests that the staining procedure 
with Hoechst dye does not have a negative effect on cell viability (Figure 5.2 B)  The live 
cell count was determined every second day for each population in triplicate samples 
following trypan blue exclusion (Figure 5.3). In general, the isolated SP and whole cell 
populations begin to proliferate immediately, whereas MP cells stagnate. For example, 
over the 10 day period the Bjab whole cell population and SP underwent almost 4 
population doublings. This is slightly less proliferative than normal for this cell line which 
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usually doubles every 50 hours (i.e. over 4.5 population doublings in 10 days). These 
data suggest that the sorting process may have a slightly negative impact on cell growth 
due to cellular stress. In comparison, the average MP cell number was 19300, or almost 
one population doubling in the same timeframe, showing that the population has 
significantly limited proliferative capabilities (Figure 5.3). Similar results were seen for 
the Raji and DG-75 cell lines. However, the Ramos cell line, whilst following a similar 
trend for the whole cell population and SP, did show a higher proliferative capacity for 
the MP cells but still significantly less than the Ramos unsorted whole cell population or 
isolated SP (p<0.005, Figure 5.3). 
Considering that the growth kinetics of the whole population of cells was almost as 
expected but that the MP cells had low proliferative abilities when isolated, we 
hypothesised that the MP cells required the SP for effective proliferation. This premise 
was investigated by re-combining SP and MP cells in the same well of a tissue culture 
plate. SP cells (1000) were added to 9000 MP cells and the total live cell count monitored 
by trypan blue exclusion. Although this is a higher ratio of SP cells than in the normal cell 
line, 1000 cells were chosen to minimise the negative impact of low confluency on SP 
cell viability. This culture set-up resulted in a growth rate similar to that of the normal 
unsorted cell line, i.e. the growth potential of the MP cells had recovered in the presence 
of the SP cells (Figure 5.3). To further determine if this recovery was due to direct cell 
contact or soluble factors secreted by the cell populations, we utilised transwell plates 
whereby two cell populations are separated by a permeable membrane that allows free 
movement of soluble factors but not cells between compartments. As was noted on re-
combining SP and MP cell fractions, free flow of media and soluble factors between the 
cell populations supported growth of the MP cells (Figure 5.3). Hence, it is likely that 






















Figure 5.2. The gating strategy for sorting cell line-derived SP and MP cells by FACS 
(A.) Following processing in either the presence or absence of verapamil, the main 
lymphocyte population was gated, followed by the singlet population and then the PI 
negative population before analysis for SP cells. The SP gate was devised based on the 
position of the Verapamil treated cells (left panel). (B.) CellTiter-Blue viability assay was 
performed on whole populations cells, as well as SP and MP cells from the Raji cell line 
which had been incubated with Hoechst dye. All populations passed through the sorter. 
Viability was normalised to unsorted control. Means and standard deviations of 
technical triplicates shown. Representative of 3 replicate experiments. 
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Figure 5.3. The SP has significantly increased proliferative capabilities in vitro and 
supports the growth of MP via production of soluble factors 
(A) MP and SP cells were separated by FACS before (co-)culture as indicated: 10,000 of 
each cell type was plated per well for (i-iii); 9000 MP and 1000 SP were plated in (iv); 
9000 MP cells were plated in (v) with 1000 SP cells in the well insert. (B) Cell growth was 
monitored every 2 days following trypan blue exclusion. Data are representative of the 
means and standard deviations of technical triplicates, ***p<0.001, **p<0.005, *p<0.0. 
Representative of three biological replicates. 
i ii iii iv v 
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5.2.3 Exosomes isolated from SP cells do not recover MP growth 
In order to try and elucidate the soluble factors that may be driving MP cell growth, 
exosomes were isolated from SP cells and exogenously applied to the MP population. 
Exosomes have been recognized as mediators of inter-cellular communication among 
different cell populations and by transfer of signalling molecules such as proteins, lipids 
and RNAs between different cell types, they are implicated in both physiological and 
pathological processes487. Several studies in recent years have highlighted that 
exosomes released by CSCs mediate cancer progression in different model systems488. 
Most notably, exosomes were found to mediate population equilibrium of lymphoma 
stem like cells and non-stem cells in DLBCL230. Following 72 hours in culture, exosomes 
produced by isolated Bjab and DG-75 SP cells were harvested and their presence verified 
by transmission electron microscopy (TEM) before supplementing the media of sorted 
MP cells (Figure 5.4); their growth rate was monitored following trypan blue exclusion 
over 6 days.  The growth rate of MP cells did not increase in the presence of SP exosomes 
(Figure 5.5), suggesting that they are not the soluble factors responsible for the 
























Figure 5.4. Confirmation of exosome presence following isolation from Bjab or DG-75 
conditioned media prior to supplementation of MP culture media 
Isolation of exosomes by ultracentrifugation was confirmed by Transmission Electron 


























Figure 5.5. SP-exosome enriched media does not recover MP cell growth 
Exosomes isolated from SP-conditioned media of the indicated cell lines were added to 
culture media and the growth rate of 10000 MP cells monitored following trypan blue 
exclusion. Data represent the means and standard deviations of technical triplicates. 
***p<0.001 
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5.2.4 The levels of certain cytokines produced by SP and MP cells differ 
An obvious method of communication between cells is via cytokines and growth factors. 
Indeed, numerous studies have highlighted the impact of cytokine expression patterns 
on cancer cell stemness226–228. In order to investigate the cytokine profile secreted by 
the SP, 20,000 SP cells from each cell line were sorted by FACS into wells in triplicate. As 
the MP does not grow successfully in vitro the whole cell population was used for 
comparison of the cytokine profile given that they consist of ~99% MP cells. After 72 
hours in culture, supernatant was separated by centrifugation and cytokine production 
determined using an Immunoplex assay. This offers broad range and sensitivity for 
cytokine detection and the panel employed detects cytokines usually produced by 
haematopoietic stem cells and B lymphocytes. Cytokines that were not detected in the 
supernatant of any of the cell populations/cell lines are not shown. Of note, there was 
no cytokine produced at a significantly higher level by either the SP or MP that was 
common to all of the cell lines. The Bjab SP produces the most differentially expressed 
cytokines with CD40L, BAFF and IL-10 significantly higher in the SP compared to the 
whole cell population (Figure 5.6). Interestingly, IL-10 was also significantly increased in 
Raji SP and BAFF in the DG-75 cell line SP, while IL11 production by DG-75 SP cells was 
also significantly higher. As such, there may be heterogeneity with respect to the 
underlying driver of the SP phenotype of the three cell lines, if cytokines are the 
responsible mechanism. However, an exhaustive list of cytokines was not investigated 
and so further studies using a wider panel may identify common cytokines that are 
significant to all three cell lines. Alternatively, a combination of factors that activate 



































































































































































































































Figure 5.6. Differential expression of cytokines in SP and whole cell populations. 
The concentration of soluble analytes of the respective cytokines present in the 
supernatant of the SP or whole cell line was determined for Bjab, DG-75 and Raji cell 
lines by Biolegend LEGENDplexTM immunoassays. Data show individual data points of 5 
technical replicates with the mean and standard error of the means for 1 representative 



































































































5.2.5 SP cells show long-term repopulating capabilities  
An important characteristic of a CSC is that it gives rise to a fully heterogenous 
population with cells that are capable of self-renewal as well as more differentiated 
progeny, by asymmetric division. In order to investigate this property, SP cells from the 
Raji cell line were isolated and cultured for a three week period. At days 6, 12 and 18 
cells were re-analysed for the SP phenotype as previously described. Over time there 
was a decrease in the SP fraction reducing from 100% at day 0 to 30% by day 6 and 
2.47% of the population by day 18 (Figure 5.7). Not only do these data show that the SP 
can give rise to both SP and MP cells, it also highlights the tendency of the cell line to 
maintain a tightly controlled population equilibrium. This phenotypic equilibrium in cell 
state proportions has been demonstrated in other SP cell line studies and has also been 
extensively studied with respect to cell surface protein expression214,489. These studies 
highlight the importance of maintenance of a steady state within many cell lines even 





























Figure 5.7. SP cells give rise to both SP and MP populations 
Isolated SP cells from the Raji cell line were grown in vitro and the proportion of SP cells 
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5.2.6 SP cells purified from BL cell lines are more likely to produce large tumours in 
NSG mice than MP cells  
Having examined the growth dynamics of the SP and MP fractions in vitro, their 
tumourigenic potential in vivo was assessed. NSG mice were injected SC with SP or MP 
Raji cells (5X104), suspended in matrigel. Tumour growth was monitored over the next 
40 days and when the first tumour reached its maximum allowed size all mice were 
culled and tumours extracted. Both the SP and MP injected mice produced tumours 
although the MP tumours were significantly smaller in size (p<0.005; Figure 5.8 A and 
C).These data were replicated for all of the cell lines and in all cases either the MP did 
not produce a tumour (i.e. Bjab and DG-75) or the tumours were significantly smaller in 
volume than the SP-derived tumours (Figure 5.8 B and C). Of note, for Bjab and DG-75 
cell lines, although the experiment was stopped when the first SP tumour reached its 
maximum allowed size, the MP-injected mouse which had not yet produced a tumour 




























Figure 5.8. SP cells are more likely than MP cells to produce tumours in NSG mice. 
(A). SP cells give rise to significantly larger tumours than MP cells of the Raji cell line. (B) 
The tumour incidence in SP and MP-injected mice for each cell line. (C) Tumours produced 
from MP cells isolated from Raji and Ramos cell lines were significantly smaller in size 



























Raji MP-derived tumours 
Raji SP-derived tumours 
C. 
 
Cell Line Tumours produced from SP-
injected mice (n=2)  
Tumours produced from 
MP-injected mice (n=2) 
Raji 2 2 
Bjab 2 1 
DG-75 2 1 
Ramos 2 2 
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5.2.7 SP cells are more resistant to chemotherapy than MP cells but are sensitive to 
PI3K/mTOR inhibition by Dactolisib 
Given the important role SP cells have in driving tumour growth, efforts to target and 
eliminate them have important implications towards successful therapy. SP cells were 
isolated from each of the three cell lines before treatment with doxorubicin or 
methotrexate at the relevant IC50 for 72 hours. Cell viability in comparison to untreated 
control cells was determined using the cell titre blue assay (Figure 5.9). For all three cell 
lines, the SP had significantly increased viability compared to whole cell populations 












Figure 5.9. SP cells are more resistant to chemotherapy than the whole cell line 
population 
SP and whole cell populations were treated with Doxorubicin (A) or Methotrexate (B) at 
the relevant cell line IC50 for 72 hours. Cell viability was then determined using the 
CellTiter-Blue viability assay compared to untreated controls. Data are representative of 






































In order to determine the chemotherapeutic sensitivity of SP cells isolated from the cell 
lines, they were exposed to a variety of chemotherapeutic agents currently under 
investigation for the treatment of B cell malignancies. These included doxorubicin, 
methotrexate, vincristine, the MYC inhibitor JQ1, the BTK inhibitor Ibrutinib, the anti-
CD20 antibody Rituximab and the PI3K/mTOR inhibitor Dactolisib. Only Dactolisib 
treatment resulted in a significantly reduced SP fraction compared to untreated controls 
in all three cell lines (Figure 5.10). Other drugs also had some impact on the overall SP 
percentage, including JQ1 which reduced the population in the DG-75 cell line. 
Furthermore, doxorubicin increased the SP proportion in all three treated cell lines and 
methotrexate enriched for the SP in two cell lines (Figure 5.11). Given the very significant 
results for Dactolisib, the reduced SP fraction in Dactolisib treated cell lines as well as 
the SP fraction from untreated cell lines were isolated by FACS. Further analysis 
identified a potential mechanism by which the PI3K/mTOR pathway regulates the SP. 
Flow cytometry analysis of untreated and treated SP cells highlighted decreased surface 
protein expression of ABCG2 in Dactolisib treated cells (Figure 5.12) and reduced mRNA 














































Figure 5.10. The SP is reduced in cell lines following Dactolisib treatment 
Whole cell populations of the indicated cell lines were treated with Dactolisib at the 
relevant IC50 for 72 hrs. Live cells were then analysed for the presence of SP cells in the 













































Figure 5.11. The proportion of SP cells in cell lines is reduced following Dactolisib 
treatment 
The indicated cell lines were treated with a range of chemotherapeutic agents as 
specified at the relevant IC50 for 72 hours before analysis for the presence of live SP cells. 
Data are representative of the means and standard deviations of technical triplicates. 



























































































































































Figure 5.12. Treatment with Dactolisib reduces expression of ABC transporters in BL 
cell lines. 
SP cells from both Dactolisib and control treated cell lines were sorted and labelled with 
ABCG2 antibody before analysis by flow cytometry. RNA was also extracted from the SP 
cells and RT-PCR carried out to detect transcript levels of ABCG2 and ABCB1. 
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5.2.8 Exposure to Dactolisib sensitises the Raji cell line to chemotherapy induced cell 
death 
Given the efficacy of Dactolisib at targeting the SP, a population with increased 
tumourigenic potential and chemoresistance, we next investigated if combined 
treatment of the chemotherapeutics doxorubicin and methotrexate with this 
PI3K/mTOR inhibitor would induce synergy. Two concentrations of doxorubicin and two 
concentrations of methotrexate were each combined with two concentrations of 
Dactolisib (Figure 5.13A). At each combined concentration a synergistic effect was 
observed with the greatest synergy observed for the combination of 100nM doxorubicin 
































Figure 5.13. Dactolisib sensitizes the Raji cell line to doxorubicin and methotrexate 
(A.) The Raji cell line was treated with doxorubicin or methotrexate either alone or in 
combination with Dactolisib at the concentrations displayed. Cells were treated for 72 
hours and viability determined using the CellTiter-Blue assay, relative to untreated 
control. Means and standard deviations of technical triplicates are shown. 
Representative of 2 biological replicates ***p<0.001. (B.) The Bliss Combination Index 
(BCI) for each combined treatment using the BCI formula, BCI<1; synergistic, BC1=1; 
additive BCI>; antagonistic. 
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The use of functional assays such as the SP phenotype to identify potential CSC 
populations has been a valuable resource and has contributed to the advancement of 
knowledge in the CSC area across numerous haematopoietic and solid malignancies. 
Indeed, cell lines have proven very useful as a resource to study the SP phenotype and 
this has been widely reported on458. Similar to investigations of the PDXs in chapter 4, 
analysis of cell lines identified expression of heterogenous surface proteins including 
ABC transporters and primitive markers (data not shown) and hence the presence of a 
SP was investigated. Following assay optimisation, the existence of a SP was verified in 
all 4 cell lines. The significant increase in the SP percentage after altering FBS content of 
culture media from 10% to 2% was an interesting finding. The influence of culture 
conditions and environment on the SP phenotype has been documented in other studies 
and the increase in the population when cells were cultured under conditions of serum 
starvation may imply that there was selective survival of SP cells or that cells transition 
to this phenotype under stressful conditions356,484. 
The limited proliferative capabilities of the MP cells compared to the SP in all four cell 
lines is a particularly interesting observation. Conflicting data exists regarding the 
proliferative potential and cell cycle dynamics of the SP. Some groups have assigned 
slow-proliferative capabilities to the SP347,490 while others have reported a high 
proliferation rate for this population491–493. An explanation for these observed 
differences may be centred on the differentiation stage from which the SP arises. For 
example, if the SP originates from an early, slowly proliferating progenitor such as a 
tissue specific stem cell then this characteristic may be retained by the SP. However, if 
the SP arises from a cycling cell such as an activated B cell then the high proliferative 
potential may be conserved. The high proliferation rate of the SP in this study further 
suggests an origin of the SP in a mature B cell that has acquired features of stemness via 
an accumulation of genetic, epigenetic and environmental conditioning. The majority of 
published studies investigating SP cells focus on colony forming assays to highlight the 
growth advantage of the SP phenotype. This includes studies in renal cell carcinoma, 
small cell lung cancer and ovarian cancer477,494,495. Fewer studies examine the in vitro 
growth rates of SP and MP cells but those that do highlight a similar trend to our data, 
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with the MP population having limited proliferative capacity compared to SP. In Multiple 
Myeloma non-SP cells showed no proliferation until day 10 in culture and then showed 
significantly slower growth than SP cells496. In ALCL, after 48 hours in culture the majority 
of MP cells were unable to survive and proliferate and in the Neuroblastoma cell line SK-
N-SH, SP cells expanded 500 fold in vitro over a two week period compared to only 2.9 
fold for the MP population430,345. Of note, when MP populations in the BL cell lines 
analysed were cultured in transwell assays with SP cells, allowing for exchange of soluble 
factors, MP growth was recovered. The concept of a minority population of cells having 
such a large impact on the majority population is a difficult concept however, this self-
maintained intra-clonal equilibrium of tumour cell populations has been well studied in 
recent years. Of particular interest, a pivotal study of DLBCL by Koch et al., showed that 
SP cells possessed a dual function in the propagation of the lymphoma bulk230. Besides 
generating progeny, the SP cells provided Wnt3a to surrounding non-SP cells. 
Clonogenicity was restricted to the SP phenotype when populations were separated 
although upon co-culturing GFP-labelled SP and non-labelled MP, the ability of MP cells 
to give rise to SP cells was observed. This transition was shown to be due to the transfer 
of Wnt3a from SP to MP cells via exosomes. This study supports the idea reviewed by 
Snijder et al., that tumour population expansion does not represent stochastic growth 
from independent cells but rather a deterministic process, where fate decisions depend 
on the cellular context or the ‘neighbourhood’497. The original idea that the CSC was a 
static, well-defined sub-population of cancer cells with invariable functional 
characteristics distinguishing them from cells of the tumour mass, has been replaced by 
the idea of CSC plasticity whereby the CSC phenotype is a transient state that many cells 
may acquire depending on cues provided by its microenvironment207. This highlights the 
importance of not just identifying the CSC population present at any one particular time 
but also of identifying the drivers of this phenotype.  
In our study, exosomes isolated from SP cultured cells did not recover MP cell growth. 
However, exosome isolation is a difficult technique that requires significant 
optimisation. The concentration of isolated exosomes achieved was not very high, hence 
in light of the above study in DLBCL it may be worth further exploring a role for exosomes 
in driving MP cell growth. In particular, the proportion and characteristics of exosomes 
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released from SP and MP cells should be compared. However, this study did identify 
differential production of cytokines by the SP and whole cell populations in three cell 
lines. Bjab SP produced 3 cytokines – BAFF, CD40L and IL-10 at significantly higher levels 
whilst Raji SP cells also produced greater amounts of IL-10 and DG-75 SP cells showed 
higher production of IL-11 and BAFF. No cytokines were significant to all three cell lines 
although IL-10 and BAFF were both significant in two of three cell lines each. The impact 
of the microenvironment on tumour cells, in particular the complex network of stromal 
cells, signalling molecules, soluble factors and the extracellular matrix has seen an 
explosion of research in recent years. In particular, cytokines have emerged as 
important players in tumour promotion and progression and their role in the CSC 
phenotype is under investigation in many labs. An early study in the Bjab cell line 
highlighted the potentially important role of cytokine signalling for the cell line 
dynamics. When cultured under suboptimal conditions only a minor subclone was 
capable of long-term growth, supported by autocrine growth factors, and most notably 
the supernatant of this subclone stimulated growth of the parental Bjab line and showed 
IL-1-like activity498. IL-1 was not in our cytokine panel and should be investigated in the 
future, although this data supports our findings that individual cytokines may have a 
very significant impact on the growth dynamics of BL cell lines and investigation of each 
of the cytokines we have identified is warranted. 
An example of a cytokine identified as important in promoting stemness is IL-6. It has 
also been shown to modify the differentiation state of cancer cells through upregulation 
of a stem-like phenotype in melanomas, breast and lung cancers226–228. Interestingly, IL-
11 which was produced to a higher level by SP cells of the DG-75 cell line is a member 
of the IL-6 family and although less well studied, is known to activate at least three major 
pathways: JAK/STAT3, PI3K/mTOR and Ras/ERK pathways499. Furthermore, in triple 
negative breast cancer, a stem cell-like population is characterised by expression of the 
IL-11 receptor although whether the SP of the DG-75 cell line express the IL-11 receptor 
remains to be determined500. CSCs and TICs have been shown to secrete anti-
inflammatory cytokines such as transforming TGF-β, IL-13 and IL-10 in vitro501 and Xu et 
al., determined that hypoxia-induced secretion of IL-10 from adipose-derived 
mesenchymal stem cells promotes growth and CSC properties of the BL cell line BL2502. 
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Given the increased production of IL-10 by Bjab and Raji SP cells, it is worth pursuing the 
role of this cytokine in the SP phenotype. Initially, expression of its receptor on SP and 
MP cells will be investigated although encouragingly, a recent genomic expression 
signature study in pBL highlighted upregulation of the IL-10 receptor in this large cohort 
of patients62. The identification of significantly higher BAFF production by the SP of two 
cell lines is another noteworthy result. BAFF is a member of the TNF family and as well 
as having important functions in normal B-cell development, has been shown to 
promote survival and proliferation of malignant B cells. Bolkun et al., recently 
demonstrated that signalling by BAFF and another TNF family member, APRIL, plays an 
important role in AML pathogenesis and correlates with resistance to cytotoxic 
therapy503. Furthermore, in breast cancer both APRIL and BAFF were shown to increase 
cancer stem cell numbers, by inducing pluripotency genes such as KLF4 and NANOG504. 
A recent study generated a novel BAFF-Receptor antibody and showed its remarkable 
single-agent anti-tumour effects; chimeric antibodies bound with high affinity to 
multiple human malignant B-cell lines and induced potent ADCC against several 
subtypes of human lymphoma and leukaemia. This included primary tumours from 
patients who had relapsed after anti-CD20 therapy, as well as against Ibrutinib-resistant 
and Rituximab-insensitive CD20-deficient variant lymphomas505. The identification of 
differentially expressed cytokines between the MP and SP populations therefore 
provides evidence of potential factors driving the dynamic equilibrium in these cell lines. 
Further studies should include testing of a broader, more exhaustive panel of cytokines 
before utilising a matrix approach to determine if any combination of cytokines can 
recover the full proliferative capabilities of the MP cells. In addition, whether the 
receptors for these cytokines are expressed on SP and/or MP should be determined. 
The SP fraction in our cell lines also showed significantly increased tumourigenic 
potential in vivo, similar to studies in PDXs. Targeting the SP fraction is extremely 
important not only due to its potential clinical relevance but will also help elucidate the 
underlying biology driving this phenotype. In this study, drugs that are readily available 
and under investigation to treat B cell malignancies were assessed for their effects on 
SP cells including traditional chemotherapeutic agents as well as the anti-CD20 antibody 
Rituximab, the MYC inhibitor JQ1, the BTK inhibitor Ibrutinib and a PI3K/mTOR inhibitor 
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Dactolisib. SP cells were shown in this chapter to have increased resistance to 
doxorubicin and methotrexate compared to the whole cell line and therefore the 
increased proportion of SP cells in the doxorubicin and methotrexate treated conditions 
is intuitive. Only Dactolisib had a significant negative impact on the survival of SP cells 
in each cell line. Schmitz et al., have previously identified a number of genomic 
abnormalities in sporadic BL cases and cell lines. In particular, activation of the PI3K/AKT 
pathway has been implicated in BL lymphomagenesis and increased PI3K/AKT activation 
has been associated with worse outcomes in adults with aggressive B-NHL39. The PI3K-
∂ isoform inhibitor Idelalisib, has been approved for relapsed and refractory FL, CLL, and 
small lymphocytic lymphoma. Although these agents are extremely active, they achieve 
primarily partial responses as single agents and require indefinite administration and 
hence their use in combination with chemotherapy may be a better strategy506. Very 
recent pre-clinical studies targeting the PI3K/AKT/mTOR pathway in models of BL have 
also shown promising potential122. The role of this pathway in CSCs has also been 
intensively study. For example, a potent and selective dual inhibitor of mTORC1/2 and 
class I PI3-kinases was able to inhibit proliferation and survival of breast CSCs in vivo and 
markedly reduced their tumour-initiating ability in limiting dilution assays507. It was also 
shown in paediatric Medulloblastoma that the CSC population is more sensitive to PI3K 
targeting compared to the whole cancerous population and its non-stem cell 
counterpart508. Other studies have also shown evidence of the underlying role of PI3K 
or AKT signalling in the CSC with Bleau et al., demonstrating that AKT, but not its 
downstream target mTOR, regulates ABCG2 activity in glioma tumour stem-like cells276. 
Furthermore, activated PI3K upregulated ABCG2 expression and increased the 
percentage of cancer stem-like cells in both AML and ALL275. This agrees with data 
presented here that highlights not only that the percentage of SP cells was diminished 
by targeting the PI3K/AKT/mTOR pathway but also that ABCG2 cell surface expression 
was reduced and both ABCG2 and ABCB1 mRNA levels decreased following Dactolisib 
treatment. This is a very interesting insight to the role this pathway may be playing in 
driving the SP phenotype. Other pathways such as the JNK1/c-jun signalling pathway in 
colon cancer was also reported to be involved in ABCG2-mediated multidrug resistance, 
hence control of ABCG2 expression may not be specific to the PI3K/AKT/mTOR and other 
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pathways in the SP cells should be investigated too, particularly as Dactolisib did not 
completely eliminate SP cells509. Going forward it is of course important to utilise more 
specific inhibitors of both PI3K and mTOR to verify which is responsible for regulating 
ABCG2 and ABCB1 expression. Furthermore, the important observation that inhibition 
of PI3K/mTOR may have synergism with chemotherapeutics should now be investigated 
with the PDX models to determine if Dactolisib is more effective either alone or in 
combination with chemotherapy, compared to chemotherapy alone at inhibiting SP cells 
in vivo. 
Overall, this chapter identifies the presence of SP cells in each of the BL cell lines and 
highlights the in vitro and in vivo growth advantage of these over MP cells. Furthermore, 
cell to cell communication is mediated via soluble factors which are important for MP 
cell growth. Soluble factors that are potential candidates mediating MP cell growth 
include cytokines secreted at a higher level by the SP, but the significance of these 
remains to be determined in future studies. Finally, ABC transporter expression on SP 
cells is mediated by the PI3K/AKT/mTOR pathway and more importantly might 
represent a therapeutic target for BL. It may be possible to target the SP, potentially by 
modulating expression of drug efflux transporters, increasing the sensitivity of SP cells 
to chemotherapeutic agents that are substrates for these.  
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Chapter 6. Relapse can be mimicked in PDXs and may identify resistance 
mechanisms in paediatric Burkitt Lymphoma 
6.1 Introduction 
Survival rates in pB-NHL have increased dramatically in recent decades to almost 90% 
although prognosis in refractory and relapse cases remains dismal, with very few options 
to successfully salvage these patients510,511. Gain of chromosome 7 and deletion of 13q 
are the only abnormalities that have been associated with an adverse prognosis in the 
context of a clinical trial65. Gains of 13q have also been reported, including gain of the 
MIR17 host gene (MIR17HG) locus and are associated with a tendency for early 
relapse69. The rarity of relapse cases combined with the fact that re-biopsy at relapse is 
not a routine procedure has meant that genomic and expression analysis of relapse and 
refractory pBL has not been extensively conducted and beyond the mentioned copy 
number alterations, that identify poorer prognosis, little knowledge exists regarding the 
drivers of relapse in pBL. 
Resistance to both chemotherapy and targeted therapy is a significant problem across 
the spectrum of B-NHLs. Several mechanisms of resistance have been proposed 
including pharmacokinetic and pharmacodynamic events along with 
microenvironmental and tumour intrinsic characteristics. At the tumour intrinsic level, 
a number of possible drivers of resistance include increased drug efflux or drug 
inactivation, evolution of mutants of the target protein, repair of drug-induced DNA 
damage, activation of alternative signalling cascades, as well as deregulation of 
apoptosis512,513. Common anti-apoptotic proteins implicated in relapse to chemotherapy 
in several tumours include the BCL2 family members while mutations in TP53 leading to 
avoidance of apoptosis following DNA damage have frequently been reported including 
in lymphoma514. Increased drug efflux via upregulation of ABC transporters is a well-
documented resistance mechanism and has been shown to be effective at elimination 
of several drugs critical to the pB-NHL regimen including doxorubicin, methotrexate and 
vincristine151,512,515. Of course, the more recent emerging knowledge regarding intra-
tumour heterogeneity and CSCs has added further complexity to the study of relapse. 
Drug resistance and relapse is thought to be either intrinsic due to heterogeneity of the 
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tumour or acquired following ongoing genomic tumour evolution under the selective 
pressure of drug treatment, or indeed it can be both. In the former, a pre-existing minor 
sub-clone may possess characteristics that confer resistance (e.g. stemness) and provide 
a survival advantage over the major non-resistant tumour population. In acquired 
resistance, genomic evolution occurs due to both selective pressure applied by the drug 
as well as genomic/genetic instability caused by alkylating and DNA intercalating agents 
present in chemotherapy regimens512.  
Studies of sequential biopsy samples in DLBCL and FL have provided insight into the 
different mechanisms of relapse and progression516,517. Relapse can evolve directly from 
a sub-clone present at diagnosis with the potential for acquisition of additional 
mutations. Alternatively, relapse may occur via early divergent evolution from an earlier 
tumour precursor shared by both the primary tumour and the relapse518. Both models 
have been identified in DLBCL and FL and it has been suggested that these alternative 
models have important implications for therapy. Less data exists in relation to BL, 
although sequential karyotyping at diagnosis and progression/relapse of paediatric 
samples in one study highlighted that for the majority of cases, aberrations present in a 
sub-clone at diagnosis were also present in the relapse sample along with additional 
karyotypic complexity519. A recent case report described whole exome sequencing data 
of matched presentation and relapse biopsies from a nine year old patient in which 
relapse occurred after four months and salvage treatment failed520. Genomic analysis 
determined that relapsed BL evolved from one of the sub-clones observed at the initial 
phase and was accompanied by additional mutations including chromatin remodelling 
genes, suggesting chromatin regulation might be associated with disease progression. 
These studies highlight the importance of understanding the heterogeneous clones 
within pBL at presentation to better predict and treat relapse cases. 
Extensive studies have highlighted the role of CSCs in drug resistance and tumour 
relapse. The characteristics of CSCs or TICs has varied across cancer types as well as their 
frequency, although it has been demonstrated that these malignant cells with stemness 
characteristics are extremely tumorigenic and are resistant to conventional 
chemotherapies and radiation. Such highly tumourigenic and drug-resistant cells are 
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therefore likely to survive chemotherapy or radiotherapy and ultimately be responsible 
for relapse415,521–524. However, cells with stemness characteristics are difficult to target 
owing to activation of pro-survival and antiapoptotic pathways, overexpression of drug 
efflux pumps and increased DNA repair capacity521–526. Several therapeutic approaches 
to target stemness have been suggested including targeting of the stemness-associated 
signalling cascades and the microenvironment as well as targeting ABC transporters and 
surface markers that identify cells with stemness (reviewed in ref 527). In studies 
utilising the SP assay to identify the CSC, this population was shown to contribute to 
relapse. In cell lines derived from relapsed neuroblastoma the SP was found not only to 
be significantly increased in size compared to the pre-treatment cell lines, but the SP 
cells also displayed increased proliferative ability and colony-forming efficiency, 
highlighting that they were not efficiently targeted by the conventional chemotherapy 
used in treatment528. The SP was also shown to be responsible for chemoresistance in 
patient-derived melanoma tissues and interestingly displayed unique resistance 
mechanisms for different drugs. ABC transporters mediated resistance against paclitaxel 
while SP resistance to temozolomide was mediated by IL-8529. The concept that the 
drug-resistant CSC population can have different driving mechanisms is a daunting one 
and within the PDX models in this thesis, various pro-survival and anti-apoptotic 
pathways were implicated in different patient samples. Efforts to target stemness to 
counteract relapse and metastasis are gaining pace and indeed the first in class cancer 
stemness inhibitor, targeting STAT3, has now reached stage III clinical trials highlighting 
the potential in this area530. In this chapter, the impact of chemotherapy on the 
heterogenous PDX tumours in vivo was evaluated to determine potential drivers of 
resistance in pBL samples. 
Aims of this chapter  
- Investigate the sensitivity of PDX SP cells to chemotherapy in vivo 
- Mimic tumour relapse in vivo by administering chemotherapy to mice 
- Investigate SP cells in relapse PDXs 
- Carry out RNA-seq analysis to compare pre-treatment and relapse tumours. 
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6.2 Results 
6.2.1 PDXs show heterogeneity with respect to drug response in vivo 
Inherent inter-patient heterogeneity may lead to varying levels of response to 
treatment. In order to investigate this in the PDX models, mice bearing PDX1 and PDX4 
tumours were treated with chemotherapy. Initial doses of chemotherapy were 
determined based on doses of doxorubicin, methotrexate and vincristine utilised in the 
induction stage of the Inter-B-NHL Clinical Trial531. These doses were converted to 
animal doses using the conversion factor of Freireich et al., as recommended by the 
FDA532. The human equivalent doses of doxorubicin, methotrexate and vincristine – 
60mg/m2, 3000mg/m2, 2mg/m2, respectively equated to 30mg/kg, 1500mg/kg and 
1mg/kg in animal doses. However, analysis of the literature for lethal doses of these 
drugs for mice highlighted that these quantities of methotrexate and doxorubicin were 
far in excess of what could be tolerated by mice. Hence, lower doses of 3mg/kg 
doxorubicin and 15mg/kg methotrexate along with 0.25mg/kg vincristine were chosen 
for initial analysis of the sensitivity of PDX tumours to treatment. Tumour cells (5X105) 
from PDX1 and PDX4 were injected sub-cutaneously into two NSG mice each and when 
tumours reached 400mm3 chemotherapy was administered every third day and tumour 
volume carefully monitored. An interesting observation was the fact that PDX4 tumours 
showed very little response to this dose of chemotherapy and continued to increase in 
volume after two treatments, while PDX1 tumours were highly responsive. Due to the 
lack of tumour-responsiveness for PDX4, the doses of each of the 3 chemotherapy drugs 
were increased by 25% from the third dosing onwards, resulting in a reduction in tumour 

















Figure 6.1. PDX4 is more resistant to chemotherapy in vivo than PDX1 
PDX1 and PDX4 tumours were treated in vivo with multiagent chemotherapy at 72 hour 
intervals beginning when the tumour volume reached 400mm3. Tumours size was 
monitored daily. Drug concentrations; 3mg/kg doxorubicin, 15mg/kg methotrexate, 
0.25mg/kg vincristine. Increased to 3.75mg/kg doxorubicin, 18.75mg/kg methotrexate, 
0.3125mg/kg vincristine for PDX4 after the second dosing. Means and standard 





























6.2.2 SP cells are more resistant to chemotherapy in vivo 
After identifying effective chemotherapy concentrations for PDX1, SP cells from 
untreated tumour were sorted by FACs and whole population cells were also passed 
through the sorter. Cells were counted in triplicate to ensure accuracy and 5X105 SP or 
whole population cells were injected into four mice each. When a tumour reached 
400mm3 in volume, doxorubicin, methotrexate and vincristine were administered every 
three days for a total of five doses. The animals were culled 48 hours after the last 
dosing. As all eight tumours did not reach 400mm3 on the same day, treatment starting 
points were staggered over two days but each mouse received the identical regimen. 
Upon completion of the dosing, animals were culled and tumours carefully measured to 
determine both volume and mass. Chemotherapy resulted in an approximate 10% 
decrease in overall body mass for all mice. SP-derived tumours show significantly 
increased resistance to chemotherapy compared to whole cell-derived tumours (Figure 
6.2A-B). The impact of chemotherapy on animal health, indicated by weight loss, was 




























Figure 6.2. SP-derived tumours from PDX1 are more resistant to chemotherapy than 
whole population-derived tumours 
SP and whole population cells (5X105 of each) were injected into 4 NSG mice. 
Chemotherapy was administered every 72 hours starting when each tumour reached 
400mm3 in volume. Tumours were extracted 48 hours after the final dosing. (A.) The 
volume of all tumours were measured following extraction. (B.) Volume and mass 
difference between SP and whole population tumours. Means and standard deviations 
of four replicates shown *** p<0.001.  (C.) Animal mass was monitored daily and means 



















































6.2.3 PDXs can be used to mimic relapse in vivo 
In order to determine potential mechanisms of relapse and resistance in pBL, efforts 
were made to induce relapse in vivo for all five PDXs following multi-agent 
chemotherapy. Following initial experiments to determine appropriate drug 
concentrations for each tumour, 5X105 cells from each of the five PDX samples were 
injected into two mice each. When tumours reached 400mm3 one PDX-bearing mouse 
was culled for each of the five PDX tumours and the other mouse was administered 
chemotherapy by IP injection every three days (Figure 6.3). In all cases, tumour volume 
decreased with successive dosing until the tumour was deemed immeasurable. Tumour 
volume was measured every day independently by two individuals to ensure accuracy. 
The period of ‘remission’ ranged from 14 to 20 days in four PDXs however PDX4, which 
was the most chemo-resistant tumour and received the highest dosage of drugs, was 
only deemed immeasurable and in ‘remission’ for seven days. Apart from PDX1, the 
other tumours were extracted before they regrew to full size for reasons of animal 
welfare. Despite this, each tumour was a minimum of 7mm in diameter upon extraction, 
giving a plentiful cell population after tumour disaggregation for further analysis of the 
SP and RNA-seq. Growth dynamics of each PDX over the treatment course are displayed 
in Figure 6.4. Chemotherapy administration began at a volume of 400m3 with PDX 1,3 
and 5 responding immediately. PDX 2 and 4 showed further growth following the first 





























Figure 6.3. Schematic of in vivo PDX chemotherapy treatment protocol 
Following passage 1, tumour cells from each PDX were injected sub-cutaneously (SC) into 
2 mice each. When tumours reached 400mm3 one PDX-bearing mouse was culled and 
the other mouse was administered chemotherapy by intraperitoneal (IP) injection every 
three days. Tumour volume was carefully monitored daily and treatment was ceased 
when the tumour was immeasurable. Following re-growth of the tumour, cells were 





































































































































Figure 6.4. Relapse can be induced in PDXs following successive multi-agent 
chemotherapy 
Chemotherapy was administered IP to mice when PDX tumours reached 400mm3 in 
volume (starting point denoted by the red line). Treatment was repeated every 72 hours 
and ceased when the tumour was immeasurable. Last chemotherapy administration 
denoted by black arrow. Graphs show tumour volume measurements from every second 
day. Tumour volume calculated using the modified ellipsoid formula 1/2(Length × 
Width2). 
 
6.2.4 The side population is increased in PDXs following regrowth after 
chemotherapy 
Evidence from chapter 3 showed that SP cells have increased expression of ABC 
transporters and anti-apoptotic programs while this chapter highlighted the significantly 
increased resistance of SP-derived tumours to chemotherapy in vivo, compared to 
whole population tumours. In order to elucidate if the SP has a role in relapse of BL 
following recurrence of PDX tumours in mice, the tumour was extracted and 
disaggregated into single cell suspension and SP analysis carried out as previously 
outlined. In all five ‘relapsed’ PDX tumours, the SP is significantly increased in size 

























































Figure 6.5. The SP is increased in PDXs following treatment with chemotherapy in vivo 
Control, untreated tumours were extracted when they reached 400mm3 in volume and 
SP analysis performed. Treatment arm tumours received chemotherapy, were extracted 
when they re-grew and SP analysis performed. (A) Representative SP graphs for 
untreated and treated tumours along with verapamil (V) controls are shown for each 




































6.2.5 Differential expression profiles exist between relapsed and untreated PDXs 
The increase in SP cells in each PDX after treatment, suggests their important role in 
relapse and resistance, although this population still makes up a small minority of cells 
in the treated tumours. In order to obtain a more global overview of expression changes 
induced by chemotherapy, RNA-Seq was carried out on the five matched pairs of 
untreated versus relapse whole population samples. Using a significance cut-off fold 
change > 1.5 and false discovery rate (FDR)-adjusted p value of 0.05, 23 differentially 
expressed genes were identified – 13 upregulated and 10 downregulated (Figure 6.6), 
suggesting that only a small number of genes are involved in tumour recurrence in all 
PDXs. Alternatively, due to the fact that our biological replicates are from five different 
patients there may be inter-patient as well as intra-patient heterogeneity, which 
together with a limited sample size, reduces statistical power. Despite the relatively 
small number of differentially expressed genes, functional annotation analysis of the 
hits using the molecular signatures database (MsigDB)533 analysis tool identified gene 
ontology (GO) functions of up and down regulated genes. The upregulated genes were 
enriched in categories associated with cell cycle and response to stimuli, while the down 
regulated genes were enriched in categories involved in regulation of apoptosis and cell 





















Figure 6.6. Differentially expressed genes in relapsed PDXs 
(A) Differentially expressed genes with FC >1.5 and FDR <0.05 were identified and ranked 
by FC. (B) The top eight differentially expressed genes in both categories were validated 
by RT-qPCR across all 5 PDXs and representative graphs are shown for ABCB1 and 
STXBP6 with means and standard deviations of technical triplicates. (C.) RT-PCR was 
carried out on a select set of genes and a representative figure for CD9 highlights the 


















Figure 6.7. Gene ontology analysis of differentially expressed genes following relapse 
Significantly (A) up- and (B) down-regulated genes were compared to GO gene sets in 
MSigDB and the top enriched biological processes for each are listed (FDR < 0.02). 
 













3      5.25 e-6 8.75 e-3 
GO_RESPONSE_TO_ABIOTIC_STIMULUS  5   6.03 e-6 8.75 e-3 
GO_CELL_CYCLE_PROCESS  5   7.85 e-6 8.75 e-3 
GO_ORGANELLE_FISSION  4   8.87 e-6 8.75 e-3 
GO_CELL_CYCLE  5   2.03 e-5 1.48 e-2 
GO_CELLULAR_RESPONSE_TO_EPIDERMAL_GROW 
ROWTH_FACTOR_STIMULUS  
2              2.21 e-5 1.48 e-2 
GO_REGULATION_OF_CELL_ADHESION  4   2.25 e-5 1.48 e-2 
GO_RESPONSE_TO_EPIDERMAL_GROWTH_FACTOR 2              3.2 e-5 1.83 e-2 
GO_POSITIVE_REGULATION_OF_PROTEIN_META 
ETABOLIC_PROCESS  
5   3.71 e-5 1.83 e-2 
GO_REGULATION_OF_CELL_DIFFERENTIATION  5   3.71 e-5 1.83 e-2 
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GO_REGULATION_OF_CELL_DEATH  5   7.38 e-6 8.51 e-3 
GO_PROTEIN_COMPLEX_SUBUNIT_ORGANIZATIO 
TION 
5   8.82 e-6 8.51 e-3 
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6.2.6 A subset of PDXs show upregulation of B cell receptor and PI3K signalling after 
chemotherapy treatment 
In order to investigate inter-tumour heterogeneity amongst the five untreated control 
patient samples, principal component analysis (PCA) was carried out. These data 
highlight the clustering of three PDXs more closely to one another, with the remaining 
two PDXs separated both from each other and from the three clustered samples (Figure 
6.8). Based on the greater similarity of PDXs 2, 3 and 5 to one another, differential gene 
expression analysis was repeated comparing just these three control PDXs to their 
matched relapsed samples. This highlighted a greater number of differentially expressed 
genes with 384 genes with a p value <0.05 (Figure 6.9A). Gene set enrichment analysis 
(GSEA)374 was carried out using normalized mRNA read counts for the six samples with 
gene sets in MsigDB533, particularly Hallmark and KEGG gene sets. Analysis of enriched 
gene sets highlighted that both the PI3K and B cell receptor signalling pathways were 










Figure 6.8. Principal component analysis demonstrates inter-tumour heterogeneity 
Principal component analysis was carried out based on gene expression profiles of each 
PDX. X and Y axes show principal component 1 and principal component 2 that explain 


















Figure 6.9. Differential gene expression analysis of relapse and control PDX 2, 3 and 5 
(A) Hierarchical clustering analysis was carried out using normalized read counts of 
differentially expressed genes (p <0.05) for each sample.  Red represents high, and blue 
low relative expression. (B) GSEA was performed to rank the genes based on their 
differential expression levels between control tumours and relapsed tumours. A 
deviation from an enrichment score (ES) of 0 in the profile (green line) reflects the degree 
of over-representation of genes at the top (positive ES score) or bottom (negative ES 
score) of the ranked gene list. 
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Given the dismal prognosis of relapse and progressive disease in paediatric B-NHL, 
efforts to gain an understanding of the mechanisms of resistance are paramount. The 
results presented in this chapter lead to a number of interesting observations with 
respect to the response of PDXs to chemotherapy. For example, PDX 1 and 4 were 
derived from patients similarly presenting with stage III disease involving pleural fluid 
from which the PDXs were generated. Despite these similarities, the PDX showed 
differential response to in vivo therapy (PDX4 was less chemo-responsive requiring 
increased drug doses compared to PDX1) supportive of inter-patient variability despite 
comparable initial disease presentation. The heterogeneity amongst the small PDX 
sample group in this study is reflective of a large scale study of 1000 PDXs developed 
from solid tumours, whereby inter-patient heterogeneity in response to therapies 
within the same cancer type was observed534. Interestingly, this study and others have 
been able to show that PDX models respond to therapy similarly to the patients from 
which they are derived, highlighting the faithfulness of the PDX model and the potential 
significance of the observed clinical responses399,534–537. Unfortunately, it has not been 
possible to compare patient clinical response to therapy, to the derived PDX outcome in 
this thesis, as clinical data were unavailable.  
Data presented in chapter 4 shows that SP cells isolated from each of the five PDXs have 
increased tumourigenic potential compared to MP cells, as well as increased expression 
of ABC transporters. Apart from common upregulation of ABC transporters the SP 
fraction isolated from each PDX has a distinct gene expression pattern. Genes associated 
with anti-apoptotic programmes were upregulated across the different PDXs and to 
determine if the detected gene expression changes specific to the SP (as compared to 
the MP) are functionally relevant to treatment resistance, whole cell and SP-derived 
tumours of PDX1 were treated with chemotherapy in vivo. The relative, diminished 
response of the four SP-derived tumours to chemotherapy compared to whole 
population-derived tumours is significant, highlighting the advantage SP cells have in 
resisting chemotherapy-induced cell death. The identification, isolation and functional 
verification of a heterogenous population within a PDX that has increased resistance to 
chemotherapy is an important insight into pBL. Increased expression of ABC 
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transporters in the SP cells is an obvious likely contributor to chemoresistance, although 
the RT-qPCR analysis presented in chapter 4 identifies other differentially expressed 
genes in the SP of PDX1 which may also be responsible for this effect, including AKT, 
MCL1 and PIM1 (Figure 4.12). Each of these have been identified as mediators of 
stemness and therapy resistance in other studies and further investigation of their 
contribution to maintaining the SP phenotype within the PDXs presented in this thesis 
would be informative466,482,538–540.  
Due to both the rarity of relapse and the lack of available relapse biopsies, it is difficult 
to study the biology underlying relapse in pBL. The PDXs developed in this thesis 
therefore provide a model system in which to ‘mimic’ relapse in vivo. The validity of the 
PDX models in achieving this aim is evidenced by the induction of a period of ‘remission’ 
after intense chemotherapy followed by re-growth, somewhat mimicking a clinical 
scenario. However, there are some limitations to this model which should be considered 
when interpreting the data produced. For example, a ‘relapsed’ tumour was produced 
for all five PDXs, whereas clinically, less than 10% of pBL patients experience relapse 
suggesting that the chemotherapy level in the PDX model was sub-optimal. However, 
chemotherapy had a significant impact on the welfare of the mice and it was necessary 
to ensure that clinical signs did not exceed acceptable severity limits such as a weight 
reduction of more than 20%. As such, it was not possible to continue chemotherapy 
during equivalent ‘remission’ as is done in the consolidation stage of human 
chemotherapy regimens. Hence, to account for the 100% rate of relapse observed in the 
PDX model, it is likely the high dose chemotherapy received clinically by patients is 
sufficient to eliminate the SP fraction identified in our PDX model if it also exists in all 
pBL cases, i.e. it is only in rare BL cases that this population is able to prevail and result 
in treatment failure. Indeed, in favour of this theory there are distinct molecular 
differences between the SP of the individual PDXs. If the SP is the cause of resistance in 
true clinical cases, it would be imperative to determine if this population have unique 
characteristics that make them more resistant than the SP in treatment-responsive 
patients. Even though our model does not fully recapitulate the intensity of treatment 
received by patients, it does confer a strong selective pressure on tumour cells which 
ultimately gives rise to a dramatic reduction in tumour size and its subsequent re-
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growth. As such, the increase in SP frequency in each of the relapse PDXs, despite still 
constituting a minority of the tumour, is an interesting observation. The most obvious 
reason for this increase is that SP cells, with their increased resistance to chemotherapy, 
are preferentially selected during chemotherapy. In time they give rise to a new tumour 
consisting of SP and MP cells, re-establishing an equilibrium as observed previously in 
chapters 4 and 5 for both PDX and cell line SP sorted cells. However, whether there is a 
gradual and relative decrease in SP cells as the tumour regrows and if indeed the 
remaining cells following chemotherapy are exclusively SP remains to be determined.  
Alternatively, residual cells following initial chemotherapy may be MP cells that 
reacquire stemness characteristics through either genetic or epigenetic aberrations 
(more likely the latter given the short time frame) giving rise to SP and ultimately MP 
subsets. In support, Gross et al. have previously shown in CLL that chemoresistance 
involves ‘innate’ and ‘acquired’ leukemic SP cells541; SP cells showed preferential survival 
compared to non-SP cells following treatment with Fludarabine, Bendamustin and 
Rituximab. They also highlighted that it wasn’t exclusively the SP cells that drove 
resistance but that drug treatment also resulted in acquired SP cells and although the 
SP still made up the minority of tumour cells, after one year of treatment patients had 
between a three and 100 fold increase in the SP fraction541. A recent publication by 
Schmitt and colleagues also highlighted mechanistic insights into the plasticity of the 
CSC in lymphoma relapse542. Significantly, temporary enforcement of senescence in p53-
regulatable models of ALL and AML was shown to reprogram non-stem bulk leukaemia 
cells into self-renewing, leukaemia-initiating stem cells. This was determined by 
increased expression of Kit and Sca1 leukaemic stem cell markers as well as transcript 
levels of stemness genes including Abcg2 and Cd44.  They suggest that Wnt signalling is 
an essential driver of the stemness exhibited by tumour cells after release from 
senescence and in patient matched presentation and relapse samples of DLBCL they 
identified activated Wnt signalling after relapse. This unexpected link between therapy 
induced senescence and stemness has important therapeutic implications and further 
highlights the complexity of the stemness state. Given evidence in this chapter, that the 
SP plays an important role in chemo-resistance, it will be essential to further elucidate 
the exact dynamics involved. Further experiments might include lineage-tracing by 
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‘barcoding’ cells to map the clonal dynamics of SP cells compared to the bulk of the 
tumour upon treatment with chemotherapy. 
Even though barcoding and lineage tracing was not conducted in this study, differential 
expression profiles between the whole untreated and treated PDXs was conducted in a 
pilot RNA-seq study of the five matched PDX pairs (primary PDX tumour and relapse) 
with differentially expressed genes identified and successfully validated across all 
samples. GO analysis of the limited set of differentially expressed genes highlighted that 
they were largely associated with cell cycle progression and apoptotic pathways 
suggesting that evasion of apoptosis is an important response to chemotherapy in BL. 
CD9 was also one of the most differentially expressed genes across all 5 PDXs. CD9 
negativity has been noted as significant throughout this thesis with CD9 negative cells 
identified as having increased tumourigenic potential in chapter 4 and CD9 surface 
expression was shown to be lower in the SP fractions of PDXs. Determining the relevance 
of CD9 expression in the context of tumour progression is difficult as its underlying 
functions are not well known and opposing roles have been reported in the literature. 
It is a membrane glycoprotein that belongs to the tetraspanin family characterized by 
four transmembrane domains543. Through partnering with integrins and 
immunoglobulin superfamily receptors on the cell surface it transduces extracellular 
signals inside to promote apoptosis, suppress metastasis, and mediate cell adhesion in 
a number of studies464,544–547. Downregulation of CD9 has also been associated with 
metastasis in pancreatic and ovarian cancer30,260.  Yoon et al., in a study of B-cell 
lymphomas showed that CD9 positive cells were more susceptible to apoptosis than CD9 
negative cells and that its expression was epigenetically regulated464. They also 
highlighted that in the transformation from indolent FL to DLBCL, patients who had high 
initial CD9 expression had lower expression following transformation to the malignant 
form. However some cases with low original CD9 expression showed no change464. A 
recent study in FL also showed that CD9 expression was associated with better 
outcomes and that CD9 expression negatively correlated with PIK3CD expression i.e. 
CD9-/PIK3CD+ patients had the shortest PFS, suggesting a potential link between CD9 
and PI3K signalling543. However, contrary to these reports, a recent study in paediatric 
B-ALL suggested that CD9 expression is associated with adverse survival outcomes548. 
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Given the recurring significance of this marker throughout this project and the 
mentioned literature, it is likely that CD9 has an important role in BL progression and 
should be further studied.  
Another gene upregulated in all five PDX relapse samples was MALAT1, which is a 
particularly interesting observation based on the emerging role of long non-coding RNAs 
(lnRNAs) in lymphomagenesis. Furthermore, MALAT1 is associated with tumour 
metastasis, progression, drug resistance and stemness in a host of malignancies with 
evidence supporting its role in cell cycle progression as well as Wnt and MAPK signalling 
pathways549–552. Indeed, its increased expression is associated with a worse OS in NSCLC, 
renal cell carcinoma, colorectal cancer,  MCL and T cell lymphoma and it has been 
reported to be upregulated in response to methotrexate553–558. Interestingly, in 
independent studies, MALAT1 has also been shown to maintain the undifferentiated 
state of early-stage haematopoietic cells and to contribute to the maintenance of 
stemness in breast CSCs by regulating Sox2 and CD133559–561. Moreover, one explanation 
for the reduced overall survival associated with MALAT1 in MCL is due to its ability to 
increase expression of EZH2, a member of the Polycomb Repressive Complex 2 (PRC2), 
resulting in cell proliferation554. Whether MALAT1 plays a similar role in BL remains to 
be investigated but EZH2 has been shown to be deregulated in BL by both activating 
mutations and repression of its negative regulator by MYC52,562. 
Due to the paucity of differentially expressed genes identified and the potential for 
inter-tumour heterogeneity to mask functionally significant results, PCA was conducted. 
These data highlight a degree of separation between PDXs with regard to their gene 
expression profiles whereby three PDX samples showed relative similarity, clustering 
separately from the other two models. As such, gene expression data from the three 
more closely related PDXs were analysed separately identifying upregulation of both the 
PI3K and B cell receptor signalling pathways in relapse tumours. The identification of 
increased PI3K signalling in these cases, after chemotherapy treatment is particularly 
interesting in light of the identified role for PI3K/mTOR signalling in maintaining the SP 
phenotype in BL cell lines in chapter 5. It is possible that the increased expression of 
genes in these pathways is due directly to the higher SP fraction in the relapse PDXs, 
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although it is not possible to determine the relative contribution of individual cells to 
the overall gene expression profile, but as they constitute approximately 5% of the bulk 
tumour, this is unlikely to be the case. It is more likely that MP cells which may (or may 
not; see discussion above) have been produced from surviving SP cells after 
chemotherapy display a PI3K signalling gene expression profile as a consequence of their 
recent differentiation from SP cells, maintaining elements of SP signalling or 
alternatively, sustained exposure to chemotherapeutic agents results in up-regulation 
of this pathway regardless of an SP or MP derivation.  
Increased expression of B cell receptor signalling on relapse of the PDX tumours is also 
an interesting finding, particularly as inhibitors of this pathway such as Ibrutinib have 
been successful in the clinic in the treatment of relapsed or refractory adult B-cell 
malignancies108. A clinical trial investigating Ibrutinib in relapsed paediatric B-NHL is 
currently underway and it will be interesting to see the initial results in the coming 
months. Of note, B cell receptor signalling was not specifically investigated in our SP 
cells, but treatment of cell lines in chapter 5 with Ibrutinib did not result in a significant 
decrease in SP cells. This highlights that the enrichment of this pathway may not be due 
to the increased SP fraction but rather may be upregulated in cells, including SP cells, 
after chemotherapy.  
Taken together this chapter offers a number of different insights to both intra- and inter-
tumour heterogeneity. We have demonstrated that one of the heterogenous 
populations identified in this thesis, the SP, has significantly increased resistance to 
chemotherapy and appears to play an important role in relapse based on its increased 
frequency in tumours after treatment. The ability to utilise PDXs to mimic patient 
treatment is also a useful resource which highlights the possibility that individual 
tumours may respond differently to chemotherapy. Indeed, despite some common 
differentially expressed genes involved in drug efflux and cell cycle progression, three 
PDXs showed upregulation of PI3K and B cell receptor signalling that was not present in 
the other two relapsed PDXs. This study is not based on clinically true relapse samples 
and includes a small sample number although it does offer preliminary data suggesting 
response to chemotherapy in patients may not be uniform.  A recent landmark paper 
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from the Staudt group has identified new subgroups of DLBCL with distinct genotypic, 
epigenetic, and clinical characteristics, providing potential for precision-medicine 
strategies in DLBCL563. A similar determination in pBL would be difficult, particularly due 
to the limited sample size, although this type of study is encouraging in the B-NHL field 
and highlights that it is possible to further categorise patients to predict their response 
to chemotherapy.  
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Chapter 7. Clustered regulatory interspaced short palindromic repeats 
(CRISPR)-Cas9 overexpression screen to identify putative resistance 
mechanisms to chemotherapy and Rituximab 
7.1 Introduction 
In previous chapters the high clinical relevance of our PDX models has been highlighted, 
and in particular they are an excellent resource for investigating potential therapeutics 
for BL. However, PDXs are not an infinite resource, particularly as efforts should be made 
to utilise low passage numbers for experiments. For this reason modern genomic and 
functional analytical techniques should first be utilised to determine novel genes and 
signalling networks that are involved in mediating resistance of tumour cells to a 
particular treatment. Identified rational targets can then be investigated in the PDX 
models. In this chapter a genome-wide CRISPR-Cas9 (CRISPR-associated protein 9) 
overexpression screen was performed to identify putative resistance mechanisms to 
therapeutic agents currently used in the frontline treatment of pB-NHL. FAB/LMB 
protocols incorporate numerous therapeutic agents - the group B backbone 
chemotherapy consists of cyclophosphamide, vincristine and prednisone followed by 
two induction cycles which incorporates these drugs along with methotrexate and 
finally consolidation cycles consisting of cytarabine plus methotrexate. Group C high-
risk protocols include each of these drugs along with etoposide for two cycles of 
intensification21. The BFM backbone is similar to the FAB/LMB regimen but also 
incorporates ifosfamide. Due to the large number of agents used it was not feasible to 
investigate all of them in our studies therefore three different agents, each with a 
different mechanism of action, were chosen for this screen; (1) doxorubicin, a 
topoisomerase II inhibitor, (2) methotrexate, an antimetabolite and (3) vincristine, an 
inhibitor of microtubulin assembly. Despite the efficacy of these chemotherapeutic 
regimens resistance still poses a significant challenge. Examples of resistance 
mechanisms can include increased drug efflux, mutations of the drug target, DNA 
damage repair, activation of alternative signalling pathways and evasion of cell death 
and were discussed in chapter 1 with respect to these drugs512. A genome-wide screen 
offers the opportunity to identify novel resistance mechanisms that may be 
therapeutically relevant. The introduction of Rituximab to front line therapy has been 
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highly effective although relapse cases still occur and for this reason Rituximab was also 
investigated in this screen102. The main mechanisms of action of Rituximab include ADCC 
and CMC while direct induction of apoptosis has also been widely reported564. We 
acknowledge that the in vitro model of resistance in this chapter does not address ADCC 
or CMC mechanisms of resistance and any identified mechanisms of resistance to 
Rituximab would require validation in further systems, for example in our PDXs models 
established in humanised mice. 
Since their introduction, genome-wide forward screens have proven powerful tools for 
the unbiased discovery and functional characterization of specific genetic elements 
associated with a phenotype of interest565. Given the relative ease of generating libraries 
containing thousands of single guide RNAs (sgRNAs) that can be used to create large 
mutant collections, CRISPR-Cas9 technology has quickly become the method of choice 
for large-scale pooled screens. In particular, a pooled screening approach provides an 
opportunity to interrogate thousands of genetic perturbations in a single experiment. 
Initially, the majority of pooled screens performed utilised wild-type (WT) Cas9 to 
perform CRISPR-Knock Out (KO) screens. However, an increasing number of studies now 
also utilize the catalytically-dead mutant of Cas9, referred to as dead-Cas9 or dCas9, in 
which the nuclease activity of the WT Cas9 has been mutated in order to render it non-
functional. dCas9 has been fused to a range of chromatin modifier fusion proteins to 
convert it into a highly versatile enzyme that can be used to perform activation (CRISPR 
activation (CRISPRa)) or repression (CRISPR interference (CRISPRi)) screens566. Critics of 
the screen approach will label it a ‘fishing expedition’ and indeed, like most omics 
approaches, genome-wide screens do not fit the hypothesis-driven research model. 
However, numerous studies have highlighted the power of this method. The Weissman 
group adapted dCas9-based activators and repressors to carry out powerful genome-
wide gene activation and repression screens which showed accurate 
complementarity567. A subsequent study by Feng Zhang’s lab also demonstrated the 
successful adaptation of dCas9-based activators for genome-wide gene activation 
screens and notably also demonstrated the feasibility of identifying mediators of 
resistance to a BRAF inhibitor375.  In positive selection screens, a strong selective 
pressure is introduced such that there is only a low probability that cells without a 
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relevant survival-enhancing perturbation will remain following selection. Usually 
positive selection screens are devised to identify perturbations that confer resistance to 
a drug, toxin or pathogen.  
CRISPRa in particular offers a significant improvement as a screening platform over 
other activation approaches. Previously gain of function (GOF) screens were primarily 
limited to cDNA overexpression libraries, which suffered from incomplete 
representation, difficulty cloning or expressing large sites of DNA construct, lack of 
isoform diversity, and high cost of construction568. CRISPRa overcomes these limitations 
because it activates gene transcription at the endogenous locus and simply requires the 
synthesis and cloning of specific RNA guides, making it much more affordable.  
This project is based on the Synergistic Activation Mediator (SAM) overexpression 
CRISPR library (Table 7.1), to identify GOF events that may induce resistance to both a 




Table 7.1. Key characteristics of the SAM screen library 
 
The SAM library is based on a dCas9-VP64 fusion protein that recruits transcriptional 
complexes to the transcription start site (TSS) of target transcripts. SAM improved upon 
the first generation of CRISPR GOF strategy by altering sgRNA to also recruit 
transcriptional co-activators to synergistically interact with the transcriptional complex 
recruited by dCas9-VP64375,569. Specifically, a hairpin aptamer that selectively binds to 
MS2 phage protein was appended to the tetraloop and stem loop #2 regions of the 
sgRNA, which were identified to be exposed outside of the Cas9 enzyme based on the 
crystal structure of the Cas9-sgRNA complex377. Then, a separate vector was constructed 
to express MS2 protein fused to p65 transcription factor and heat shock transcription 
 SAM 
Induced phenotype Overexpression 
Number of genes targeted 23,430 (all coding isoforms) 
sgRNAs per gene 3 
Total sgRNA constructs 70,290 
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factor 1 (HSF1). This allowed for additional recruitment of transcriptional activators to 
the TSS, leading to significantly (sometimes >500-fold increase in targeted mRNA level 
vs. dCas9-VP64 alone) enhanced overexpression capability for genes that were 
considered to be difficult to overexpress with the previous CRISPR overexpression (OV) 
systems375. For this reason, the SAM screen library was selected for this investigation. 
This chapter overviews preparation for the screen as well as quality control and 
validation of the data followed by analysis of clinical relevance of the identified 
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Figure 7.1. Key characteristics of the SAM screen library 
Genome-scale Cas9 transcriptional activation screens begin with the construction of a 
plasmid library encoding the effector protein and sgRNAs. The SAM genome-scale sgRNA 
library consists of 70,290 guides, targeting every coding isoform from the RefSeq 
database (23,430 isoforms, three guides per isoform). The plasmid library is packaged 
into lentivirus and then transduced into the cell type of interest to generate stably 
expressing lines for the screen, along with an accessory transcriptional activator 
complex. A selection pressure – e.g. Rituximab – is applied and genomic DNA is 
harvested. Surviving sgRNA sequences (coloured bars) are amplified from genomic DNA 
and then analysed by deep sequencing to identify candidate genes. Individual candidate 
genes are then validated. Chemo = a standard chemotherapy backbone, Ritux = 
Rituximab. 
 
Aims of this chapter 
- Determine concentrations of drugs to use for multiagent treatment in the screen 
- Perform quality control analysis of the screen results (NGS readout) at the 
sequence, read count and sample levels 
- Perform multiple data analysis to obtain a list of candidates that may induce 
resistance to chemotherapy and/or Rituximab 
- Perform individual validation (viability-based) assays for candidate genes to 
confirm their capability to induce resistance to chemotherapy and/or Rituximab 









7.2.1 Validation of CRISPR/dCas9-VP64 induced overexpression phenotype in the 
Raji cell line 
Before validating SAM functionality, the successful transduction of dCas9 into the Raji 
cell line was verified by Western blot (Figure 7.2). Following this, the functionality of the 
SAM library three-vector overexpression system was investigated by targeting 15 genes 
(2 sgRNAs per gene) in the SAM library-ready (stably expressing dCas9-VP64 and MS2-
P65-HSF1) Raji cell line. These genes encode for growth factors, guanine nucleotide 
exchange factors, transcription factors, kinases and adapter proteins. The SAM system 
was validated to be functional in Raji cells as the target genes were overexpressed at a 
fold-difference range of 2 to 3200 at the mRNA level (Figure 7.3). The 15 genes included 
in the assay are ones that are expressed at low, medium and high endogenous levels in 
B-NHL cells and so allowed for the relationship between endogenous expression and 








Figure 7.2. Successful transduction of dCas9 in Raji cells was verified by Western blot 
Following transduction of dCAS-VP64_Blast and lenti MS2-P65-HSF1_Hygro into Raji 
cells, protein lysates from transduced and untransduced control Raji cells were prepared 


























Figure 7.3.  The SAM system induces overexpression of various endogenous genes in 
Raji cells. 
RT-qPCR was conducted five days after sgRNA transduction (2 sgRNAs per gene) in 
technical triplicates and ΔΔCT analysis was conducted with GAPDH as an internal control 
with normalization to the non-targeting (NT) sgRNA sample. Means and standard 
deviations of technical triplicates are shown. 
 
Although the functionality of the SAM system was confirmed, it is clear from these data 
that overexpression (OV) of some genes is to a higher level than others; six genes (FOS, 
SPDEF, PSD2, PTGES, EREG, NR4A2) were overexpressed at a much higher level 
compared to the rest of the target genes (Figure 7.3). Furthermore, four genes 
(PLEKHG6, CRK, RORC, PRKACA) showed very little response to the SAM system’s OV 
induction (Figure 7.3). To determine whether this was due to certain genes already being 



























































































cell line was obtained from the Cancer Cell Line Encyclopaedia570, and compared to the 
fold change induction but these data did not correlate (Figure 7.4), suggesting the 
variation in the SAM system’s OV induction is due to inherent characteristics of this 












Figure 7.4. Pearson correlation between the endogenous unmodified expression level 
of the target genes and the level of SAM-mediated overexpression induction. 
Both the endogenous expression levels and the fold change in gene expression induced 









































7.2.2 Determining optimal drug concentrations for individual arms of the screen 
In order to determine the optimal drug concentrations to use in the screen, a bliss 
independence model was used to determine which concentrations of drugs gave 
synergistic, additive or antagonistic effects. The Bliss Combination Index (BCI) can be 
calculated with the following equation:  𝐵𝐶𝐼 = 	 /01/2#/0∗	/2
/02
 , where Ea indicates the 
viability effect of drug A (in this case, doxorubicin) and Eb indicates the viability effect 
of drug B (in this case, methotrexate) and Eab indicates the viability effect of being 
treated with drug A and drug B together365. As such, a BCI less than 1 indicates 
synergism, a BCI equal to 1 suggests an additive effect and a BCI greater than 1 is 
indicative of antagonism between two drugs. Initially the dose response curve for each 
drug was carefully determined using a range of eight concentrations of drug and non-
linear regression methods (Figure 7.5). Once the ED50 had been determined, the ED20, 
ED25, ED30 and ED35 for each drug was calculated. Employing a matrix approach, 
combinations of the drugs were then applied to the cells to generate a heat map of BCI 
values (Figure 7.6A). As indicated, there is no significant synergy nor antagonism 
associated with any combination of drugs with most BCI values being close to one 
indicating additive effects. Nonetheless, the two combinations that gave the lowest BCI 
values were selected (doxorubicin ED30 + methotrexate ED25 and doxorubicin ED30 + 
methotrexate ED30) and used as fixed doses for assessing the effects of combining with 
four different doses of vincristine (Figure 7.6B). Given the observed synergy, albeit at a 
low level, the doxorubicin ED30, methotrexate ED30 and vincristine ED35 dosages were 
chosen for the chemotherapy arm of the screen. Cell viability assay after treatment of 
Raji cells with these concentrations of drugs determined an ED of 70. The theoretical 
value using the enumerator of the BCI formula would predict an ED of 68, highlighting 
that there is some minor synergy observed (BCI = 0.97). In order to determine the 
effective dose for Rituximab, the combination of doxorubicin at the ED30, methotrexate 
at the ED30 and vincristine at the ED35 was applied to the cells together with Rituximab 
at a range of doses from the ED20 to the ED40 (Figure 7.6C). There was a minor 
synergistic effect for the combination of Rituximab at its ED40 with the fixed 
chemotherapy dose. Therefore, the dosage used for the chemotherapy + Rituximab arm 
of the screen was doxorubicin ED30, methotrexate ED30, vincristine ED35 and 
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Rituximab ED40. Following treatment of Raji cells at these dosages, an ED value of 85 
was observed, slightly greater than the mathematically predicted ED value of 80 giving 














Figure 7.5. Dose response curves for individual drug treatments 
Raji cells were treated with increasing concentrations of doxorubicin, methotrexate, 
vincristine or Rituximab for 72 hours. End point viability compared to untreated control 
was determined by the CellTiter-Blue viability assay. ED50s are listed beside the non-
linear regression plot displaying mean viabilities and the 95% CI of technical triplicates. 
 
 





































































































Figure 7.6. Bliss independence analysis to determine possible synergistic drug 
combinations. 
Raji cells were treated in a matrix format with doxorubicin and methotrexate at 
concentrations that equated to the ED20, ED25, ED30 and ED35 for each drug for 72 
hours in triplicates (A), doxorubicin at the ED30 and methotrexate at the ED25 as well as 
doxorubicin at the ED30 and methotrexate at the ED30 were applied to Raji cells 
together with vincristine at the ED20, ED25, ED30 or ED35 (B) or doxorubicin at the ED30, 
methotrexate at the ED30 and vincristine at the ED35 were combined with Rituximab at 
its ED20, ED25, ED30, ED35 and ED40 (C). End point viability compared to the untreated 
control was determined by CellTiter-Blue viability assay and the BCI determined for each 
















































7.2.3 Quality control analysis of the SAM screen 
The SAM screen was performed as illustrated in Figure 7.1. Briefly, the sgRNA library 
was transduced into ~2 billion Raji cells at ~0.3 MOI and the transduced cells were then 
cultured in the presence of DMSO (negative control) or drugs (chemotherapy, Rituximab 
or chemotherapy + Rituximab) at the chosen ED values (chemotherapy = ED70, 
Rituximab = ED70, chemotherapy + Rituximab = ED85) for 12 days before genomic DNA 
was extracted from all samples and the sgRNA region amplified by PCR to generate 
Illumina-ready libraries for analysis on a HiSeq platform (conducted at Bauer Core, 
Harvard University).  
Before conducting any gene-based analysis to identify putative resistance mechanisms, 
three layers of quality control (QC) analysis were performed with MaGECK-VISPR to 
ensure that the screens were adequately executed. Specifically, QC analysis of all raw 
fastq files derived from the screen samples was conducted at the sequence, read count 
and sample levels.   
The sequence level QC was designed to identify potential technical issues associated 
with the sequencing process itself and was conducted with FastQC script (Babraham 
Bioinformatics) that was embedded in MaGECK-VISPR. Sequence level analysis of SAM 
















Figure 7.7. Sequence level QC of SAM screen samples. 
(A) Distribution of per-read ‘mean base quality’ for each sample. All samples from the 
SAM screen overlap perfectly with a peak at ~38, which is well beyond the general 
threshold value of 30. (B) Per sample distribution of mean GC content of reads. An 
acceptable mean should be ~40-50% and samples from the same screen should have 
similar GC content; the SAM samples satisfy those criteria.  
 
Following satisfactory QC results at the sequence level, read count level QC was 
performed. Read count level QC is based on the sgRNA read counts generated from 
mapping raw sequence reads to sgRNA sequences thereby assigning each read to one 
of the 70,290 sgRNAs present in the SAM library (Figure 7.8). The mapping process was 
conducted by MaGECK with zero tolerance for nucleotide mismatches380. Read count 
level QC included the determination of the percentage of reads successfully mapped to 
the expected sgRNA sequences, calculation of the number of sgRNAs with 0 read count, 
and determination of the Gini Index which measures the evenness of the read counts 
per sgRNA. The SAM screen showed slightly less than ideal ‘mapability’ with ~37% of 
reads not mapping to any of the sgRNAs; greater than 65% mapped is deemed optimal. 
Allowing for tolerance of one nucleotide mismatch during mapping would likely have 
improved this figure but over 10 million mapped reads for each sample was considered 
sufficient. The number of missed sgRNAs per sample is well below the maximum 
threshold of 1%381. The Gini index across all samples is elevated compared to the Day 0 
sample, which represents the starting point of the screen population. This was expected 
A. B. 
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Figure 7.8. Read count level QC of samples from the SAM screen. 
(A) Mapability of sequence reads to expected sgRNA guide sequences present in the SAM 
library. Indicated %s represent unmapped reads (B) Log-transformed counts of sgRNAs 
with no reads; represents missing sgRNAs from the screen library in each sample. (C) Gini 
index, which measures inequality between read counts with 1.0 indicating maximum 
inequality (i.e. all reads mapped to a single sgRNA within the library), 0.0 corresponding 














































































































































































Sample level QC was conducted to analyse the level of consistency between samples 
(Figure 7.9). Sample level QC determined the distributions of normalized sgRNA read 








Figure 7.9. Sample level QC of samples from the SAM screen. 
(A) Log-transformed read counts of the sgRNAs in a box plot. (C) Log-transformed read 
counts of the sgRNAs in a CDF plot show relatively equal distribution of log-transformed 



























































































































7.2.4 Data analysis of the SAM screen to identify putative Chemotherapy and 
Rituximab resistance mediators 
7.2.4.1 MaGECK-maximum likelihood estimation approach 
Several different distinct approaches of data analysis exist to interpret screen data. 
Traditional methods include RNAi gene enrichment ranking (RIGER) or Redundant siRNA 
Activity (RSA) analysis380. More recent introductions including MaGECK version 1 RRA, 
which relies on a modified robust ranking aggregation have improved upon these 
methods. Recently the second edition of MaGECK, MaGECK-VISPR, which uses a 
maximum likelihood estimation (MLE) approach instead of RRA, was released381. Briefly, 
the key advantage of MaGECK-MLE over MaGECK-RRA (or RIGER, RSA) is its improved 
capability to accurately compare gene enrichment or dropout across multiple treatment 
conditions within a single comparison. More specifically, MaGECK-MLE does not rely on 
a rank-based analysis, allowing for greater accuracy and detailed comparisons of gene 
selections. Therefore, MaGECK-MLE allows a screener to distinguish ‘stronger’ 
enrichment from ‘strong’ enrichment derived from their actual fold differences instead 
of their rank differences. This allows MaGECK-MLE to establish more refined clusters of 
genes that could not be revealed by previous methods. Therefore, MaGECK-MLE was 
applied to conduct k-means clustering analysis for the SAM screen (Figure 7.10). It 
appears that the chemotherapy and chemotherapy plus Rituximab samples are more 
similar to each other whereas the Rituximab only arm has a unique set of enriched and 

























Figure 7.10. k-means clustering views of β scores derived from MaGECK-MLE of 
conditions in the SAM screens from the top selected genes (k = 8). 
The yellow box highlights the cluster of genes selectively enriched in chemotherapy and 
chemotherapy plus Rituximab treated samples. Red indicates enrichment whilst blue 
shows depletion.  
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In addition, employing a default FDR of < 0.5, MaGECK-MLE analysis of the OV screen 
identified 16 candidate genes for the chemotherapy, 12 for the chemotherapy plus 













Table 7.2. MLE-derived ‘hits’ with a FDR <0.5 
Red identifies hits common to both the chemotherapy and the chemotherapy plus 
Rituximab arms. Blue identifies hits common to both the Rituximab and chemotherapy 







 Chemotherapy Chemotherapy + 
Rituximab 
Rituximab 
ABCC1 ABCC1 IRAK1 
ABCB1 ABCB1 SLITRK4 
PIM1 PIM1 PPP5D1 
ADAM9 ADAM9 GPR65 
JARID2 JARID2 FBXO36 
PEG10 PEG10 ITGB1  
DDB2 DDB2 ATG10 
DKK3 DKK3 LIN7B 
MAD2L2 MAD2L2 CITED2 
NFATC4 NFATC4 RAC2 
PDCD1 ALCAM ALCAM 
BRCC3 ASAP3 ASAP3 
MAP3K4  MAPK13 
IKZF2  ZC4H2 
ARGEF1  IL36B 
CBX3  RAB12 
  ROM1 
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Perhaps as expected, ABCB1 and ABCC1 are by far the most significant hits detected in 
both the chemotherapy and chemotherapy plus Rituximab arms with both a p-value and 
FDR of 0 and several hundred-fold enrichment, implying ABC transporters are the most 
efficient resistance mechanism against multi-agent chemotherapy. In the chemotherapy 
+ Rituximab arm there is significant overlap with hits in the chemotherapy only arm. 
These include the ABC transporters, anti-apoptotic gene PIM1, NFATC4 - a member of 
the NFATC transcription complex - and genes involved in DNA damage response 
including BRCC3 and DDB2. Despite the clear overlap, the chemotherapy plus Rituximab 
arm has less hits than the Chemotherapy only arm. This may be due to the introduction 
of a fourth drug with a completely different mechanism of action making it more difficult 
for MAGECK to call significance. Rituximab alone has a distinct set of hits involved in TLR 
signalling, the MAP Kinase pathway and signalling by Rho GTPases. It shares some 
common hits with the chemotherapy plus Rituximab arm including ALCAM and ASAP3 
but overall, as suggested by the k means clustering shown in Figure 7.10, it appears that 
the dominant resistant mechanisms of the chemotherapy plus Rituximab arm are driven 











7.2.4.2 Fold difference and weighted average analysis 
Analysis of the enriched genes reported by MaGECK-VISPR highlighted that that there 
would be a significantly higher number of identified candidate genes if p-values 
associated with enriched genes were used to compile the lists. Essentially, the MLE 
approach may have been too stringent. Hence, an alternative, simplified analysis 
method based on the calculation and comparison of fold differences (FD) of sgRNAs was 
applied following consultation with bioinformaticians. This approach required manual 
analysis of the sgRNA counts and did not necessarily require the computing power of 
bioinformatics scripts. Briefly, the weighted average of the sgRNA read counts between 
biological replicates were calculated first for all of the sgRNAs present in the library. The 
derived weighted average read counts of the sgRNAs from drug-treatment samples 
were compared against those from the DMSO-exposed samples to identify sgRNAs that 
were preferentially enriched under the various drug treatment conditions. Within each 
treatment condition, an arbitrary threshold (>1.5 FD) was set and the genes with 
multiple sgRNAs exceeding the FD threshold were considered to be significantly 
enriched. For the purpose of this study, due to the use of multiple drugs within 
treatment arms, the threshold was increased to 5 fold for extra stringency instead of the 
1.5 FD suggested in the above analysis method. This method resulted in 72 hits in the 
Chemotherapy only arm, 55 hits in the Chemotherapy plus Rituximab arm and 92 hits in 









7.2.5 Individual validation of candidates identified from the SAM screen 
In order to validate hits from the SAM screen, 21 genes were selected for analysis and 
functionally validated by individually transducing Raji cells with two sgRNAs per gene. In 
some cases, where only one sgRNA out of three had given significant enrichment, an 
alternative sgRNA, not in the screen library was chosen. This approach was taken based 
on the fact that since the design of the CRISPR activation library v1, more specific and 
efficient sgRNAs for many of the genes have been identified. Indeed, the Feng Zhang lab 
provides a tool, in which guide RNAs for each gene are sorted in order of specificity, 
based on methods described in their publication375. Examination of the sgRNAs 
employed in this study with the tool highlighted that for most of the genes identified by 
the screen, that only showed enrichment for one of the three sgRNA, there were several 
more specific predicted sgRNAs. In fact, the three sgRNAs present in the screen library 
were often the lowest ranked sgRNAs. The sgRNA that had resulted in a positive hit in 
this screen was therefore selected for validation but with a second sgRNA replaced and 
selected using the tool, as the one ranked as most specific for that gene. The selected 
two sgRNAs per candidate gene were then cloned and packaged into lentivirus particles 
to produce 43 stable cell lines (42 sgRNAs targeting candidate genes and 1 non-targeting 
control). In addition, validation was carried out on some hits that were not identified by 
the original analysis method (i.e. with a FDR<0.5) but were instead identified by the FD 
method, in order to determine if this analysis method is reliable. Genes identified by the 
FD method that were included in validation are marked with # in the figures. The 
established cell lines were treated with drugs at the ED value used in the screen for three 
days, after which cell viabilities were measured and compared to NT sgRNA transduced 
control cells. Increased ABCC1 expression induced by two alternative sgRNAs resulted 
in a significant increase in cell viability following treatment with both multiagent 
chemotherapy and chemotherapy plus Rituximab compared to control NT sgRNA (Figure 
7.11A). The fact that the viability of cells is significantly lower compared to the untreated 
control in the chemotherapy plus Rituximab treated ABCC1 expressing cells than the 
chemotherapy only treated cells (Figure 7.11B), suggests that the increased expression 
of ABCC1 may not be driving resistance to Rituximab. Analysis of ectopic levels of ABCC1 
expression due to SAM activity highlighted that sgRNA 2 results in a greater fold change 
 216 
induction of ABCC1 mRNA than sgRNA 1, likely explaining the significantly increased 




















































































































































Figure 7.11. Ectopic expression of ABCC1 by CRISPR SAM activity induces resistance to 
multiagent chemotherapy 
(A). sgRNA transduced cell lines were treated with either chemotherapy or 
chemotherapy plus Rituximab for 72 hours at the concentration utilised in the screen 
(ED70 and ED85 respectively). Cell viability was determined by cell titre blue assay. Data 
represent the means and standard deviations of technical triplicates.  
(B). Viability of both ABCC1 sgRNA1 and sgRNA2 transduced cell lines compared to 
untreated control cells is less when treated with chemotherapy plus Rituximab compared 
to chemotherapy alone.  
(C). RT-qPCR to determine the level of overexpression induced by SAM screen sgRNAs. 
Fold-differences were determined relative to NT sgRNA for both of the sgRNAs designed 
to target the TSS of the ABCC1 gene. RT-qPCRs were performed from RNA extracted 5 
days after sgRNA transduction and conducted in technical triplicates, means and 
standard deviations are shown. Chemo = chemotherapy, Chemo + Ritux = chemotherapy 





































This validation process was repeated for each of the selected sgRNAs and the viability 
of the transduced cell lines following treatment calculated (Figure 7.12). After 
completing the validation process across all three arms of the screen, a trend was seen 
whereby the number of successfully validated sgRNAs and the significance level was 
greater in the single agent Rituximab arm than in the multi-agent arms. Of the sgRNAs 
tested, 80% conferred resistance to Rituximab alone, including 7 out of 8 sgRNAs that 
were identified by the FD method. For chemotherapy, the percentage of validated 
sgRNAs was 67% while 63% of sgRNAs were validated in the chemotherapy plus 
Rituximab arm. This implies that combination treatment may result in the reporting of 
significant hits that do not confer resistance to all drugs. These are not technically false 
negatives as resistance and enrichment did occur but only as a result of an sgRNA 







































































































































































































































































Figure 7.12. Viability of sgRNA transduced cells following drug treatment 
sgRNA transduced cell lines were treated with either Rituximab (A) chemotherapy (B) or 
chemotherapy plus Rituximab (C) for 72 hours at the concentration utilised in the screen 
(ED70, ED70 and ED85 respectively). Cell viability was determined by the cell titre blue 
assay. Data represent the means and standard deviations of technical triplicates 
*p<0.05, **p<0.01, ***p<0.001. # marks sgRNAs identified by the FD method. 
 
In order to determine if the increased viability induced by sgRNA transduction in many 
cases was due to increased resistance to all drugs or just some, the established cell lines 
were treated with a range of concentrations of single agent drug for 3 days, after which 
the cell viabilities were measured and the ED50 was established for each pair of sgRNA 
transduced cell lines as well as the NT sgRNA cell line. An example of the data for ABCC1 
for doxorubicin, vincristine, methotrexate and Rituximab is shown in Figure 7.13 along 

















































































































































Non-targeting sg ABCC1 sg1  ABCC1 sg2 
1.6nM 3.9nM 4.5nM 
Non-targeting sg ABCC1 sg1  ABCC1 sg2 
22nM 66nM 49nM 
























































































Figure 7.13. Overexpression of ABCC1 induces resistance to chemotherapy but not 
Rituximab. 
Cell viability was normalized to Raji cells treated with vehicle control alone. Non-linear 
regression plots display mean viabilities and the 95% confidence interval of technical 
triplicates with ED50s listed below. All shifts in ED50 values for doxorubicin, 
methotrexate and vincristine were determined to be significant (p < 0.001) by one-way 
ANOVA analysis. Rituximab was not significant (Table 7.3). 
Non-targeting sg ABCC1 sg1  ABCC1 sg2 
157nM 324nM 420nM 
Non-targeting sg ABCC1 sg1  ABCC1 sg2 
965nM 1002nM 940nnM 



































































































These data highlight that although ABCC1 was a significant hit in the chemotherapy plus 
Rituximab arm of the screen, the increase in cell viability conferred by over expression 
of this gene was only due to increased resistance to the three chemotherapy drugs. 
There was no significant ED50 shift for the ABCC1-transduced cell lines compared to the 
NT sgRNA transduced cell line highlighting that ABCC1 does not confer resistance to 
Rituximab. Similar results were seen throughout the single drug validation process. 
Table 7.3 shows the statistical significance levels of the ED50 shift conferred by each 
sgRNA-transduced cell line treated with single agents and highlights that PIM1, PEG10 
and KRAS caused a significant ED50 shift for all 4 drugs, NFKB1 confers resistance to two 
chemotherapy drugs and Rituximab, while ABCB1, ABCC1 and JARID2 confer resistance 

















Table 7.3. Significance levels of ED50 shifts for the indicated sgRNA-transduced cells 
exposed to single drugs 
One-way ANOVA tests were performed for all conditions to determine the significance 
of the shifts in drug sensitivities compared to that observed in NT sgRNA transduced cells. 
* p < 0.05; ** p < 0.01; *** p < 0.001; ns – not significant. n/a – drug not tested.  
 
7.2.6 Different pathways drive resistance to chemotherapy and Rituximab in vitro 
The previous section highlighted the successful validation of sgRNAs identified by the FD 
method indicating that, as expected the FDR threshold is overly stringent and the second 
method of validation is reliable and effective at identifying numerous genes conferring 
resistance to the drugs used in this screen. The 92 genes identified as having greater 
than 5 fold enrichment in the Rituximab arm were subjected to GSEA and overlap with 
gene sets in the Broad Institute MSigDB database was determined. Hallmark and KEGG 
gene sets were included in the output which identified some interesting pathways 
 sgRNA ID Doxorubicin Methotrexate Vincristine Rituximab 
ABCC1 sg1  *** *** *** ns 
ABCC1 sg2 *** *** *** ns 
ABCB1 sg1 *** ** *** ns 
ABCB1 sg2 *** *** ** ns 
PIM1 sg1 ** ** ** * 
PIM1 sg2 *** *** * ** 
JARID2 sg1 *** *** ** ns 
JARID2 sg2 ** *** *** ns 
NFKB1 sg1 ** ns *** * 
NFKB1 sg2 ** ns ** ** 
KRAS sg1 * * ** ** 
KRAS sg2 *** ** ** ns 
PEG10 sg1 * ** ** ** 
PEG10 sg2 ** ** * * 
MAPK13 
sg1 
n/a n/a n/a ** 
MAPK13 
sg2 
n/a n/a n/a * 
IRAK1 sg1 n/a n/a n/a *** 
IRAK1 sg2 n/a n/a n/a *** 
ITGB1 sg1 n/a n/a n/a ** 
ITGB1 sg2 n/a n/a n/a ** 
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implicated in conferring resistance to Rituximab including MAP Kinase and Toll-like 
receptor signalling as well as genes associated with up regulation of chemokine 
signalling (Figure 7.14).  Similarly, the 72 identified hits in the chemotherapy arm were 
also subjected to GSEA to identify dominant molecular signatures in the hit list. 
Importantly, it should be remembered that at the validation stage a lower number of 
hits in the chemotherapy arm were successfully validated upon treatment with all drugs 
(67%), so it is likely some hits in this list are conferring resistance to only 1 or 2 of the 
three chemotherapeutics. Nonetheless, this gives us an overview of the enriched 
signatures in response to these chemotherapeutic drugs. Interestingly, a different set of 
pathways to Rituximab were identified as significant when these hits were compared 
with gene sets and PI3K signalling was one the most significant pathways in the 
chemotherapy treatment arm. This suggests that Rituximab, although essentially acting 
as a chemotherapeutic in the absence of immune components, has a different set of 
























Figure 7.14. GSEA analysis of hits identified as conferring resistance to Rituximab and 
chemotherapy in the SAM screen. 
Gene sets in MSigDB, specifically hallmark gene sets and KEGG gene sets, were compared 
to the hit lists. The top enriched pathways (FDR < 0.1X10-5) are shown for the Rituximab 
candidate list (A) and the chemotherapy candidate list (B). 
 
7.2.7 Clinical relevance of the identified candidates 
An important consideration when utilising prospective screen based studies in research 
is how translationally relevant the findings will be. For example if an identified candidate 
confers resistance upon ectopic expression in vitro but is never expressed in patient 
tumours the translational potential is limited. In order to determine if some of the most 
significant hits in this SAM screen may be clinically relevant targets, endogenous levels 
of expression of the genes were examined in the RNA-seq PDX data generated in chapter 
6. Kaplan-Meier EFS analysis based on expression level of the candidate genes identified, 
was also produced from larger published patient cohorts with matched clinical data. All 
genes that were included in the validation process were expressed in our untreated 
B. 
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PDXs with log-transformed expression levels of example genes shown in Figure 7.15. In 
addition, using PRECOG (PREdiction of Clinical Outcomes from Genomic Profiles)571, 
associations between gene expression and outcome were investigated by Kaplan-Meier 
analysis of treatment naïve BL datasets from the Hummel and Dave studies58,572 (Figure 
7.16). Exact patient age was not available for the Hummel cohort but 50% of patients in 
the Dave study were under 18 years of age. IRAK1 expression has the highest association 
with reduced OS (Figure 7.16). Other identified hits from our study that did not reach 
statistical significance, likely due to the limited number of patients, but showed a trend 










Figure 7.15. Candidate genes conferring resistance to chemotherapy and Rituximab 
are expressed endogenously in patient-derived PDX samples. 
Log-transformed read counts for each gene in all five PDX samples are displayed. Read 












































































Figure 7.16. Kaplan-Meier OS trends align with candidates identified from the SAM 
screen. 
PRECOG Kaplan-Meier OS analysis was carried out in BL datasets by gene expression. 
Only IRAK1 shows a statistically significant worse OS (log-rank test, p=0.018) with 






The SAM screen with chemotherapy, Rituximab or chemotherapy plus Rituximab 
treatment arms produced a number of interesting observations. Initial validation of the 
CRISPR/dCas9-VP64 induced overexpression phenotype highlighted that not every gene 
in our sample gene set was significantly upregulated upon targeted sgRNA transduction 
in the Raji cell line. Furthermore, in some cases the induced expression level varied 
significantly between the two tested sgRNAs. This result was also noted during 
validation of SAM activity by other researchers in the lab, using different cancer type 
cell lines. In one case a trend was determined whereby lower levels of endogenous 
(unmodified) expression level of the target genes were associated with more potent 
induction of SAM-mediated overexpression of the same genes. However, this trend was 
not seen in the Raji cell line and any failure of induction of overexpression is likely due 
to the level of specificity and efficiency of individual sgRNAs within the library. 
Nonetheless, 11 out of 15 of the genes tested showed a greater than 10 fold increase in 
mRNA levels in response to the SAM system and hence a large majority of the 23,430 
genes targeted in this screen should have successful induction of overexpression.  
Before conducting any gene-based analysis to identify potential resistance mechanisms, 
three layers of QC analysis were performed on the data with MaGECK-VISPR. 
Specifically, QC of all raw fastq files derived from the screen samples were conducted at 
the sequence, read count and sample levels. Following verification that all levels of QC 
exceeded the minimum threshold requirements, a concise list of genes was derived for 
the three treatment arms based on FDR values using the MaGECK-MLE approach. The 
most significant hits in the chemotherapy containing arms were ABC transporters which 
is somewhat expected but also an interesting observation and a positive control for the 
successful conduction of the screen. The identification of strongly enriched hits such as 
IRAK1 in the Rituximab arm is also particularly interesting as the exact mechanisms of 
action of this drug in vitro, in the absence of ADCC and CMC, are poorly understood. 
During the validation stage the complexity introduced by multiagent treatment was 
highlighted and likely explains the relatively short list of hits produced. While certain 
sgRNAs increased cell viability following chemotherapy plus Rituximab treatment, 
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investigation of the ED50 shift produced by these sgRNAs for each single agent 
highlighted that some sgRNAs only conferred resistance to certain agents. For example, 
ABCC1 which is a drug transporter known to have doxorubicin, methotrexate and 
vincristine as substrates was the most significant hit for both the chemotherapy and 
chemotherapy plus Rituximab arms with a p value and FDR of zero. However, single 
agent dose response curves of the ABCC1 sgRNA transduced cell lines compared to the 
non-targeting sgRNA transduced cell line verified that ABCC1 does not confer resistance 
to Rituximab and the increased viability was due only to the significant resistance ABCC1 
induces to the three other drugs. It is therefore clear that when conducting multidrug 
treatment screens, the validation process is extremely important and also significantly 
more laborious than for single agent screens. Furthermore, ensuring the correct balance 
of each drug is also a challenge. Significant effort was made to determine optimum 
doses of each drug to ensure contribution of each agent to the induction of resistance. 
Using the bliss independence model concentrations of vincristine, doxorubicin and 
methotrexate were identified that resulted in minor synergy. For the addition of 
Rituximab it was decided to keep the chemotherapy concentrations the same to have a 
direct comparison between the two arms, with the addition of Rituximab the only 
variable. This resulted in minor synergy and an ED value of 85. An unexpected 
observation over the course of the screen was the poor survival of cells in the 
chemotherapy plus rituximab arm, beyond the expected effect of the ED85 dose. This 
highlighted that the dosing may have been incorrect or that with 4 drugs in total, at 
relatively low individual concentrations and with diverse mechanisms of action, there 
was not enough selective pressure from any to drive a resistant phenotype. 
Despite the complexity of a multiagent screen and the requirement for single agent 
validation, hits that were identified in both the chemotherapy and chemotherapy plus 
Rituximab arms, including PIM1 and PEG10, were successfully validated and shown to 
confer resistance to all 4 drugs. PIM1, a serine/threonine protein kinase has been 
associated with BL in previous studies and is enhances the rate of occurrence of c-Myc-
induced lymphomas, by blocking genotoxic stress-induced apoptosis573. It is mainly 
involved in the development of hematopoietic malignancies, including BL by stimulating 
cell survival and proliferation and inhibiting apoptosis through phosphorylation and 
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subsequent inactivation of pro-apoptotic proteins such as Bad466,574. Interestingly, PIM1 
expression was shown to be increased in the SP of three of our PDXs, along with other 
anti-apoptotic proteins, highlighting the significance of this survival pathway in BL and 
its potential role in driving the stemness phenotype. PEG10 has also been reported in 
BL before but to a lesser extent; it is a c-MYC target gene in cancer cells and interestingly 
is located on chromosome 7q, amplifications of which have been associated with an 
adverse prognosis in BL67,575,576. Similarly, PEG10 has been reported to promote 
progression, proliferation and metastasis of numerous cancers including prostate, 
breast and lung577–579. In CLL, PEG10 is significantly overexpressed in patients and 
inhibition leads to apoptosis of cells579. Furthermore, in BL, PEG10 promotes the 
migration of cells by up-regulating the expression of matrix metalloproteinases and 
inhibition of expression again resulted in apoptosis580. JARID2 is also a noteworthy gene 
based on the significant increased resistance it conferred against all three 
chemotherapy drugs. JARID2 is a cofactor of PRC2 and based on studies involving its 
relationship with EZH2, its methylation fine-tunes PRC2 activity depending on the 
chromatin context581. Aberrant expression of JARID2 has been reported in several 
cancers and in ovarian cancer its knockdown inhibits proliferation and invasion through 
the PI3K/AKT signalling pathway582. Interestingly it has been shown to be essential for 
the maintenance of TICs in bladder cancer583.  
Validation of the hits from the Rituximab arm of the screen was more straight forward 
and yielded some interesting results. The most significant hit was IRAK1; the IRAKs are 
key mediators of TLR and interleukin-1 receptor (IL1R) signalling processes. TLR/IL1R-
mediated signalling controls diverse cellular processes including inflammation, 
apoptosis, and cellular differentiation584. TLR/IL1R signalling is achieved through 
differential recruitment of adaptor molecules such as MyD88, Mal/TIRAP, TRIF, and 
TRAM585. These adaptors function in the subsequent recruitment and activation of IRAK 
family kinases. Cancer-specific dependencies on IRAK signalling became evident 
following the discovery of oncogenically active MyD88 mutations in ABC DLBCL586. 
Notably, in a large set of tumour biopsies, sequence analysis of the MyD88 coding region 
revealed that 29% of ABC DLBCL tumours harbour the L265P single amino acid 
substitution within the MyD88 TIR domain. However, this mutation is absent in GC 
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DLBCL and BL. Interestingly, however, a recently published comparative genomic 
expression signature study in pBL identified potential new signal transduction pathways 
that are involved in pBL. These mainly include TLR, JAK-STAT and MAPK signalling and in 
particular IRAK1 was shown to be overexpressed 34 fold in this pBL cohort making the 
discovery that expression of this gene can confer resistance to Rituximab particularly 
interesting as we move into the era of Rituximab treatment for B-NHL in children62. Of 
course it remains to be investigated if this mechanism of resistance is relevant in the 
context of ADCC and CMC. 
The second method of analysis using the FD method was based on manual analysis of 
read counts and determination of fold change compared to a DMSO control. It was 
decided to include this alternative method based on the observation that there were a 
large number of hits with extremely low p values that fell outside the FDR threshold set 
by MaGECK-VISPR. It was therefore likely that a significant number of positive hits were 
being omitted from analysis. For the purpose of this study a conservative minimum fold 
change of 5 was chosen which yielded a significant number of hits in each treatment 
arm. Most importantly, hits from this method were also included in the validation stage 
and were successfully validated. These included NFKB1 and KRAS which were both 
outside the FDR threshold but induced resistance to chemotherapeutic drugs and 
Rituximab. The validation of genes that did not appear in the original FDR-compiled hit 
list is an encouraging indicator of the degree of accuracy of the hits derived from the FD 
method. Furthermore, enrichment screens are generally considered to be less rigorous 
and more flexible in the data analysis phase compared to negative selection (‘dropout’) 
screens587. Based on the evidence that 80% of sgRNAs were successfully validated in the 
Rituximab arm, the 92 hits with FD >5 from the Rituximab screen were compared to 
gene sets in MSigDB, specifically to Hallmark and KEGG pathway gene sets and several 
pathways were found to be enriched with significant FDR values. Of particular note, TLR 
and MAP Kinase signalling were significantly enriched in the Rituximab arm. Of note, 
when the hits in the chemotherapy only arm were compared to MsigDB gene sets a 
different set of resistance mechanisms was identified with PI3K signalling the dominant 
enriched pathway. Due to the fact that Rituximab is acting without immune components 
in this in vitro system, it could be viewed as a direct chemotherapeutic, but despite this, 
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it appears to induce a different resistant phenotype to the other three combination 
chemotherapeutics. 
An obvious limitation and cause for criticism in overexpression screens is the 
translational significance of the results. Indeed, ectopic alteration of the expression of a 
gene may induce a resistance phenotype in cell lines but if that gene is never altered in 
primary tumours in patients, then that potential resistance mechanism carries little 
relevance and benefit in the clinic.  The agreement of some of our hits with well-known 
genes involved in BL and chemotherapy resistance such as PIM1 and ABC transporters 
was an encouraging observation as was the fact that components of the TLR and MAPK 
pathway were identified as being differentially expressed in pBL62. Furthermore, the 
endogenous expression of all genes at the validation stage was validated in the five PDX 
samples. These tumours were of course treatment-naïve but the fact that they are 
actively expressed in pBL samples supports the idea that they may be capable of driving 
a response to chemotherapy upon treatment.  No clinical study of expression profile for 
treated pBL tumours was available to investigate this further, although, analysis of the 
‘relapsed’ tumours in our study in chapter 6 highlighted that PIM1 was upregulated in 
all 5 PDXs, and the FDR value (0.061) fell just outside the stringent 0.05 threshold set for 
the study. Finally, Kaplan-Meier OS analysis based on gene expression levels of 
presentation samples was available for some of the SAM screen hits and although study 
numbers are relatively small and hence statistical significance is not always met, there 
is a trend towards worse prognosis associated with some of the identified hits in this 
screen. In particular, IRAK1 is one of the genes that gives the most significant association 
with reduced OS. 
Overall, this SAM overexpression screen gave interesting insights into potential 
mechanisms of resistance in pBL but also highlighted some caveats and limitations 
associated with this form of prospective study. In particular, for our screen, the use of 
multi-agent chemotherapy proved a challenge. As long as a gene confers a survival 
advantage against one agent, it will give the cells some increased survival advantage in 
the screen setting and it will not be clear which agent/s it confers resistance to. So 
although multi-agent drug treatment is more clinically relevant, it requires laborious 
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validation with individual drugs. In this screen, there were no significant hits present in 
the chemotherapy + Rituximab arm only that might signify synergy between these drug 
treatments, rather the chemotherapy plus Rituximab arm was very similar to the 
chemotherapy alone arm. This may be due to the fact that the resistance mechanisms 
for both the three chemotherapeutics and Rituximab in vitro are separate but it is also 
possible that the drug concentrations were not optimal and hence the correct 
concentrations to use is a further complexity to be considered in the design of this type 
of screen. An alternative method could involve sequential treatment of SAM-ready cells 
with different drugs to ensure each individual drug is able to apply a strong selective 
pressure. However, as this screen was carried out over 13 days to ensure sufficient time 
for selection to occur this might pose an issue in sequential studies as the SAM activity 
may reduce over time. However, this was provisionally investigated in our lab and the 
SAM activity remained stable after four weeks. Alternatively, in order to maintain the 
use of clinically relevant combination immuno-chemotherapy a possible future step 
would be to perform a secondary screen with a library designed to contain just several 
hundred of the hits identified in this original screen with an increased number of sgRNAs 
per gene. This would minimise the laborious amount of scale up required for a large 
genome-wide library and importantly would enable further validation of hits across 
multiple cell lines and potentially at different concentrations of combination therapies. 
Indeed, recently it was suggested that this strategy should be adapted in screening 
experiments - perform a primary screen with a small number of sgRNAs per gene at 
genome-scale, use a relatively relaxed cut-off for hit selection and then perform a 
secondary screen on hundreds of primary screen hits using additional sgRNAs per 
gene588. As our screen was carried out in one cell line only it would be interesting to 
validate these hits in other cell lines before investigation in PDXs. 
Other main concerns surrounding an overexpression screen involve the non-clinically 
relevant level of ectopic expression that can be induced. Indeed, in our original 
validation of 15 genes the fold change in expression of some genes was up to 3000 which 
is not a fold expression increase likely in a patient tumour. However, more relevant 
expression levels were seen in the majority of other sgRNA transduced cells. Despite the 
acknowledgments of the limitations and caveats that are associated with 
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overexpression screens, they can be a valuable tool to identify putative resistance 
mechanisms. Particularly in a cancer such a pBL, where relapse is detrimental and poorly 
understood, the ability to prospectively identify potential resistance mechanisms that 
can be further investigated, for example in in vivo models, is a valuable pre-clinical tool. 
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Chapter 8. Final discussion and future directions 
8.1 Final discussion 
Despite the exceptional improvements in curative outcome in pB-NHL over the last 3 
decades salvaging of patients with relapse or refractory disease has not seen a similar 
improvement. This remains an inordinate challenge and there is an unmet need for 
improved therapeutic strategies. Data presented here has a broad scope with several 
different lines of investigation, all with the aim of identifying potential mechanisms of 
resistance in paediatric BL. Having discussed these data in the context of the literature 
at the end of each chapter, this chapter will combine the key findings and in particular 
address the therapeutic implications these discoveries may have. 
8.1.1 Patient Derived Xenografts can be established for paediatric BL 
The aim of chapter 3 was to establish a PDX resource to provide translationally relevant 
models for the study of heterogeneity and resistance mechanisms in pBL. PDXs have 
been shown to maintain the properties and heterogeneity of original patient samples 
and have much greater predictive power in translational research than cell lines383. PDXs 
were successfully established from pleural effusion, peripheral blood and bone marrow 
from patients with high-risk disease and significantly, in samples where detailed analysis 
of initial biopsy was possible, minute populations of cells were successfully maintained 
after passage in the mouse. Furthermore, serial passage of PDXs did not appear to 
impact the characteristics of the tumours with maintenance of histology, MYC 
translocation, gene expression and cell surface phonotype through multiple passages, 
highlighting the excellent clinical relevance of these models. To our knowledge this is 
the largest well-characterised paediatric BL PDX resource and offers excellent potential 
for pre-clinical research. 
8.1.2 Heterogeneous populations exist in paediatric BL 
The heterogenous nature of cancer is widely accepted at both the inter- and intra-
tumour level and is considered one of the greatest challenges of cancer therapy. Despite 
the clinical significance of tumour heterogeneity, it has not been studied in paediatric 
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BL. Our well-characterised PDX models offer an excellent resource to investigate the 
different populations within each tumour and determine their clinical significance. Of 
particular note, the presence of cell surface proteins associated with stemness were 
identified in all PDXs including ABCG2 and CD34. Furthermore, PDX4 had a high 
proportion of CD90 positive cells, a HSC marker not usually present on mature B cells. 
Sorting of populations based on cell surface protein expression identified the varying 
levels of tumourigenic potential within PDXs, which is particularly striking in BL, a 
tumour with an extremely rapid turnover rate. For example, the CD9 negative 
population had significantly increased tumourigenic potential compared to the CD9 
positive population across 4 PDXs, while other populations such as CD44+ and CD24+ 
cells also possessed increased tumourigenic potential in different PDXs. Despite the 
advantage conferred by some surface phenotypes, all PDXs maintained a constant 
population equilibrium with no outgrowth or loss of any population over 4 passages in 
mice. This highlights the potential importance of maintaining a tightly controlled 
equilibrium within the tumour.  The intriguing level of heterogeneity was not just 
present at an intra-tumour level but also at an inter-tumour level with a distinct set of 
surface proteins expressed across the 5 PDXs. This heterogeneity is likely to be clinically 
relevant, indeed despite both PDXs being derived from pleural effusion of stage III BL, 
PDX4 was shown to be significantly more resistant to chemotherapy than PDX1. The 
heterogeneity was also evident at the molecular level and PCA of gene expression data 
in chapter 6 highlighted inter-patient heterogeneity and quite remarkably PDXs that 
were more closely related showed upregulation of common pathways following 
chemotherapy that was not observed in the other two PDXs. 
8.1.3 A population with stemness exists in paediatric BL 
It was not possible, based on surface protein expression alone, to identify a population 
with unique tumour propagating potential in the PDX models although a population with 
functional stemness was identified utilising the SP assay. Of particular importance, a SP 
was identified in the original biopsy sample from which PDX5 was derived, further 
validating the PDX model and highlighting that the SP is not an artefact of engraftment. 
Other biopsy samples were insufficient in size to carry out SP analysis, although 
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considering our emerging data showing the potential clinical relevance of this stem-like 
population, identification of an SP in biopsy samples received in the future will be a 
priority. The SP had significantly increased tumour initiating potential compared to MP 
cells in vivo and also gave rise to fully heterogenous tumours consisting of SP and MP 
cells. Further stemness features associated with the SP fraction include increased 
expression of ABC transporters and genes associated with anti-apoptotic programmes. 
Intriguingly, although all five PDXs showed upregulation of ABC transporters, there was 
heterogeneity with respect to other differentially expressed genes. For example NANOG 
expression was increased in the SP of only PDX1 while OCT4 was upregulated in the SP 
of two different PDXs and SOX2 expression was higher in the SP of three PDXs. Anti-
apoptotic genes were differentially expressed in all five PDXs although the specific genes 
also varied for each SP. These data highlight that the SP phenotype may differ between 
tumours but they all converge on a stemness programme. The concept of a CSC in a 
mature B cell malignancy is not intuitive and the origin of this population must be 
considered. Significant evidence exists verifying the GC origin of the MYC translocation 
in BL. Gene expression profiling studies of BL samples have shown a strong relationship 
of BL cells with GC cells while DNA sequencing analysis showed that t(8;14) breakpoints 
are either in the switch regions or in the JH region, implying the involvement of VDJ 
recombination or SHM and immunoglobulin CSR589,590. Given the fact that the MYC 
translocation occurs in a GC B cell, a possible explanation for a CSC in BL is the acquisition 
of a mutation in a HSC or early progenitor followed by full malignant transformation in 
the GC. Indeed, transmission of premalignant lymphoid cells from 1 individual to 
another has been reported in at least 7 studies of mature lymphoid malignancies 
including CLL, FL and MCL although no evidence of this exists for BL or DLBCL283–285. An 
alternative explanation is the possibility that a cell harbouring the MYC translocation 
may undergo genetic or epigenetic reprogramming, conferring a stemness program on 
the background of a mature B cell which is the more likely scenario in light of the fact 
that GC cells can possess self-renewal potential that allows rapid lymphocyte division. 
The fact that the SP cells identified in this study are highly proliferative suggests that this 
population is more likely to arise from reprogramming of a mature, proliferative B cell 
rather than a quiescent progenitor. The growing body of evidence highlighting the 
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potential for the microenvironment experienced by tumour cells in lymph nodes and 
bone marrow to mediate stemness pathways as well as the exceptional plasticity 
demonstrated by B cells provide support for a this reprogramming hypothesis591. The 
exact cell of origin of the SP in BL will be an exciting project to pursue. 
Regardless of the exact origin, the SP in our study has several characteristics of a CSC 
including significantly increased tumourigenic potential compared to MP cells as well as 
the ability to produce fully heterogenous tumours composed of both SP and MP cells. 
They also express high levels of ABC transporter proteins and anti-apoptotic 
programmes. However, the MP cells are not completely devoid of tumourigenic 
potential and it was not possible to prospectively isolate the exact population by flow 
cytometry using cell surface proteins, an important characteristic of the CSC according 
to Dick and colleagues202. Hence, although we cannot assign the term CSC to the SP, this 
population does undoubtedly represent a heterogenous compartment with increased 
stemness in BL. Koch et al. in their study of SP cells in DLBCL suggest the existence of a 
self-maintained intra-clonal equilibrium of tumour cell populations230. Indeed, our study 
of heterogenous populations in BL suggest a similar tightly controlled equilibrium. All 
tumour populations are maintained at a constant level regardless of the increased 
tumourigenic potential of the SP and other populations identified by surface protein 
expression levels. Furthermore, in vitro the minority SP was shown to significantly 
influence the bulk cell population’s growth, via soluble factors, highlighting the 
importance of maintenance of a very minor population for overall tumour growth 
dynamics. Significantly, we were able to identify differentially produced cytokines 
between the SP and MP, suggesting this is one way the equilibrium between SP and MP 
cells is maintained. Interestingly, although the exchange of soluble factors between the 
SP and MP is essential for MP proliferative capabilities during early culture, following 
several weeks a SP is present in MP-derived cell lines, further supporting the  idea that 
there may be plasticity and interconversion of MP to SP cells under certain conditions. 
Irrespective of whether a distinct hierarchical organisation exists in BL or not, the data 
from this thesis highlight that a tightly controlled sub-clonal architecture is present in BL 
and the disease is not as homogenous as assumed. 
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8.1.4 Inhibition of PI3K/mTOR signalling may be a therapeutic strategy for targeting 
the SP 
An aim of this thesis was to determine if heterogenous populations within BL could have 
clinical significance. SP cells within cell lines and PDXs have increased propagating 
potential with in vitro evidence highlighting that soluble factors produced by the SP are 
important for MP growth. As well as this, SP cells have significantly increased resistance 
to chemotherapy compared to the normal whole cell population and evidence that this 
population may be important in driving resistance to chemotherapy is provided by the 
enrichment of this population in the ‘mimicked’ relapsed PDXs. Given the significant 
data pointing to an essential role for the SP in tumour dynamics and response to 
chemotherapy, the ability to target this population could have important clinical 
implications. In vitro analysis highlighted that inhibition of PI3K/mTOR signalling 
diminished the SP phenotype by downregulating expression of ABCG2 and ABCB1 and 
significantly it had a synergistic interaction with doxorubicin and methotrexate in the 
treatment of the Raji cell line. PI3K signalling was also enriched in three PDX tumours 
following the induction of relapse. This increase cannot be attributed specifically to the 
SP fraction although it provides further support for the important role of this pathway 
in mediating a resistance phenotype in BL. Furthermore, in the CRISPR screen, 
chemotherapy treatment resulted in enrichment of hits associated with 
PI3K/AKT/mTOR signalling. With all evidence pointing to the important role of this 
pathway in the SP and drug resistance phenotypes it will be important to further 
investigate this target in the PDX models. The PI3K inhibitor Idelalisib has shown an 
objective response in phase II data evaluating adults with relapsed indolent mature B-
NHL, as well as significantly improved outcomes in combination with Rituximab in adults 
with relapsed CLL112. Interestingly, a phase II trial of Idelalisib in children and adolescents 
with relapsed or refractory DLBCL or mediastinal B-cell lymphoma has just recently 
started (NCT03349346) but does not include BL. More pre-clinical data such as ours may 
lead to a trial for BL in the future. 
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8.1.5 Other potential therapeutic strategies in resistant disease were identified 
A number of lines of investigation in this thesis highlight the possibility that ABC 
transporters are important mediators of the response to chemotherapy in BL. Not only 
does ABCG2 and ABCB1 define the SP but ABCB1 was significantly upregulated in all 
relapsed PDXs and ectopic expression of it, and ABCC1 in the overexpression screen also 
strongly mediated resistance to chemotherapy. Several chemotherapy drugs were not 
included in our studies and indeed these drugs, particularly prednisolone, should be 
studied in the context of the SP and ABC transporter expression in future experiments. 
Despite this, these significant data suggest that ABC transporter targeting should be 
investigated in BL. Initial clinical trials involving three generations of inhibitors of ABC 
transporters were not successful, although a new era of research in this area has 
presented some strategies with increased promise592. Examples of improved 
approaches include inactivation of ABC transporter associated genes by microRNA and 
RNA interference as well as delivery of these microRNAs or other anti-cancer drugs 
directly to resistant cells by nanoparticles155. Monoclonal antibodies targeting the 
encoded P-glycoprotein also exist and one is currently in clinical trials for leukaemia593. 
Enrichment of the B cell receptor pathway in a subset of PDXs after relapse is a further 
interesting insight as it provides evidence of the translational relevance of our PDX 
relapse model, particularly in light of the establishment of an Ibrutinib clinical trial in 
relapse and refractory paediatric B-NHL (NCT02703272). Interestingly, Ibrutinib was 
shown to sensitize primary resistant cells and cell lines to chemotherapeutics by 
inhibiting P-glycoprotein ATPase activity and hence further investigation of the impact 
of this drug on the SP fraction in our PDXs is warranted594. 
8.1.6 A CRISPR-Cas9 overexpression screen prospectively identified putative drivers 
of resistance to both chemotherapeutics and Rituximab 
A genome-wide CRISPR-Cas9 overexpression screen was carried out to provide a broad 
overview of putative resistance mechanisms to both chemotherapy and Rituximab that 
could then be further validated in our PDX model. As well as the very significant 
resistance conferred by ectopic expression of ABC transporters and enrichment of PI3K 
signalling components, other potential targets such as PIM1 and PEG10 were drivers of 
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resistance to the chemotherapeutic agents. Of note, PIM1 was upregulated in the SP of 
four out of five of our PDXs and should be investigated further. In the Rituximab arm, a 
number of interesting resistance mechanisms were also elucidated that warrant further 
investigation. Rituximab has now been integrated into frontline therapy for pBL and 
although overall survival rate is excellent, some patients still relapse and therefore it is 
necessary to identify novel strategies that may mediate resistance to this drug. We 
acknowledge that without the presence of a functioning immune system, the data from 
this model are preliminary and will need to be investigated in a more clinically relevant 
model. Regardless, IRAK1 expression was shown to strongly induce resistance to 
Rituximab in the in vitro screen setting. This gene was recently reported to be 
upregulated for the first time in a large study of untreated paediatric BL62. It will be 
interesting to investigate if this gene, or indeed the identified MAPK and TLR signalling 
pathways, drive resistance to Rituximab in our PDXs, for example, in a humanised mouse 
model. 
8.2 Future work 
8.2.1 Further characterisation of the PDX models 
Given the excellent translational potential of our PDX resource, further methods will be 
undertaken to fully validate this model. Whole exome sequencing will be carried out 
comparing DNA from the original patient biopsy samples to DNA extracted from 
tumours at various passages in mice. This will allow us to investigate the genetic stability 
of these models and elucidate if any mutations occur as a result of engraftment and 
adaption to in vivo murine growth while also determining if populations are being 
selected or lost due to engraftment.  
In order to incorporate Rituximab into our future in vivo experiments we will consider 
the use of humanised NSG mice. For example, huCD34+ NSG mice which reconstitute 
mice with the major cell types of the human immune system would allow for 
investigation of resistance mechanisms to Rituximab in the context of ADCC and CMC 
and would allow us to validate the putative resistance mechanisms to Rituximab 
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identified in chapter 7 such as MAPK and TLR signalling in a more clinically relevant 
model. 
8.2.2 Investigation of targeted therapies in relapsed PDXs 
Given the successful establishment of an in vivo model of relapse we will further develop 
this project to determine effective therapeutics for relapse disease. Three 
chemotherapeutic agents (doxorubicin, methotrexate and vincristine) were used in this 
project and the effective concentrations determined. Future studies may incorporate 
further drugs including prednisolone and Rituximab, the latter of course with the 
caveats of requiring a functional immune system. Following the emergence of relapse 
of the PDX tumours, the efficacy of different drugs will be investigated including 
Ibrutinib and Idelalisib as well as inhibitors of anti-apoptotic proteins such as PIM1 
kinase and BCL2, particularly given the recurring evidence in this thesis that anti-
apoptotic programmes are important in resistance in BL. This will provide valuable pre-
clinical data that is currently lacking in the field of relapse in pBL. Given the striking 
increased resistance of the PDX SP to chemotherapy, Ibrutinib, Dactolisib, Idelalisib and 
PIM1 kinase inhibitors will also be compared to chemotherapy to determine the most 
effective mechanism of targeting this population. Based on our in vitro data we would 
expect Dactolisib to be effective at targeting the SP and studies involving Idelalisib will 
be informative to determine whether PI3K or mTOR signalling is more important in 
mediating the SP phenotype through ABC transporter regulation. Indeed, as it is unlikely 
that targeted therapies will be utilised in paediatric BL as single agents the effect of 
these drugs combined with chemotherapy will be investigated and the potential for 
synergistic combinations will be determined, as was noted for chemotherapy plus 
Dactolisib in vitro. We have also recently acquired a PDX model derived from an in situ 
relapsed tumour through a collaboration which, when established in our lab, will offer 
an excellent resource to compare with our PDX models of relapse. In particular, we will 
examine this tumour for the presence of a SP. Of note, a SP is present in all our PDXs 
derived from tumours at primary presentation although clinically, only a small number 
of BL patients relapse. It would therefore be particularly informative to compare the SP 
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of a bone fide relapsed sample with the SP of patients who did not relapse, for example 
by RNA-seq, to determine if any unique characteristics can be identified. 
8.2.3 Investigation of the clonal dynamics of pBL 
Given the fact that we have highlighted the potential clinical significance of the stemness 
population in pBL but have not yet determined the exact origin of this population, clonal 
dynamics of BL will be investigated. We have recently acquired FFPE material of a 
presentation and relapse pBL sample along with matched healthy tissue. High coverage 
multi-region whole exome or genome sequencing will be carried out on these paired 
samples. Phylogenetic trees will be inferred to depict the evolutionary history of the 
tumour, and therefore unveil the temporal and spatial occurrence of mutations, and the 
origins of a population that leads to relapse.  
In vivo the clonal dynamics within PDXs will be investigated to determine if the increased 
number of SP cells identified in our relapsed PDX models are directly related to the SP 
in the untreated tumour or if therapy resulted in acquisition of de novo SP cells. Lineage 
tracing or fate mapping will be utilised to identify all the progeny of the SP within the 
tumour cell following chemotherapy. Traditional methods to trace cell lineage such as 
vital dyes, fluorescent proteins and DNA tags may be sufficient to monitor the clonal 
dynamics of the SP versus the bulk tumour population with and without chemotherapy. 
More modern and sophisticated methods that harness the power of CRISPR cas9 such 
as genome editing of synthetic target arrays for lineage tracing (GESTALT) will also be 
considered594. This method uses genome editing to generate a combinatorial diversity 
of mutations that accumulate over many cell divisions so that each progeny possess a 
unique mark and is not identical, enabling more detailed analysis of cellular 
relationships. Determination of the best method to use will likely involve the outcome 
of efforts to grow our PDXs ex vivo (see below). 
8.2.4 Identification of SP-derived soluble factors that mediate MP growth 
The identification of differentially expressed cytokines in the SP of three cell lines is an 
encouraging indicator that we may be able to elucidate the mechanisms of cross-talk 
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between SP and MP cells. Future experiments will involve the use of further cytokine 
panels to produce a more exhaustive overview of the cytokine profiles of the SP and MP 
cells in each cell line. This may lead to the identification of cytokines that are increased 
in the SP of all cell lines. We will devise a matrix approach to supplement MP cells with 
the cytokines that were identified as significantly increased in the SP in an attempt to 
recover MP growth. The data produced so far was produced from studies of cell lines 
hence we will endeavour to measure the cytokine production by MP and SP cells from 
PDXs ex vivo. It has thus far not been possible to grow the PDXs in vitro although we 
have recently acquired a feeder cell layer that has proven effective at supporting the 
growth of the tumours ex vivo, based on the expression of CD40L and IL21 production. 
After further validation of this resource, particularly verification that it does not induce 
phenotypic or genetic changes of the PDX-derived cells, we will culture SP and whole 
population cells ex vivo and measure the production of cytokines in both populations, 
starting with cytokines identified as potential mediators of MP growth in the cell line 
studies. As well as informing us about the biology of these tumour cells, identification 
of cytokines involved in driving bulk tumour growth would present potential therapeutic 
opportunities.  
Overall, this study has provided an interesting insight into the heterogeneity within pBL 
and the potential clinical implications of this heterogeneity. Furthermore, it has 
identified mechanisms of resistance to therapies and has provided significant 
groundwork for future studies. Completion of the above lines of investigation will likely 
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Appendix 1:  
CRISPR Cas9 Screen Hits 
Chemotherapy Rituximab Chemotherapy + Rituximab 
ABCB1 ADH1C ABCB1 
ABCC1 AGAP3 ABCC1 
ACTR2 AKT1 ACTR2 
ADAM9 AKT2 ADAM9 
AKT1 ALCAM AKT1 
ALCAM ASAP3 ALCAM 
ARGEF1 ATAD3A ARGEF1 
ARHGAP21 ATG10 ARHGAP21 
ARHGAP21 ATP5S ASAP3 
ARHGDIA ATXN7L2 BACE2 
ASAP3 C1QL4 BCL2 
BACE2 CACHD1 BRCC3 
BCL2 CACNA2D3 CADM2 
BRCC3 CACNG5 CALCR 
C6orf1 CADM2 CASP6 
CADM2 CAPNS2 CBX3 
CALCR CELA2A CD3G 
CASP6 CITED2 CDC25B 
CBX3 CMTM6 CDK4 
CDC20B COLEC11 DDB2 
CDK4 CXCL11 DDX55 
DDB2 CYP46A1 DKK3 
DDX55 DCAF16 EPB41 
DIO3 DCUN1D4 EPHA1 
DKK3 DEFB110 FABP4 
DLX6 FAM110A FAM86B2 
EGFR FBXO36 FRMD3 
EPHA1 FXR2 GLB1 
FABP4 GNA12 GNA14 
FAM24B GPR65 GRB2 
FAM86B2 HAUS1 HR 
FBXO27 HAUS8 IKZF2 
FRMD3 HAX1 ITGB1 
FZD6 HPN JARID2 
GFI1 HTN3 KRAS 
GLB1 HTR3D LIN7B 
GNA14 IL10RA MAD2L2 
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GRB2 IL36B MALT1 
HDAC6 IRAK1 MAPK1 
HDAC9 ITGB1 MCL1 
HR JPH1 MMRN2 
IKZF2 KCNG3 NFATC4 
ITGA6 KHDRBS1 NFKB1 
ITGB1 KIAA0930 OR10G7 
JARID2 KRAS PARD6B 
KRAS KRT3 PDCD1 
LIN7B KRT6B PDS5B 
MAD2L2 LHFPL3 PEG10 
MCL1 LIMK1 PIM1 
MMRN2 LIN7B PITX1 
NFATC4 LMCD1 RAC1 
NFKB1 LMX1A RBM24 
OR10G7 MAD2L2 RLIM 
OR6C76 MAP3K15 STAT5B 
PARD6B MAPK1 TTC5 
PDE6H MAPK13   
PDS5B MPZL1   
PEG10 MTX2   
PIM1 MZT2B   
PITX1 NADK2   
RAC1 NFKB1   
RAF1 NIPAL4   
RBM24 NUP210   
RIC8B NXT2   
RLIM PCDH1   
RLIM PHF21B   
SNCB PRDM16   
STAT5B PRDM2   
STAT6 PRPF40B   
TTC5 RAB12   
WNT5B RAC1   
ZNF254 RAC2   
  RGS5   
  RIBC2   
  ROM1   
  RPS6KC1   
  S1PR5   
  SAMD1   
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  SEMA3F   
  SH3BGR   
  SLC14A2   
  SLC29A1   
  SLITRK4   
  SOX14   
  TAF11   
  TMEM106C   
  TMEM141   
  TMEM204   
  TMX1   
  TP53BP2   
  USP10   
  XRCC6   
 
